

# **Table of Contents**

# PART I

ITEM 1. Business

ITEM 2. Properties

ITEM 3. Legal Proceedings

ITEM 4. Submission of Matters to a Vote of Security Holders

# PART II

ITEM 5. Market for the Registrant's Common Equity and Related Stockholder Matters

ITEM 6. Selected Financial Data

ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of

**Operations** 

ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk

ITEM 8. Financial Statements and Supplementary Data

Item 9. Changes in and Disagreements with Accountants and Financial Disclosure

# PART III

Item 10. Directors and Executive Officers of the Registrant

Item 11. Executive Compensation

<u>Item 12.</u> <u>Security Ownership of Certain Beneficial Owners and Management and Related</u>

Stockholder Matt

Item 13. Certain Relationships and Related Transactions

Item 14. Controls and Procedures

# **PART IV**

Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8–K

**SIGNATURES** 

Certifications

EX-3.(II) (By-laws)

EX-10.(XV)

EX-21 (Subsidiaries of the registrant)

EX-23 (Consents of experts and counsel)

EX-99.(I)(A)

EX-99.(I)(B)

# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

# FORM 10-K

# ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended	d December 31, 2002
OR	
☐ TRANSITION REPORT PURSUAN SECURITIES EXCHA	T TO SECTION 13 OR 15(d) OF THE NGE ACT OF 1934
For the Transition Period Fro	mto
Commission file n	umber 1–6450
GREAT LAKES CHEMI (Exact name of registrant as	
<b>DELAWARE</b> (State or other jurisdiction of incorporation or organization)	95–1765035 (IRS Employer Identification No.)
500 EAST 96TH STE INDIANAPOLIS, I (Address of principal execution)	NDIANA 46240
Registrant's telephone number, include	ling area code 317-715-3000
Securities registered pursuant	to Section 12(b) of the Act:
<u>Title of each class</u> Common stock, \$1.00 par value	Name of each exchange on which registered  New York Stock Exchange  Pacific Stock Exchange
Securities registered pursuant to S	ection 12 (g) of the Act: None
Indicate by check mark whether the registrant (1) has filed all reports required to be the preceding 12 months, and (2) has been subject to the filing requirements for the	e filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during past 90 days. Yes No
Indicate by check mark whether the registrant is an accelerated filer (as defined in	Rule 12b−2 of the Act). Yes 🗷 No 🗆
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Re registrant's knowledge, in definitive proxy or information statements incorporated to 10–K.	

As of March 3, 2003, 50,200,485 shares of the registrant's stock were outstanding.

price on the New York Stock Exchange.

# DOCUMENTS INCORPORATED BY REFERENCE

As of June 28, 2002, the aggregate market value of the voting stock held by non-affiliates of the registrant was \$1,329,445,286 based on the last reported sales

Portions of the Proxy Statement for the Registrant's Annual Meeting of Shareholders to be held on May 1, 2003 are incorporated by reference into Part III.

# TABLE OF CONTENTS

	PART I	
Item 1.	Business	3
Item 2.	Properties	7
Item 3.	Legal Proceedings	7
Item 4.	Submission of Matters to a Vote of Security Holders	9
	PART II	
Item 5.	Market for the Registrant's Common Equity and Related Stockholder Matters	10
Item 6.	Selected Financial Data	11
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	28
Item 8.	Financial Statements and Supplementary Data	30
Item 9.	Changes in and Disagreements with Accountants and Accounting and Financial Disclosure	66
	PART III	
Item 10.	Directors and Officers of the Registrant	66
Item 11.	Executive Compensation	69
Item 12.	Security Ownership of Certain Beneficial Owners and Management	69
Item 13.	Certain Relationships and Related Transactions	69
Item 14.	Controls and Procedures	69
	PART IV	
Item 15.	Exhibits, Financial Statement Schedule and Reports on Form 8–K Signatures	70 74
	Certifications	75
	2	

### **PART I**

# ITEM 1. Business

# **GENERAL**

Great Lakes Chemical Corporation is a Delaware corporation incorporated in 1933 having its principal executive offices at 500 East 96th Street, Suite 500, Indianapolis, Indiana 46240. As used in this report, except where otherwise stated or indicated by the context, "Great Lakes" or "the Company" means Great Lakes Chemical Corporation and its consolidated subsidiaries.

Great Lakes is a customer–focused supplier of innovative specialty chemical solutions and consumer products. The Company serves customers and markets through a global network of integrated sales, production, research, technical service and distribution facilities. The Company is organized into three global business units:

**Polymer Additives** – The Polymer Additives business unit is a leading developer, producer and marketer of bromine–, phosphorus– and antimony–based flame retardants and synergists; value–added antioxidants; UV absorbers; light stabilizers; performance additives and fluids; and optical monomers. These compounds are integrated into customer solutions that resist ignition and ensure the stability of products during processing or while in use.

**Performance Chemicals** – The Performance Chemicals business unit is a collection of individual businesses that apply their expertise in fire suppression for mission critical and high–value assets; fluorinated intermediates; bromine and brominated intermediates; soil, crop and pest control; and all phases of nonclinical toxicological testing. As a result of the Company's decision in 2002 to sell its Fine Chemicals business, which provides complex chemical synthesis and process development for the pharmaceutical and agrochemical markets, the net assets of Fine Chemicals have been reclassified as assets held for sale, with operating results reported in Discontinued Operations for all periods presented

Water Treatment – The Water Treatment business unit is the world's premier formulator of water treatment biocides and related specialty chemicals for recreational and commercial pools and spas. This business unit extends innovative recreational water treatment products across the value chain to mass merchants, wholesale distributors, specialty store owners and retail customers. Its bromine–based biocides and proprietary polymer–based antiscalants, corrosion inhibitors, dispersants, antifoam, hydantoin derivatives, formulated oxidizers and biocide dispensing equipment are used by industrial customers in global cooling processing, industrial and municipal wastewater, pulp and paper, food processing and desalination industries.

Segment data for the Company's operations for the three years ended December 31, 2002 are presented in Note 15 to the Consolidated Financial Statements.

# PRODUCTS AND SERVICES

The following is a list of the principal products and services, markets and production facilities of the Company:

# POLYMER ADDITIVES

Bilding and construction materials electrical components and antimony—based flame retardants and synergists marketed under the trade names Firemaster®, Kronites®, Rogendo, Rogard®, Rogendo, Plyzoblec®, Suchebebe® and Timonos®, as well as flame retardant physical for compounds and blocks sold under the trade names Firemaster®, Kronites®, Rogendo, Rogard®, Rogendo, Plyzoblec®, Suchebebe®, and Timonos®, as well as flame retardant physical for compounds and blocks sold under the trade name Firemaster, and polytrae processing under the trade names Alamovo®. Anos N. Lowlite® and Lowins® monderal monomers.    Polytre Stabilizers   Poly	Products and Services	Products and Services Principal Markets	
Bromine - phosphorus- and antimony-based flame retardants and sprengists antacked under the trade names Firemastery Knoines, Reofus@, Roogar@, Oncar^N. Pyroble.@, Smokeblo.@ and Timmonow. as well as flame retardant physical for compounds and blend sold under the trade name Firemaster@ and the sold under the trade name Ahlanos.@, Anax. "Lowlite@ and Lowinoux@: non-fusting and construction state and bend sold under the trade name Ahlanos.@, Anax." Lowlite@ and Lowinoux@: non-fusting and construction and bend sold under the trade name Ahlanos.@, Anax. "Lowlite@ and Lowinoux@: non-fusting and construction and bend sold under the trade name Ahlanos.@, Anax." Lowlite@ and Lowinoux@: non-fusting and construction. Cosmetics and optical lenses  PERFORMANCE CHEMICALS  Products and Services  Principal Markets  Principal Markets  Principal Markets  Production Facilities  Soil, crop and structural pest control  El Dorado, AR  From the Fire Suppression agent  Information technology including computer and control rooms; telecommunications and emergency response centers; transportation such as airplanes, military vehicles and marrine vessels, medical equipment; document vaults and archives; and art  El Dorado, AR  El Dorado, AR  El Dorado, AR  El Dorado, AR  Fluorine Specialties  Organo-fluorine compounds and fluorinated intermediates  Pharmaceuticals and automotive components  Pharmaceuticals and automotive components  Pharmaceuticals and apponenticals  Fine Chemicals descontinued operations)  Specially and fine chemical intermediates  Pharmaceuticals and agrochemicals  Halebank, U.K.; Holywell, U.K.			
Antioxidans, Uw absorbers, light stabilizers, marketed under the trade names Alkanox®, Anox®, Loron, Prince; marketed under the trade name Anox®, Anox®, Loron, Prince; automotive, packaging, textiles, building and construction, cosmetics and optical lenses  PERFORMANCE CHEMICALS  Products and Services  Principal Markets  Principal Markets  Production Facilities  Agricultural Products Michyl bromide  Bromine Intermediates Bromine Intermediates Bromine derivatives and bromine—based specialty chemicals  Fire Suppression FM—200% fire suppression agent  Information technology including computer and control rooms; telecommunications and emergency response centers; ransportation such a surplanes, military vehicles and marine vessels, medical equipment.  Fluorine Specialties Organo—lhorine compounds and fluorinated intermediates  Pharmaceuticals and automotive Compounds  Pharmaceuticals and appochemicals  Halebank, U.K.; Holywell, U.K.	Bromine-, phosphorus- and antimony-based flame retardants and synergists marketed under the trade names Firemaster®, Kronitex®, Reofos®, Reogard®, Ongard®, Oncor™, Pyrobloc®, Smokebloc® and Timonox®, as well as flame retardant physical for compounds and	components; wire and cable; information technology and consumer equipment including computers, television cabinetry and textiles; printed wiring boards;	
Agricultural Products Methyl bromide  Soil, crop and structural pest control  El Dorado, AR  El Dorado, AR  El Dorado, AR; Amlwch, U.K.  Fire Suppression EM-200® fire suppression agent  Information technology including computer and control rooms; telecommunications and emergency response contests: transportation such as sirglasse, military vehicles and marine vessels; medical equipment; laboratories, hazardories, hazardories, hazardories, hazardories, hazardories hazardories, hazardories hazardories, hazardories hazardories, hazardo	Antioxidants, UV absorbers, light stabilizers, marketed under the trade names Alkanox®, Anox™, Lowilite® and Lowinox®; non–dusting blends sold under the trade name Anox™ NDB™; and optical	equipment, computer and business machines, automotive, packaging, textiles, building and	Waldkraiburg, Germany; Pedrengo, Italy; Ravenna,
Agricultural Products Methyl bromide  Soil, crop and structural pest control  El Dorado, AR  Bromine Intermediates Bromine, bromine derivatives and bromine—based specialty chemicals Bromine, bromine derivatives and bromine—based specialty chemicals  Fire Suppression FM—2009 fire suppression agent  Information technology including computer and control rooms; telecommunications and emergency response centers; transportation such as airplanes, military veicles and marine vessels; medicules and arrain evessels mediculities; document vaults and archives; and art galleries and museums  Fluorine Specialties Organo—fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive compounds and fluorinated intermediates  All phases of nonclinical toxicological testing and bioanalytical services, design of specialized toxicological, metabolic and analytical cleministry programs  Fine Chemicals (classified as discontinued operations)  Specialty and fine chemical intermediates  Pharmaceuticals and agrochemicals  Halebank, U.K.; Holywell, U.K.	PERFORMANCE CHEMICALS		
Methyl bromide Soil, crop and structural pest control Bromine Intermediates Bromine Intermediates Bromine promine derivatives and bromine—based specialty chemicals Fire Suppression FM—200® fire suppression agent Information technology including computer and control rooms; telecommunications and emergency response centers; transportation such as airplanes, military vehicles and marine vessels; medical equipment; laboratories; hazardous and airplanes military vehicles and marine vessels; medical equipment; laboratories; hazardous and filmamable liquid storage facilities; document vaults and archives; and art galleres and museums  Fluorine Specialties Organo—fluorine compounds and fluorinated intermediates Refrigerants, pharmaceuticals and automotive components  Fluorine Specialized Services All phases of nonclinical toxicological testing and bioanalytical services; design of specialized toxicological, metabolic and analytical chemistry programs  Fine Chemicals (classified as discontinued operations) Specialty and fine chemical intermediates  Pharmaceuticals and agrochemicals  Halebank, U.K.; Holywell, U.K.	Products and Services	Principal Markets	Production Facilities
Methyl bromide Soil, crop and structural pest control Bromine Intermediates Bromine Intermediates Bromine promine derivatives and bromine—based specialty chemicals Fire Suppression FM—200® fire suppression agent Information technology including computer and control rooms; telecommunications and emergency response centers; transportation such as airplanes, military vehicles and marine vessels; medical equipment; laboratories; hazardous and airplanes military vehicles and marine vessels; medical equipment; laboratories; hazardous and filmamable liquid storage facilities; document vaults and archives; and art galleres and museums  Fluorine Specialties Organo—fluorine compounds and fluorinated intermediates Refrigerants, pharmaceuticals and automotive components  Fluorine Specialized Services All phases of nonclinical toxicological testing and bioanalytical services; design of specialized toxicological, metabolic and analytical chemistry programs  Fine Chemicals (classified as discontinued operations) Specialty and fine chemical intermediates  Pharmaceuticals and agrochemicals  Halebank, U.K.; Holywell, U.K.	-		
Bromine, bromine derivatives and bromine—based specialty chemicals  Fire Suppression FM—200® fire suppression agent  Information technology including computer and control rooms; telecommunications and emergency response centers; transportation such as airplanes, military vehicles and marine vessels; medical equipment, alboratories; hazardous and flammable liquid storage facilities; document vaults and archives; and art galleries and museums  Fluorine Specialties Organo—fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive components  Fluorine Specialties Organo—fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive components  Fluorine Specialties Organo—fluorine compounds and fluorinated intermediates  Pharmaceutical, chemical and biotechnology industries  All phases of nonclinical toxicological, metabolic and analytical chemistry programs  Fine Chemicals (classified as discontinued operations) Specialty and fine chemical intermediates  Pharmaceuticals and agrochemicals  Halebank, U.K.; Holywell, U.K.		Soil, crop and structural pest control	El Dorado, AR
Fluorine Specialties Organo–fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive components  Fluorado, AR  Fluorine Specialties Organo–fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive components  Fluorine Specialties Organo–fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive components  Fluorine Specialties Organo–fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive components  Fine Chemicals (classified as discontinued operations) Specialty and fine chemical intermediates  Pharmaceuticals and agrochemicals  Pharmaceuticals and agrochemicals  Pharmaceuticals and agrochemicals  Pharmaceuticals and agrochemicals			El Dorado, AR; Amlwch, U.K.
Organo—fluorine compounds and fluorinated intermediates  Refrigerants, pharmaceuticals and automotive components  Toxicological Services All phases of nonclinical toxicological testing and bioanalytical services; design of specialized toxicological, metabolic and analytical chemistry programs  Pharmaceutical, chemical and biotechnology industries  Fine Chemicals (classified as discontinued operations)  Specialty and fine chemical intermediates  Pharmaceuticals and agrochemicals  Halebank, U.K.; Holywell, U.K.		rooms; telecommunications and emergency response centers; transportation such as airplanes, military vehicles and marine vessels; medical equipment; laboratories; hazardous and flammable liquid storage facilities; document vaults and archives; and art	El Dorado, AR
All phases of nonclinical toxicological testing and bioanalytical services; design of specialized toxicological, metabolic and analytical chemistry programs  Pharmaceutical, chemical and biotechnology industries  Ashland, OH  Fine Chemicals (classified as discontinued operations)  Specialty and fine chemical intermediates  Pharmaceuticals and agrochemicals  Pharmaceuticals and agrochemicals  Halebank, U.K.; Holywell, U.K.			El Dorado, AR
(classified as discontinued operations) Specialty and fine chemical intermediates Pharmaceuticals and agrochemicals Halebank, U.K.; Holywell, U.K.	All phases of nonclinical toxicological testing and bioanalytical services; design of specialized toxicological, metabolic and analytical	Pharmaceutical, chemical and biotechnology industries	Ashland, OH
4	(classified as discontinued operations)	Pharmaceuticals and agrochemicals	Halebank, U.K.; Holywell, U.K.
		4	

# WATER TREATMENT

Products and Services	Principal Markets	<b>Production Facilities</b>

#### Recreational (BioLab Inc.)

Water treatment sanitizers AquaBrom®, AquaChem®, Bayrol®, BioGuard®, Guardex®, Hydrotech™, Miami®, OMNI™, Pool Season™, Pool Time®, Spa Guard®, Sun® and Vantage®; algicides, biocides oxidizers, pH balancers, mineral balancers and specialty chemicals

Pool and spa dealers and distributors, mass market retailers, residential and commercial pools, pool service companies, residential and commercial builders Conyers, GA; Lake Charles, LA; Adrian, MI; Melbourne, Australia; Toronto, Canada; Le Chambre, France; Barbera Del Valles, Spain; Kyalami, South Africa; Andoversford, U.K.

### Industrial (BioLab Water Additives)

Antiscalants, biocides, corrosion inhibitors, dispersants, antifoams, hydantoin derivatives, formulated oxidizers and biocide dispensing equipment

Industrial cooling water treatment, industrial and municipal wastewater treatment, municipal desalination, pulp and paper processing, food processing and preservative intermediates Adrian, MI; El Dorado, AR; Conyers, GA; Trafford Park (Manchester), U.K.

#### RAW MATERIALS

The sources of essential raw materials for bromine are the brine from Company–owned wells in Arkansas and a sea water extraction plant in Europe. The Arkansas properties are located atop the Smackover lime deposits, which constitute a vast underground sea of bromine–rich brine. The 35–mile area between El Dorado and Magnolia, Arkansas, provides the best known geological location for bromine production in the United States, and both major domestic bromine manufacturers are located in this area. Based on projected production rates, the Company's brine reserves are estimated to be adequate.

Other raw materials used in the business are obtained from outside suppliers through purchase agreements. The cost of raw materials is generally based on market prices, although risk management tools may be utilized, as appropriate, to mitigate short–term market price fluctuations. Other raw materials purchased include chlorine, caustic, hexafluoropropene, phenol, bisphenol A and antimony oxide.

The Company has multiple suppliers for most key raw materials and uses quality raw materials management principles, such as the establishment of long-term relationships with suppliers and ongoing performance assessment and benchmarking, as part of the total supplier selection process. In addition, the Company uses electricity and natural gas to meet its energy needs.

# INTERNATIONAL OPERATIONS

Great Lakes has a significant presence in foreign markets, principally Western Europe and Asia. Approximately one—third of the Company's assets and sales are outside the United States. The geographic segment data is set forth in Note 15, "Segment Information," of the Notes to Consolidated Financial Statements.

#### CUSTOMERS AND DISTRIBUTION

During the last three years, no single customer accounted for more than 10% of Great Lakes' total consolidated sales. The Company has no material contracts or subcontracts with government agencies. A major portion of the Company's sales are to industrial or commercial businesses for use in the production of other products. Some products, such as recreational water treatment chemicals and supplies, are sold to a large number of retail pool stores, mass merchandisers and distributors. Some export sales are marketed through distributors and brokers.

The Company's business does not normally reflect any significant backlog of orders.

# COMPETITION

Great Lakes is in competition with businesses producing the same or similar products, as well as businesses producing products intended for similar use. There is one other major bromine producer in the United States, which competes with the Company to varying degrees, depending on the product. In addition, the Company competes with only one major overseas manufacturer of bromine and brominated products, which competes with the Company's products primarily in Europe and Asia. Several small producers in the United States and overseas are competitors for several individual products. Furthermore, there are numerous manufacturers that compete with the Company by offering alternatives to Great Lakes products. In Polymer Stabilizers, the Company competes with a significantly larger supplier across this entire product line and with a number of smaller companies in individual product areas. Within Performance Chemicals, the Fluorine business competes with a global manufacturer producing similar products, as well as manufacturers with products intended for similar use. The Company's Water Treatment business competes with several manufacturers and distributors of swimming pool and spa chemicals.

Principal methods of competition are innovation, price, product quality and purity, technical services and service delivery. The Company is able to move quickly in providing new products to meet identified market demands. Management believes these factors, combined with highly qualified technical personnel, allow the Company to compete effectively.

# SEASONALITY AND WORKING CAPITAL

The Company's products sold to the swimming pool industry exhibit some seasonality. The Company experiences higher sales and profits in the second and third quarters for pool products. Seasonality also requires that the Company build inventories for rapid delivery at certain times of the year. In particular, sales related to the pool product season require a build—up of inventory at the beginning of the year. Certain arrangements with mass market customers permit returns of unsold material at the end of a season. The effect of the these items on working capital and liquidity requirements is not material.

#### RESEARCH AND DEVELOPMENT, PATENTS AND TRADEMARKS

The Company holds various patents and trademarks covering a number of its products and processes. While the Company believes these patents and trademarks offer significant commercial benefits, the Company's management does not believe any individual patent or trademark is of material importance to the Company's business as a whole or that the success of the Company's business is dependent upon its portfolio of patents and trademarks.

Research and development expenditures are described in Note 14, "Research and Development Expenses," of the Notes to Consolidated Financial Statements.

#### **ENVIRONMENTAL**

The Company's operations are subject to various laws and regulations relating to maintaining or protecting the quality of the environment. Information regarding environmental compliance and contingencies is set forth under the "Environmental" caption in "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in Note 18, "Commitments and Contingencies," of the Notes to Consolidated Financial Statements.

# **EMPLOYEES**

The Company currently employs approximately 4,600 people, 40% of whom are employed outside the United States. Approximately 190 U.S. employees are represented by collective bargaining agreements. The Company maintains good employee relations and is currently in negotiations with its one union whose contract expires in the first quarter of 2003. While the Company has successfully completed its past labor negotiations without a work stoppage, it cannot predict the outcome of current or future contract negotiations.

#### AVAILABLE INFORMATION

The Company's Annual Reports on Form 10–K, Quarterly Reports on Form 10–Q, Current Reports on Form 8–K, proxy statements and amendments to those reports, are available free of charge on the Company's Internet website at http://www.greatlakes.com as soon as reasonably practicable after such reports are filed with the Securities and Exchange Commission.

# ITEM 2. Properties

The Company leases its principal executive offices in Indianapolis, Indiana, and owns its principal corporate facility in West Lafayette, Indiana. The Company operates 24 production facilities in 11 countries. The Company has distribution facilities at all of its manufacturing sites. Listed under "Item I. Business" above in the table captioned "Products and Services" are the production facilities by business unit. The Company's principal research facilities are in West Lafayette, Indiana; Decatur, Georgia; and Trafford Park (Manchester), U.K. Most principal locations are owned.

In addition, the Company owns or leases warehouses, distribution centers and office space for administrative and sales activities throughout the world. All of the Company's facilities are in good repair, suitable for the Company's businesses, and have sufficient capacity to meet present market demands at an efficient operating level.

#### ITEM 3. Legal Proceedings

The Company has been cooperating with the United States Department of Justice (DOJ) and the European Commission since the spring of 1998 in their respective investigations of the bromine and brominated products industry. Both investigations were initiated after the Company self–reported to those agencies certain business practices that raised questions under antitrust laws. As a result of the Company's cooperation, the Company and its current directors and employees were accepted into the DOJ's amnesty program. Concurrently, the Company sought favorable treatment under a program in the European Union that also rewards self–reporting and cooperation. To the Company's knowledge, no proceedings have ever been instituted in the European Union in connection with the investigation.

The Company believes it has fully complied with all applicable conditions to date and has continued to cooperate with the DOJ in connection with certain follow—up matters arising out of the investigation, all of which are covered by the Company's acceptance into the amnesty program. Although, to the Company's knowledge, there have been no additional matters that have arisen in connection with the investigations, the Company intends to continue to be in full compliance with the DOJ and European Union programs.

There were ten federal purported class action lawsuits and five California purported class actions naming the Company, each claiming treble damages arising out of an alleged conspiracy concerning the pricing of bromine and brominated products. The federal lawsuits were consolidated in the District Court for the Southern District of Indiana, which, over the Company's opposition, certified a class of direct purchasers of certain brominated products.

On September 10, 2002, the Company agreed to settle all of the federal class actions. The settlement agreement affects direct purchasers from the Company of brominated diphenyl oxides (decabromodiphenyl oxide, octabromodiphenyl oxide and pentabromodiphenyl oxide) and their blends, tetrabromobisphenol—A and its derivatives and all methyl bromide products and their derivatives in the United States between January 1, 1995 and April 30, 1998. The Company agreed to a \$4.1 million cash payment and \$2.6 million in vouchers for the future purchase of decabromodiphenyl oxide and/or tetrabromobisphenol—A, to be distributed to class members. The settlement was reflected in the third quarter of 2002 as a reduction to litigation reserves previously recorded in prior periods.

Pursuant to the settlement agreement, the Company remitted the cash portion to an escrow account on November 8, 2002, subject to final approval of the settlement agreement by the federal court. After notice to class members, the federal court gave final approval to the settlement in January 2003. In addition, the plaintiffs submitted a plan of distribution for court approval. The plan included a form of voucher agreed to by the Company.

The California cases pending in the Superior Court for San Francisco County claim alleged violations of California competition laws and were stayed pending resolution of the federal cases. The cases are not impacted by the federal settlement. The Company has denied that the cases were legitimately filed as class actions, denies all liability and intends to defend the cases vigorously.

OSCA, the interest in which the Company divested to BJ Services Company as of May 31, 2002, is a party to certain pending litigation regarding a blowout of a well in the Gulf of Mexico operated by Newfield Exploration Company. In the lawsuit, the plaintiffs claimed that OSCA and the other defendants breached their contracts to perform work—over operations on the well and were negligent in performing those operations. On April 4, 2002, a jury reached a verdict on those claims, finding OSCA and the other defendants responsible for those claims and determining OSCA's share of the damages. In connection with the lawsuit, the Company asserted claims against its insurers and insurance brokers in support of insurance coverage for this incident. A related trial on these insurance coverage claims was conducted by the submission of legal briefs. Thereafter, the court issued its final judgments on the underlying liability claims and the insurance coverage claims, entering judgment against OSCA for a net amount of approximately \$13.3 million plus interest, and finding that such amount was only partially covered by insurance. Pursuant to an indemnification agreement between the Company and BJ Services entered into at the time of the sale of OSCA (see Note 4 to the Consolidated Financial Statements), Great Lakes has agreed to pay BJ Services a certain percentage of any uninsured cash damages in excess of an amount paid by OSCA upon settlement or final determination of this pending litigation. As of December 31, 2002, the Company recorded a \$9.0 million reserve in discontinued operations for this indemnification liability. Great Lakes and BJ expect to appeal some or all of the liability and insurance coverage decisions.

On May 28, 2002, Albemarle Corporation filed two complaints against the Company in the United States District Court for the Middle District of Louisiana, one alleging that the Company infringed on three process patents held by Albemarle Corporation relating to bromine vacuum tower technology, and the other alleging that the Company had infringed or contributed or induced the infringement of a patent relating to the use of decabromodiphenyl ethane as a flame retardant in thermoplastics. On a motion by the Company and over Albemarle's objection, the cases were consolidated. In addition, the Company has filed a counterclaim with the District Court in the flame retardant cases, alleging, among other things, that the Albemarle patent is invalid or was obtained as a result of inequitable conduct in the United States Patent and Trademark Office.

With respect to the Albemarle case, the Company believes that the allegations of the complaints are without basis factually or legally, and intends to defend the cases vigorously.

There are also various other lawsuits and claims, other than those mentioned above, pending against the Company and certain of its consolidated subsidiaries. While it is not possible to predict or determine the outcome of legal actions brought against the Company or the ultimate cost of these actions, the Company believes the costs associated with all such actions in the aggregate will not have a material adverse effect on its consolidated financial position, liquidity or results of operations. Furthermore, no director, officer or affiliate of the Company, or any associate of any director or officer is involved, or has a material interest in, any proceeding that would have a material adverse effect on the Company.

# ITEM 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of security holders during the quarter ended December 31, 2002.

# **PART II**

# ITEM 5. Market for the Registrant's Common Equity and Related Stockholder Matters

The common stock of Great Lakes Chemical Corporation is traded on the New York Stock Exchange (the "NYSE") under the trading symbol GLK. The following table sets forth the quarterly dividends paid per share and the ranges of high and low market prices per share on the NYSE for the last two fiscal years, based upon information supplied by the NYSE.

2002	Ma	rch 31	J	une 30	Sep	tember 30	Dec	ember 31
Cash dividends paid per share	\$	0.08	\$	0.08	\$	0.08	\$	0.08
Stock Price Data							_	
High	\$	28.59	\$	28.40	\$	29.31	\$	26.75
Low		21.55		23.70		21.24		22.51
Year-end close								23.88
2001	Ma	arch 31	J	une 30	Sep	tember 30	Dec	ember 31
Cash dividends paid per share	\$	0.08	\$	0.08	\$	0.08	\$	0.08
Stock Price Data								
High	\$	37.63	\$	34.75	\$	32.01	\$	25.12
Low		29.40		29.85		20.00		20.16
Year-end close		th. C.						24.28

As of March 3, 2003, there were approximately 2,128 stockholders of record of the Company's common stock.

ITEM 6. Selected Financial Data

(millions, except per share data) Year Ended December 31,	_	2002		2001		2000		1999		1998
Statement of Operations Data										
Net sales	\$	1,401.5	\$	1,352.8	\$	1,449.8	\$	1,291.1	\$	1,233.1
Operating income before special charges		116.3		7.2		200.5		190.0		187.0
Operating income (loss) <sup>(1)</sup>		111.2		(141.4)		146.2		171.0		74.3
Income (loss) from continuing operations before income				(224.0)						<b>=</b> 0.0
taxes		68.7		(221.0)		117.4		187.5		70.9
Income taxes (credit)		21.3	,	(39.8)	,	36.6		39.7		8.8
Effective income tax rate	Φ.	31.0%		(18.0)9		31.2%		21.2%	Φ.	12.4%
Income (loss) from continuing operations	\$	47.4	\$	(181.2)	\$	80.8	\$	147.8	\$	62.1
Income (loss) from discontinued operations		77.6		(108.3)	_	46.2		(8.2)	_	26.9
Net income (loss)	\$	125.0	\$	(289.5)	\$	127.0	\$	139.6	\$	89.0
Balance Sheet Data - Year-End(2)										
Working capital		4.50.0				••••		-0-		
(excluding cash and cash equivalents)	\$	150.3	\$	116.2	\$	294.8	\$	282.6	\$	163.6
Current ratio	Φ.	2.0	Ф	1.4	Φ	2.5	Ф	3.7	Ф	2.8
Capital expenditures	\$	64.8	\$	131.2	\$	132.9	\$	94.9	\$	125.2
Total assets		1,663.6		1,475.3		1,782.4		1,888.2		1,691.4
Noncurrent liabilities		103.1		67.9		28.4		29.9		32.1
Debt (net of cash and cash equivalents)		181.5		456.2		444.4		420.8		119.6
Debt		440.6		511.7		663.0		889.1		519.6
Percent of total capitalization	Φ.	37.1%		45.5%		41.1%		47.2%	Φ.	33.0%
Stockholder's equity	\$	745.7	\$	613.5	\$	949.7	\$	994.1	\$	1,054.3
Share Data										
Basic earnings (loss) per share										
Continuing operations <sup>(2)</sup>	\$	0.94	\$	(3.60)	\$	1.54	\$	2.56	\$	1.05
Discontinued operations		1.54		(2.16)		0.88		(0.14)		0.46
Total	\$	2.48	\$	(5.76)	Ф	2.42	\$	2.42	\$	1.51
Diluted earnings (loss) per share	Ψ	2.46	Ψ	(3.70)	Ψ	2.42	Ψ	2.42	Ψ	1.31
Continuing operations <sup>(3)</sup>	\$	0.94	\$	(3.60)	Φ	1.54	\$	2.55	\$	1.05
Discontinued operations	Ψ	1.54	Ψ	(2.16)	Ψ	0.88	Ψ	(0.14)	Ψ	0.45
Discontinued operations		1.54	_	(2.10)	_	0.88	_	(0.14)		0.43
Total	\$	2.48	\$	(5.76)	\$	2.42	\$	2.41	\$	1.50
Cash dividends per share										
Declared during year	\$	0.33	\$	0.32	\$	0.32	\$	0.32	\$	0.40
Paid during year		0.32		0.32		0.32		0.32		0.48
Payout as a percent of net income (loss)		12.9%	ò	(5.6)%	6	13.2%		13.2%		26.5%
Shares outstanding (basic)										
Average during year		50.2		50.3		52.4		57.8		59.0
At year-end		50.2		50.2		50.3		54.5		58.4
Stock price <sup>(4)</sup>										
At year-end	\$	23.88	\$	24.28	\$	37.19	\$	38.19	\$	40.00

After special charges of \$5.1 million, \$148.6 million, \$54.3 million, \$19.0 million and \$112.7 million in 2002, 2001, 2000, 1999 and 1998, respectively.

(2)

(3)

(4)

# ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following provides a review of the consolidated financial position of Great Lakes Chemical Corporation ("the Company"), at December 31, 2002 and 2001, the consolidated results of operations for the three years ended December 31, 2002, and where appropriate, factors that may affect future financial performance. Please read this discussion in conjunction with the accompanying consolidated financial statements, notes and selected consolidated financial data. As described

Amounts reflect balances for continuing operations.

Earnings per share from continuing operations for 2002 were reduced by \$0.01 per share, reflecting adjustments made subsequent to the Company's press release issued January 28, 2003, as described in Management's Discussion and Analysis of Financial Condition and Results of Operations.

Stock prices prior to May 22, 1999, do not reflect the Octel spin-off.

in Note 3 to the Consolidated Financial Statements, the results of the Fine Chemicals business as a part of the Performance Chemicals business unit and OSCA, formerly the Energy Services and Products business unit, are reported in Discontinued Operations for all periods presented.

#### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

The Company is including the following cautionary statement to make applicable and take advantage of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 with respect to any forward–looking statement made by, or on behalf of, the Company. Forward–looking statements generally may be identified by words such as "believes," "expects," "intends," "may," "will likely result," "estimates," "anticipates," "should," and other similar expressions, or the negative of such words or expressions. The factors identified in this cautionary statement are important factors (but do not necessarily constitute all important factors) that could cause actual results to differ materially from those expressed in any forward–looking statement made by, or on behalf of, the Company.

Where any such forward-looking statement includes a statement of the assumptions or bases underlying such forward-looking statement, the Company cautions that, while it believes such assumptions or bases to be reasonable and makes them in good faith, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or bases and actual results can be material, depending upon the circumstances. Where, in any forward-looking statement, the Company, or its management, expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation or belief will result or be achieved or accomplished.

Taking into account the foregoing, certain factors, including, but not limited to, those listed below, may cause actual results to differ materially from those expressed in any forward–looking statement made by, or on behalf of, the Company.

- Economic factors over which the Company has no control, including changes in inflation, tax rates, interest rates and foreign currency exchange rates.
- Competitive factors such as pricing pressures on key products and the cost and availability of key raw materials.
- Governmental factors including laws and regulations and judicial decisions related to the production or use of key products such as bromine and bromine derivatives.
- The difficulties and uncertainties inherent in new product development. New product candidates that appear promising in development may fail to reach the market because of safety concerns, inability to obtain necessary regulatory approvals, difficulty or excessive costs to manufacture, or infringements of the patents or intellectual property rights of others.
- Legal factors, including unanticipated litigation of product liability claims, antitrust litigation, environmental matters or patent disputes with competitors, which could preclude commercialization of products or negatively affect the profitability of existing products.

12

- Inability to obtain existing levels of product liability insurance or denial of insurance coverage following a major product liability claim.
- Changes in tax laws, including future changes in tax laws related to the remittance of foreign earnings or investments in foreign countries with favorable tax rates.
- Changes in accounting standards promulgated by the Financial Accounting Standards Board; the Securities and Exchange Commission; or the American Institute of Certified Public Accountants, which are adverse to the Company.
  - Internal factors such as changes in business strategies and the impact of cost control efforts and business combinations.
  - Loss of brine leases or inability to produce the bromide ion in required quantities due to depletion of resources or other causes beyond the Company's control.

# CRITICAL ACCOUNTING POLICIES

Financial Reporting Release No. 60 requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. See Note 1 to the Company's audited Consolidated Financial Statements for a summary of the significant accounting policies and methods used in the preparation of the consolidated financial statements. We believe the following are some of the more critical judgment areas in the application of our accounting policies that currently affect our consolidated financial condition and results of operations.

#### **GENERAL**

The preparation of the Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The most significant estimates and assumptions relate to special charges, impairment of goodwill and intangible assets, income taxes, pensions and contingencies related to litigation and environmental matters. Actual amounts could differ significantly from these estimates.

The Company recorded special charges, net of adjustments, of \$5.1 million, \$148.6 million and \$54.3 million in 2002, 2001 and 2000, respectively. These charges and adjustments were made in connection with detailed repositioning and restructuring plans, which provided for a series of cost reduction initiatives to further streamline operations, strengthen the Company's competitive position and provide a platform for future growth. The charges associated with these plans included estimates for amounts related to asset impairments, employee severance costs, plant closure and related environmental costs and the settlements of various contractual obligations resulting from these repositioning and restructuring actions. When it is determinable that the actual costs differ from the original estimates, adjustments, either additional charges or reversals, are made to the remaining special charge reserves at that time.

# IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS

The Company evaluates long-lived assets, including goodwill and other intangible assets, annually or when events occur or circumstances change that may result in a potential impairment. Judgments regarding the existence of impairment indicators are based on legal factors, market conditions and operational performance of acquired businesses. If impairment indicators are present, the Company is required to assess the recoverability of these assets. In assessing the recoverability of the Company's goodwill and other intangible assets, the Company must make assumptions regarding

estimated future cash flows and other factors to determine the fair value of the respective assets. If these estimates or their related assumptions change in the future, the Company may be required to adjust the impairment charges for these assets.

#### INCOME TAXES

The Company accounts for income taxes in accordance with Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes," which requires that deferred tax assets and liabilities are recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. The statement also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

At December 31, 2002, the Company had deferred tax assets in excess of deferred tax liabilities of \$9.9 million. At December 31, 2002 and 2001, management determined that it is more likely than not that \$35.7 million and \$49.4 million, respectively, of certain deferred tax assets will not be realized, requiring the Company to establish a valuation allowance for those amounts.

The Company evaluates on a quarterly basis its ability to realize its deferred tax assets by assessing its valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization are the Company's forecast of future taxable income and available tax planning strategies that could be implemented to support realization of certain deferred tax assets.

Failure to achieve forecasted taxable income might affect the ultimate realization of certain deferred tax assets. Factors that may affect the Company's ability to achieve sufficient forecasted taxable income include, but are not limited to, increased competition, general economic conditions, a decline in sales or earnings, loss of market share or delays in product availability.

In addition, the Company operates within multiple taxing jurisdictions and is subject to audits in these jurisdictions. These audits can involve complex issues, which may require an extended period of time to resolve. In management's opinion, adequate provisions for income taxes have been made.

# DEFINED BENEFIT PENSION PLANS

The Company sponsors various non–contributory and contributory defined benefit pension plans which have significant pension benefit costs developed from actuarial valuations. Inherent in these valuations are key assumptions including discount rates, expected return on plan assets and rates of increases in compensation levels. The Company is required to consider current market conditions, including changes in interest rates and plan asset investment returns in determining these assumptions. At October 1, 2002 (the annual plan measurement date), appropriate changes were made in the discount rates and expected return on plan assets assumptions for all plans. See Note 13 to the Company's Consolidated Financial Statements for detail of these assumptions. The Company currently expects pension costs to increase approximately \$8 million to \$9 million in 2003 compared to 2002. The Company has no funding requirements for 2003 as actuarially determined for the U.S. plans. The Company does expect, however, to make a voluntary contribution to the U.S. qualified plan of approximately \$7 million. It is anticipated that this contribution will consist primarily of Company stock. Company contributions to the non–U.S. plans in 2003 are expected to be approximately \$3 million, in line with 2002 amounts.

An increase in either the discount rate or expected return on plan assets of one—fourth of 1 percentage point, holding all other assumptions constant, would decrease the Company's pension expense by \$1.7 million and \$0.5 million, respectively. Correspondingly, a decrease in these

assumptions of one-fourth of 1 percentage point, holding all other assumptions constant, would increase the Company's pension expense by \$1.7 million and \$0.5 million, respectively.

#### CONTINGENCIES

The Company is subject to legal proceedings, lawsuits and other claims related to environmental, labor, product and other matters. The Company is required to assess the likelihood of any adverse judgments or outcomes related to these matters, as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual issue. The Company records a reserve when management considers the likelihood of an unfavorable outcome probable and when a reasonable estimate of the liability can be made. At December 31, 2002, the Company had accrued \$16.8 million and \$45.2 million related to litigation and environmental liabilities, respectively. These accruals are estimates and may change in the future as new developments arise as changes are made in settlement strategy.

# RESULTS OF OPERATIONS

The following table sets forth the percentage relationship to net sales of certain income statement items for the Company's continuing operations:

Year Ended December 31	2002	2001	2000
Net sales	100.0%	100.0%	100.0%
Cost of products sold	76.3	82.9	71.3
Gross profit	23.7	17.1	28.7
Selling, general and administrative expenses	15.3	16.6	14.9
Operating contribution Special charges	8.4 0.4	0.5 (11.0)	13.8 3.7
Operating income (loss) – Continuing operations	8.0	(10.5)	10.1
Interest income (expense) – net Other income (expense) – net	(2.0) (1.1)	(2.4) (3.5)	(2.2) 0.2
Language (Language) before in company	4.0	(16.4)	0.1
Income (loss) before income taxes Income taxes (credit)	4.9 1.5	(16.4) (3.0)	8.1 2.5
Net income (loss) – Continuing operations	3.4%	(13.4)%	5.6%

# 2002 COMPARED WITH 2001

# **Continuing Operations**

Net sales increased 3.6% to \$1,401.5 million from \$1,352.8 million in the prior year. Strong volume gains in the Water Treatment and Polymer Additives business units were offset by lower sales in Performance Chemicals related to the Fluorine business and lower selling prices in the Polymer Additives and Performance Chemicals business units. For the Company as a whole, sales volumes increased 5% while pricing was down 2%.

Gross profit margins increased to 23.7% from 17.1% in the prior year. Included in the gross profit margin in 2001 are \$59.7 million of repositioning activity costs (see Note 2 to the Consolidated Financial Statements). Excluding these costs, gross profit margins increased to 23.7% from 21.5%. The increase reflects the benefits realized from improved manufacturing efficiencies, lower raw material costs and productivity gains associated with the repositioning efforts undertaken in the

second half of 2001. These items more than offset reduced selling prices in Polymer Additives and Performance Chemicals.

Selling, general and administrative expenses decreased \$9.5 million to \$215.0 million. As a percent of sales, selling, general and administrative expenses decreased from 16.6% to 15.3%. These decreases reflect the benefits of repositioning efforts undertaken in the second half of 2001, as well as lower information technology and legal spending, which more than offset higher pension and insurance costs. Included in 2001 are \$0.9 million of repositioning activity costs (see Note 2 to the Consolidated Financial Statements).

Special charges of \$5.1 million in 2002 reflect net adjustments to special charge activities recorded in 2001 based on changes in original estimates. The \$148.6 million of special charges in 2001 reflects \$153.6 million of charges recorded during 2001 for a series of cost reduction initiatives undertaken by the Company, offset by \$3.5 million of reversals of special charges taken in the second quarter of 2001 and \$1.5 million of reversals of special charges taken in 2000. The net of the 2002 and 2001 special charges and reversals are reflected in the consolidated statement of operations as a separate component of operating income.

Operating income (loss) was \$111.2 million compared to \$(141.4) million in the prior year. Included in operating income in 2002 are \$5.1 million of special charges and \$1.0 million of reversals of previously recorded repositioning items. Operating income in 2001 includes the effects of \$209.7 million of special charges and other repositioning activities. Excluding the impact of special charges and repositioning items, operating income increased \$47.0 million year over year. This increase reflects the higher sales volumes, productivity gains, lower raw material costs and the decrease in selling, general and administrative expenses, all of which more that offset lower selling prices.

Interest income (expense) – net decreased \$5.2 million to \$(27.6) million in 2002 reflecting reduced net debt levels in the current year and the effects of an interest rate swap entered into during the first quarter of 2002, which reduced interest expense by \$2.1 million in 2002.

Other income (expense) – net decreased \$31.9 million from other expense – net of \$(46.8) million in the prior year to \$(14.9) million in 2002. Other income (expense) in 2002 includes \$4.6 million of fixed asset write—downs net of a reversal of \$(2.7) million for litigation and other settlements. Included in the fixed asset write—downs of \$4.6 million is a \$1.6 million impairment of the Water Treatment business unit's BioLab corporate facility as a part of a management plan to move to a leased facility in 2003. The existing facility was sold in January 2003. Other income (expense) in 2001 includes one—time charges of \$33.8 million (see Note 2 to the Consolidated Financial Statements). In addition, as of January 1, 2002, the Company ceased amortization of goodwill in accordance with the adoption of SFAS No. 142 (see Note 1 to the Consolidated Financial Statements.) Goodwill amortization of \$6.5 million was recognized in 2001. The absence of \$6.5 million in goodwill amortization in other income (expense) – net in 2002 was more than offset by lower earnings of affiliates and higher foreign exchange losses due to the weakening of the U.S. dollar against the euro and the British pound.

Income tax expense (credit) for the year ended December 31, 2002, amounted to an expense of \$21.3 million or an effective tax rate of 31.0% compared to a credit of \$(39.8) million or effective tax rate of (18.0)% in the prior year. The 2002 effective income tax rate of 31% was higher than the Company's 2001 income tax rate due primarily to the increase in the valuation allowance and non-deductible goodwill write-offs related to the 2001 repositioning activities.

Income (loss) from continuing operations was \$47.4 million or \$0.94 per share in 2002, as compared to \$(181.2) million or \$(3.60) per share in 2001.

The Company had reported in a press release on January 28, 2003, income from continuing operations of \$48.0 million or \$0.95 per share in 2002. The \$0.6 million decrease is attributable to adjustments for inventory and employee benefit accruals, which arose subsequent to the issuance of the news release.

#### SEGMENT INFORMATION

Set forth below is a discussion of the operations of the Company's business segments: Polymer Additives, Performance Chemicals and Water Treatment. Operating income, which is the income measure the Company uses to evaluate business segment performance, represents net sales less costs of products sold and selling, general and administrative expenses. The operating income data presented below is before special charges. Each of the Company's segments uses bromine as a raw material in their production process. Bromine is transferred at cost to all business segments. In addition, assets used in the production of bromine are allocated to each business unit based on the percentage of production consumed.

# **Polymer Additives**

The Polymer Additives business unit is a leading provider of flame retardants, polymer stabilizers and optical monomers and brings the most comprehensive product basket to the global marketplace. Polymer Additives provides its customers an array of integrated polymer additive solutions that meet specific, well–defined customer needs in a variety of products including consumer electronics, computers and business equipment, automotive, furniture, fibers, wire and cable, household appliances, communications equipment, building and construction materials, packaging, textiles, polymers, cosmetics and optical monomers.

	2002	2001
Net sales	\$ 618.2	\$ 581.7
Operating income (loss)	16.4	(70.8)

Net sales increased \$36.5 million or 6.3% in 2002. New product introductions and stronger end market demand drove an increase in sales volumes of 8%. This volume growth was partially offset by a 3% decline in selling prices. Roughly one—half of the 8% volume growth, or \$25 million, is attributable to new product growth.

Operating income (loss) increased \$87.2 million to \$16.4 million for the year. Excluding inventory write—downs, environmental remediation costs and other repositioning items of \$41.6 million included in operating income (loss) in 2001(see Note 2 to the Consolidated Financial Statements), operating income increased \$45.6 million. Higher sales volumes and new product growth contributed \$25 million to the increase. In addition, benefits derived from restructuring activities, lower raw material costs and focused productivity efforts added \$39 million. These benefits more than offset the decrease in selling prices of \$18 million in the current year.

#### **Performance Chemicals**

The Performance Chemicals business unit is a global supplier of fluorine–based fire suppression agent FM–200®, fluorine–based intermediates, bromine and brominated derivatives and all phases of nonclinical toxicological testing to broad and diverse markets that include information technology; telecommunications; transportation; medical; automotive; electronics; photographic paper and films;

rubber compounds; detergents; soil, crop and structural pest control; pharmaceuticals; and the chemical and biotechnology industry.

		2002	2001	
	_		_	
Net sales	\$	232.7	\$	250.2
Operating income		52.6		60.9

Net sales decreased \$17.5 million or 7.0% in the current year. Sales decreased 3% from lower volumes and 4% from a decline in selling prices, primarily in the Fluorine business. These decreases reflect the continued slow–down in information technology and telecommunication infrastructure spending.

Operating income decreased \$8.3 million or 13.6% in the current year. Excluding inventory write—downs, environmental remediation costs and other repositioning items of \$8.8 million included in operating income in 2001 (see Note 2 to the Consolidated Financial Statements), operating income decreased \$17.1 million. Lower sales volumes contributed \$10 million to the decrease while lower selling prices added \$6 million to the decrease.

#### Water Treatment

The Company's Water Treatment business unit, through its BioLab subsidiary, is the world's leading provider of recreational water care products to the consumer. By deploying a brand/channel segmentation strategy, BioLab is able to maintain a strategic position in every important retail class of trade and leverage its resources. BioLab Water Additives, through its proprietary position in polymaleate chemistry, and as the world's foremost provider of bromine—based biocides, is a leading supplier of antiscalants, corrosion inhibitors, dispersants, antifoams, hydantoin derivatives, formulated oxidizers and desalination solutions.

	2002		2001
Net sales	\$ 543.0	\$	507.0
Operating income	83.1		54.1

Water Treatment net sales increased 7% to \$543.0 million in the current year. Market penetration led by growing consumer acceptance of innovative product offerings and warmer weather patterns throughout most of the 2002 pool season drove the increase.

Operating income increased from \$54.1 million in 2001 to \$83.1 million in 2002. Included in 2002 are reversals of \$1.0 million of previously recorded reserves for contract cancellation and other costs. Excluding these 2002 reversals and inventory write—downs, contract cancellation costs and other repositioning items of \$10.7 million included in operating income in 2001 (see Note 2 to the Consolidated Financial Statements), operating income increased \$17.3 million. The positive impact of higher sales volumes and the strength of the new product portfolio contributed \$10 million. In addition, focused productivity efforts and lower raw material costs each added \$5 million. Acquisitions also added \$1 million. The positive impact of these items more than offset the effect of slightly lower selling prices of \$4 million.

# 2001 COMPARED WITH 2000

#### **Continuing Operations**

Net sales decreased 6.7% to \$1,352.8 million from \$1,449.8 million in the prior year. Volume growth in the Water Treatment business unit, which includes the effects of the acquisition of Aqua Clear, was offset by slowing end markets and lower selling prices in the Polymer Additives and Performance Chemical business units. Additionally, unfavorable foreign exchange impacted all business units.

Gross profit margins decreased to 17.1% from 28.7% in the prior year. Included in gross profit margin in 2001 are \$59.7 million of repositioning activity costs (see Note 2 to the Consolidated Financial Statements). The adverse effects of price and volume decreases in the Polymer Additives business unit, efforts to reduce inventory levels across all business units and volume decreases in the Performance Chemicals business unit also contributed to the decrease.

Selling, general and administrative expenses increased \$8.4 million to \$224.5 million. As a percent of sales, selling, general and administrative expenses increased from 14.9% to 16.6%. These increases reflect higher sales and marketing costs in the Water Treatment business unit, including the impact of the Aqua Clear acquisition, and increased information technology and legal expenses partially offset by several cost containment efforts undertaken by the Company. Included in 2001 are \$0.9 million of repositioning activities.

Special charges of \$148.6 million reflect \$153.6 million of charges recorded during 2001 for a series of cost reduction initiatives undertaken by the Company, offset by \$3.5 million of reversals of special charges taken in the second quarter of 2001 and \$1.5 million of special charges taken in 2000. The net of the 2001 special charges and reversals is reflected in the consolidated statement of operations as a separate component of operating income.

Operating income (loss) in 2001 decreased \$287.6 million to \$(141.4) million compared to \$146.2 million in the prior year. Included in operating income in 2001 and 2000 are \$209.7 million and \$54.3 million of special charges and repositioning activities, respectively (see Note 2 to the Consolidated Financial Statements). Excluding the impact of these special charges and repositioning activities, operating decreased \$132.2 million year over year. This decrease reflects the impact of lower sales volumes and prices, inventory reduction efforts and higher selling, general and administrative expenses.

Interest income (expense) - net increased \$1.2 million to \$(32.8) million in 2001 reflecting a slightly higher average net debt level.

Other income (expense) – net increased \$49.6 million from other income – net of \$2.8 million in the prior year to other expense – net of \$(46.8) million in 2001. The increase is primarily attributable to lower earnings from affiliates and \$33.8 million of repositioning activities recorded in 2001 (see Note 2 to the Consolidated Financial Statements).

Income tax expense (credit) for the year ended December 31, 2001, amounted to a credit of \$(39.8) million or an effective tax rate of (18.0%) compared to an expense of \$36.6 million or an effective tax rate of 31.2% in the prior year. The 2001 effective income tax rate is lower than the Company's expected ongoing effective income tax rate of 31% due primarily to the increase in the valuation allowance and non-deductible goodwill write-offs

Income (loss) from continuing operations was \$(181.2) million or \$(3.60) per share in 2001, as compared to \$80.8 million or \$1.54 per share in 2000.

#### SEGMENT INFORMATION

Set forth below is a discussion of the operations of the Company's business segments: Polymer Additives, Performance Chemicals and Water Treatment. Operating income, which is the income measure the Company uses to evaluate business segment performance, represents net sales less costs of products sold and selling, general and administrative expenses. The operating income data presented below is before the special charges. Each of the Company's segments uses bromine as a raw material in their production process. Bromine is transferred at cost to all business segments. In addition, assets used in the production of bromine are allocated to each business unit based on the percentage of production consumed.

#### Polymer Additives

		2001		2000	
	-				
Net sales	\$	581.7	\$	690.1	
Operating income (loss)		(70.8)		52.4	

Net sales decreased \$108.4 million or 15.7% in 2001. A sharp decline in demand in several key end markets, particularly consumer electronics, automotive and information technology, affected both volume and price in 2001. The acquisition of the optical monomers business partially offset the decrease.

Operating income (loss) decreased \$123.2 million to a loss of \$(70.8) million for the year. Excluding the inventory write—downs, environmental costs and other repositioning items of \$41.6 million included in operating income (loss) in 2001 (see Note 2 to the Consolidated Financial Statements), operating income (loss) decreased \$81.6 million. This decrease was attributable to lower sales levels, production cutbacks to align inventories with customer order patterns and higher raw material and energy costs in the first half of 2001. These items more than offset the cost savings resulting from productivity and cost savings initiatives.

# **Performance Chemicals**

	2001	2000
Net sales	\$ 250.2	\$ 280.5
Operating income	60.9	100.2

Net sales decreased \$30.3 million or 10.8% from 2000 to 2001. This decrease was driven by lower than expected sales in the Fluorine business, predominately due to the significant slow–down in information technology and telecommunication infrastructure spending.

Operating income decreased \$39.3 million or 39.2% in the current year. Excluding inventory write—downs, environmental costs and other repositioning items of \$8.8 million included in operating income in 2001 (see Note 2 to the Consolidated Financial Statements), operating income decreased \$30.5 million. This decrease in operating income reflects the impact of the sharply lower sales volumes in the Fluorine businesses. These lower sales volumes had a negative impact on unabsorbed manufacturing costs throughout the year. These items more than offset the record—setting performance of WIL Research Laboratories in 2001.

### **Water Treatment**

		2001		2000	
Net sales		\$ 507.0	\$	474.5	
Operating income	20	54.1		85.0	

Water Treatment net sales increased 6.8% to \$507.0 million in the current year. New products capturing increased market share as well as the effects of the Aqua Clear acquisition drove the increase.

Operating income declined from \$85.0 million in 2000 to \$54.1 million in 2001. Excluding inventory write—downs, contract cancellation costs and other repositioning items included in operating income in 2001 of \$10.7 million (see Note 2 to the Consolidated Financial Statements), operating income declined \$20.2 million. The positive impact of increased sales was more than offset by higher raw material costs and production cutbacks to lower inventory levels. Higher selling and marketing costs necessary to drive future growth in the mass market channel also contributed to the decrease.

### **Discontinued operations**

The sale of the Company's Energy Services and Products business unit, OSCA, to BJ Services Company was completed on May 31, 2002. Under the terms of the sale, BJ Services acquired all outstanding shares of OSCA, including the Company's 53.2% holding, for \$28.00 per share in cash, or \$221 million, resulting in a gain of \$175.4 million. This transaction provided the Company with net proceeds of approximately \$200 million in cash, a part of which was used to reduce the Company's debt position. As a result of this transaction, the Company has reflected OSCA as discontinued operations for all periods presented.

During the second quarter of 2002, management, with the approval of the Board of Directors, committed to a plan to divest the Company's Fine Chemicals business, previously a part of the Performance Chemicals business unit. The Company is now engaged in efforts to sell the net assets of the Fine Chemicals business. As a result of these actions, the Company has reflected the Fine Chemicals business as discontinued operations for all periods presented.

Net sales and operating income (loss) relating to OSCA and Fine Chemicals for 2002, 2001 and 2000, are as follows:

Year ended December 31	2	2002		2001		2000	
Net sales							
OSCA	\$	58.1	\$	175.9	\$	131.9	
Fine Chemicals		55.2		66.0		88.7	
On anothing in course (love)							
Operating income (loss)		(1.5.0)		10.1		10.1	
OSCA		(16.3)		18.1		13.1	
Fine Chemicals		(33.7)		(154.0)		(19.2)	

Included in operating income (loss) in 2002 are special charges for the Fine Chemicals business of \$26.7 million, which include \$22.9 million of fixed asset

impairment charges and \$3.8 million of severance accruals. These charges were recorded in conjunction with the intended sale of the Fine Chemicals business. Net special charges recorded in 2001 for Fine Chemicals totaled \$118.5 million and consisted of \$106.0 million of asset impairments, including \$22.0 million of fixed asset impairments and \$84.0 million of impaired goodwill, \$5.8 million of severance accruals, \$5.1 million of plant closure and environmental costs and \$1.4 million of other costs, as well as adjustments of \$0.2 million related to special charges taken in 2000. The 2001 charges were undertaken as a part of a detailed repositioning plan approved by the Company's Board of Directors in 2001. Included in 2000 operating income (loss) in 2000 are net special charges of \$9.1 million, which reflect \$10 million of charges recorded in 2000 offset by a reversal of \$0.9 million related to reversals of certain charges taken in 1999 and 1998. The 2000 charges of \$10 million included \$5.8 million of asset impairments and \$4.2 million of severance accruals.

As of December 31, 2002, \$2.9 million of the \$26.7 million of special charges recorded in 2002 and \$7.9 million of the \$118.3 million of charges recorded in 2001 remains to be spent. There are no amounts outstanding related to charges taken in 2000.

#### FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents at December 31, 2002 were \$259.1 million, which represents an increase of \$203.6 million from \$55.5 million at year-end 2001.

Cash provided by operating activities – continuing operations was \$152.3 million in the current year compared to \$128.6 million in the prior year. Cash provided by operating activities in 2002 benefited from higher earnings and the Company's continued focus on working capital improvement. Included in operating activities – continuing operations in 2002 was approximately \$20 million of spending related to 2001 and 2000 repositioning plans.

Cash used for investing activities – continuing operations amounted to \$77.3 million in 2002 compared to \$161.6 million in the prior year. The decrease reflects the Company's emphasis on controlling capital expenditures, which were \$66.4 million lower than in the prior year. The current year investing activities also include the Flexsys acquisition of \$11.1 million. Investing activities in the prior year reflect the acquisition of the optical monomers business of approximately \$30 million.

Financing activities – continuing operations used \$101.9 million of cash in 2002 compared to a use of \$167.6 million in 2001. Net repayments of debt were \$80.5 million in the current year and \$156.8 million in 2001. The Company paid dividends of approximately \$16 million in both years. No repurchases of common stock were made in the current year. Repurchases of common stock totaled \$2.2 million in 2001.

In addition, as described in Note 3 to the Consolidated Financial Statements, the Company received net cash proceeds from the sale of OSCA of approximately \$200 million in the second quarter of 2002. The proceeds from the sale of OSCA and the related gain from the transaction have been reflected in the consolidated statements of cash flows as operating and financing activities from discontinued operations, respectively. These proceeds were used to reduce the Company's debt position, as reflected in the net repayments on borrowings, and to increase cash and cash equivalents from the prior year—end.

The Company anticipates that cash provided by operating activities in the future will be sufficient to fund its operating costs and expenses, debt service obligations, dividend payments to common shareholders and capital expenditures.

Long-term debt, less current portion decreased \$68.2 million to \$432.6 million from \$500.8 million at the end of the prior year reflecting the cash activity noted above. The Company's total long-term debt, including the current portion, as a percentage of total capitalization at December 31, 2002, was 37.1%. This compares to 45.5% at December 31, 2001. The Company's net debt, defined as total long-term debt less cash and cash equivalents, was \$181.5 million or 19.6% of capitalization at December 31, 2002. This compares to 42.6% at December 31, 2001.

On October 3, 2002, the Company renewed the 364–day portion of its unsecured revolving credit facility established on October 4, 2001. This 364–day credit facility was originally established along with a facility with a five–year term. Under these combined facilities, the Company may borrow up to \$462.5 million. These facilities are used to support the Company's commercial paper program. These facilities contain certain covenants that include, among others, requirements to limit the maximum ratio of Debt to EBITDA to 3.5 to 1, as defined in the agreement. Debt to EBITDA, as defined in the agreement, was 1.3 as of December 31, 2002. Interest on borrowings outstanding under the agreement is based upon a variable rate tied to LIBOR. There were no outstanding borrowings on these facilities as of December 31, 2002 and 2001.

During 1999, the Company sold \$400 million of 7% notes due July 15, 2009. The notes were sold under a shelf registration process. Under this process, the Company filed a Registration Statement on Form S–3 with the Securities and Exchange Commission and may sell various debt securities, common stock or rights or warrants to purchase common stock individually or in combination up to \$750 million. The unissued securities remaining on the registration statement is \$350 million at December 31, 2002. The registration provides the Company with increased flexibility to finance its growth. The amount and timing of any borrowings will depend on the Company's specific cash requirements.

At December 31, 2002, the Company's senior debt rating with Standard & Poor's and Moody's was A- and A2, respectively, and its commercial paper rating was A2 and P1, respectively.

As of December 31, 2002, the Company had the following contractual obligations for continuing operations:

### **Contractual Obligations:**

Pav	vments	Due	bv	Period

	_					-	_			
		Total	_	2003		2004 and 2005	_	2006 and 2007	_	2008 and beyond
Long-term debt	\$	440.6	\$	8.0	\$	5.6	\$	2.6	\$	424.4
Operating leases		48.9		10.7		14.0		11.4		12.8
Purchase obligations		38.5		11.0		22.0		5.5		_
Other noncurrent liabilities		60.0		6.5		5.9		4.0		43.6
	_		_		_		_		_	
Total contractual cash obligations	\$	588.0	\$	36.2	\$	47.5	\$	23.5	\$	480.8

As of December 31, 2002, the Company had a long-term arrangement that requires the purchase of raw materials to be used in operations. The arrangement requires the purchase of a supplier's output up to a maximum quantity of material at prices negotiated during the term of the contract. It is expected that all purchases under this arrangement will be utilized in production. Other noncurrent liabilities primarily relate to environmental liabilities and long-term employee benefit obligations.

No common stock share repurchases were made in the current year. The Company purchased approximately 0.1 million shares of common stock during 2001 at an average price of \$22 per share. At December 31, 2002, a total of 2.8 million shares remain available for repurchase under existing Board authorizations. Management continues to analyze share repurchases as cash flow, market conditions and investment opportunities warrant.

At December 31, 2002, the Company had guaranteed \$22.2 million of debt of an unconsolidated affiliate. The unconsolidated affiliate was in violation of several covenants related to its debt that the Company guarantees. The affiliate is currently negotiating with the respective lenders to amend its loan agreements. The banks have not called the loan, and the Company believes that a waiver or amendment will be received and has not recorded a liability as of December 31, 2002.

Capital expenditures (excluding acquisitions) in 2002 of \$64.8 million were significantly lower than the \$131.2 million spent a year ago. Major projects for which capital expenditures were incurred in 2001 included the replacement of the bromine extraction towers at the Company's El Dorado, Arkansas, facility, the expansion of a Polymer Additives manufacturing site in Ravenna, Italy, to achieve backward integration of a key raw material and the expansion of Water Treatment's Lake Charles, Louisiana, plant. Capital spending is expected to be above depreciation levels in 2003, with expenditures estimated to be in the \$85 million-\$90 million range. Future capital spending, including amounts for environmental and safety projects, is expected to be financed primarily with cash provided by operating activities and, if necessary, with available debt financing. Great Lakes

continues to evaluate potential acquisitions of facilities and/or businesses, particularly in the segments in which the Company currently does business or in market segments in which the Company believes it has synergistic competencies.

#### OTHER MATTERS

# **Special Charges and Repositioning**

# 2001

On June 27, 2001, the Company's Board of Directors approved a detailed repositioning plan which provides for a series of cost reduction initiatives which were intended to streamline operations, to strengthen the Company's competitive position and to continue to provide a strong platform for future growth. Additionally, on September 15 and December 6, 2001, the Company's Board of Directors approved an additional series of cost reduction initiatives developed to minimize the effects of the current economic conditions. The major components of these repositioning plans included the consolidation of certain Polymer Additives and Fine Chemicals operations, resulting in three planned plant closures; elimination of approximately 485 manufacturing, research and development, sales and other management positions; and the impairment of certain underperforming and non–strategic long–lived assets, including goodwill.

The special charges related to this repositioning plan totaled \$153.6 million, \$118.9 million after income taxes or \$2.36 per share for the year ended December 31, 2001. The special charges consisted of \$106.1 million of asset impairments, including \$61.3 million for fixed asset impairments and \$44.8 million of impaired goodwill, \$25.6 million of severance costs, \$15.3 million for plant closure and environmental costs and \$6.6 million of other costs.

Net special charges for the year ended December 31, 2001 totaled \$148.6 million, \$115.4 million after income taxes or \$2.29 per share. This reflects the \$153.6 million of charges recorded 2001 offset by a reversal of \$3.5 million related to changes in estimates in the 2001 special charge and certain reversals of the special charges taken in 2000 totaling \$1.5 million, as detailed below. The net effect of the special charge reversals after income taxes was \$3.7 million or \$0.07 per share. The net of the 2001 special charges and reversals are reflected in the 2001 consolidated statement of operations as a separate component of operating income. Additional information regarding the 2001 special charges is provided in Note 2 to the Consolidated Financial Statements.

As of December 31, 2002, \$15.7 million of the \$148.6 million charge remains to be spent. This remaining amount includes the effects of \$5.1 million of net special charges recorded in 2002 related to changes in estimates in the special charge reserves recorded in 2001. The major components of this remaining reserve relate to severance and plant closure costs yet to be spent for the two plant closures and the shutdown of two unprofitable product lines. The majority of the severance costs are expected to be paid out by the second quarter of 2003 and the plant closure and environmental costs by the end of 2005.

Also, during 2001 the Company recorded lower of cost or market inventory write—downs totaling \$25.7 million. These write—downs were recorded as a component of cost of products sold and resulted primarily from significant declines in forecasted revenue for the Polymer Additives business unit. In addition, the Water Treatment business incurred some lower of cost or market valuation adjustments due to some unsuccessful promotional inventory buys.

Additionally, as part of these repositioning actions, the Company recorded a \$24.5 million liability for environmental remediation costs, \$7.4 million for plant shutdown operating inefficiencies, a \$1.5 million cumulative U.K. pension liability, \$0.9 million of accounts receivable write—offs and \$1.0 million of contract cancellation costs. These items amounted to \$35.3 million and were recorded

in the 2001 consolidated statement of operations as follows: \$33.9 million to cost of products sold and \$1.4 million as a component of selling, general and administrative expenses.

Certain other charges were also recorded during 2001. These charges, which netted to \$33.8 million, included \$11.6 million related to the write—off of an uncollectible note receivable from the sale of a previously owned business, \$10.7 million for losses incurred on fixed asset replacement activities, primarily at one of the Company's U.S. plants, \$13.4 million of increases in litigation accruals resulting from estimated settlement amounts on outstanding litigation matters, a \$(3.2) million net foreign exchange gain arising from the repatriation of cash from a foreign subsidiary partially offset by a loss from a fair value adjustment on an intercompany loan of a foreign subsidiary and \$1.3 million of other costs. All of these charges are reflected in the 2001 consolidated statement of operations as a component of other income (expense) – net.

#### 2000

The major components of the repositioning plan included the consolidation of the Company's three antimony manufacturing operations, elimination of approximately 309 manufacturing and research and development positions, primarily in the Polymer Additives business unit, and impairment or disposal of certain underperforming and nonstrategic assets. The asset impairments related to four Polymer Additives manufacturing locations, including sites in Europe and the United States, and two Performance Chemicals locations, including sites in the United States and the United Kingdom. The special charges related to this repositioning plan totaled \$56.4 million, \$38.9 million after income taxes or \$0.77 per share for 2000. The \$56.4 million special charge consisted of \$38.0 million for asset impairments, \$12.2 million for severance costs and \$6.2 million for plant closure and environmental costs. Additional information regarding the 2000 special charges is provided in Note 2 to the Consolidated Financial Statements.

Net special charges for the year ended December 31, 2000 totaled \$54.3 million. This reflects the \$56.4 million charge offset by a reversals of \$2.1 million, which related to a change in estimate in the 2000 special charge and certain reversals of the special charges taken in 1999 and 1998. The net effect of the special charge reversals after income taxes was \$1.5 million or \$0.03 per share. The net of the 2000 special charges and reversals are reflected in the 2000 consolidated statement of operations as a separate component of operating income.

The 2000 repositioning plan has now been substantially completed, with only \$4.1 million of the original \$56.4 million remaining to be spent. The primary component of this remaining reserve, or \$4.0 million, relates to costs yet to be incurred for the closure of a brine pond in El Dorado, Arkansas. All of the 2000 remaining reserves are expected to be fully utilized by the end of 2005.

Cash outlays for all remaining special charge reserves are expected to be substantially complete by the end of 2005. Operating cash flows are expected to be sufficient to fund the remaining repositioning activities.

# Acquisitions

On December 3, 2002, the Company acquired certain assets of Flexsys America's non-staining phenolic antioxidants business for approximately \$11 million. Assets acquired included inventory, other intangibles and the process technology associated with Santonox® TBMC, Santovar® TAHQ and Santowhite® BBMC. Great Lakes will market these products under the Company's established line of Lowinox® non-staining antioxidants. Goodwill resulting from the acquisition amounted to approximately \$3 million.

On February 14, 2001, the Company acquired the Optical Monomers business from Akzo Nobel Polymer Chemicals LLC for approximately \$30 million in cash. The Optical Monomers business operates at a leased manufacturing site in Pasadena, Texas, and has sales and support networks

throughout the United States, Europe and Asia. This acquisition was accounted for using the purchase method of accounting with its results of operations included since the date of acquisition. Goodwill resulting from the acquisition amounted to \$11.5 million.

On July 14, 2000, the Company acquired Aqua Clear for \$40.7 million. Aqua Clear, a manufacturer and distributor of specialty pool chemical products, operated a manufacturing site in Watervliet, New York, which was closed in 2001. Aqua Clear continues to operate distribution sites in St. Louis, Missouri, and Waterford, New York, as well as sales and support networks throughout the United States and Canada. Goodwill resulting from the acquisition amounted to \$37.8 million.

These acquisitions were funded with available cash and borrowing capacity.

#### **Dispositions**

The sale of the Company's Energy Services and Products business unit, OSCA, to BJ Services Company was completed on May 31, 2002. Under the terms of the sale, BJ Services acquired all outstanding shares of OSCA, including the Company's 53.2% holding, for \$28.00 per share in cash, or \$221 million, resulting in a gain of \$175.4 million. This transaction provided the Company with net proceeds of approximately \$200 million in cash, a part of which was used to reduce the Company's debt position. As a result of this transaction, the Company has reflected OSCA as discontinued operations for all periods presented.

In each of the first and second quarters of 2001, the Company sold 250,000 shares of its Class B common stock of OSCA pursuant to Rule 144 under the Securities Act of 1933 for a total of 500,000 shares being sold for the year ended December 31, 2001. The terms of these transactions provided that upon the sale of these Class B shares, the shares were automatically converted to OSCA Class A common stock. Net proceeds were \$5.4 million and \$6.3 million and the related taxable gains were \$4.2 million and \$5.2 million for the first and second quarters of 2001, respectively. There were no sales in the third or fourth quarters of 2001.

Effective June 15, 2000, the Company had sold 40% of its ownership in OSCA through an initial public offering. Net proceeds of approximately \$79 million from the initial sale were paid to the Company by OSCA to satisfy indebtedness. The initial sale resulted in a \$51.9 million gain to the Company, which was recognized in the second quarter of 2000. Subsequently, on July 13, 2000, the over–allotment option granted to the underwriters was exercised and resulted in an additional \$12 million of net proceeds. The over–allotment exercise resulted in an additional gain to the Company of \$8.5 million, which was recorded in the third quarter of 2000. The initial sale and the over–allotment option exercise resulted in the Company selling a total of 43.4% of its ownership interest in this subsidiary.

#### **Environmental**

The Company is subject to various U.S. and international federal, state and local environmental, health and safety laws and regulations. The Company is also subject to liabilities arising under the Comprehensive Environmental Response Compensation and Liability Act ("CERCLA"), the Resource Conservation and Recovery Act ("RCRA") and similar state and international laws that impose responsibility for remediation of hazardous substances and hazardous waste constituents released into the environment.

The Company provides reserves for environmental liabilities that management considers probable and for which a reasonable estimate of the liability can be made. Accordingly, the Company's reserves for environmental liabilities, including reserves associated with restructuring charges, were approximately \$45.2 million and \$53.7 million at December 31, 2002 and 2001, respectively. While it is difficult to predict or determine the outcome of actions brought against the Company or the ultimate cost of environmental matters, management believes that the ultimate cost, if any, in excess

of the amounts already provided is not likely to have a material adverse effect on its consolidated financial position, consolidated results of operations or liquidity.

The Company's operating costs relating to environmental compliance and safety charged directly to expense were approximately \$30 million, \$40 million and \$36 million in 2002, 2001 and 2000, respectively.

#### Inflation

Inflation has not been a significant factor for the Company over the last several years. Management believes that the effect of inflation on Company operations will continue to be moderate for the foreseeable future.

# **New Accounting Standards**

In December 2002, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) 148, "Accounting for Stock-Based Compensation -Transition and Disclosure." The statement amends SFAS 123, "Accounting for Stock-Based Compensation," to provide alternative methods of transition to SFAS 123's fair value method of accounting for stock-based employee compensation. In addition, SFAS 148 requires disclosure in the Summary of Significant Accounting policies of the effects of the Company's accounting policy with respect to stock-based employee compensation on net income and earnings per share in annual and interim financial statements accounted for using the intrinsic value method prescribed by Accounting Principles Board Opinon (APB) 25, "Accounting for Stock Issued to Employees." The Company has adopted the disclosure requirements of SFAS 148 as of December 31, 2002

In June 2002, the FASB issued SFAS 146, "Accounting for Costs Associated with Exit or Disposal Activities." SFAS 146 requires that a liability for costs associated with exit or disposal activities be recognized when the liability is incurred rather than when an entity commits to an exit plan. SFAS 146 also provides that the liability be initially measured at fair value. The statement is effective for the Company beginning January 1, 2003. Management expects the new standard to have an impact on the timing of recognition of any future restructuring charges.

In October 2001, the FASB issued SFAS 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," which addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes SFAS 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of," and the accounting and reporting provisions of APB Opinion 30, "Reporting the Results of Operations for a Disposal of a Segment of a Business." SFAS 144 is effective for fiscal years beginning after December 15, 2001. The Company adopted SFAS 144 as of January 1, 2002. As a result of the application of SFAS 144 and the classification of the Energy Services and Products business unit (OSCA) and the Fine Chemicals portion of the Performance Chemicals business unit as discontinued operations (see Note 3 to the Consolidated Financial Statements), the Company was required to restate its consolidated financial position, results of operations and cash flows for all periods presented.

In June 2001, the FASB issued SFAS 143, "Accounting for Asset Retirement Obligations." The statement requires legal obligations associated with the retirement of long-lived assets to be recognized at their fair value at the time that the obligations are incurred. Upon initial recognition of a liability, the cost is capitalized as part of the related long-lived asset and allocated to expense over the useful life of the asset. The Company will adopt the new rules on asset retirement obligations effective January 1, 2003. The Company currently has legal obligations to plug bromine supply and disposal wells, as well as waste disposal wells, at the end of the assets' useful lives. Upon adoption, the Company will record an increase in plant and equipment, net of \$0.6 million and recognize an asset retirement obligation of \$5.7 million, resulting in a cumulative effect from a change in

accounting principle upon adoption that will reduce net income and stockholders' equity by \$3.5 million, net of income taxes.

In June 2001, the FASB issued SFAS 141, "Business Combinations," and SFAS 142, "Goodwill and Other Intangible Assets," effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill is no longer amortized but is subject to annual impairment tests in accordance with the statements. Intangible assets having finite lives will continue to be amortized over their useful lives. The pooling of interest method is no longer permitted for business combinations initiated after June 30, 2001. The Company adopted these new standards January 1, 2002.

The Company completed the transitional impairment tests required by SFAS 142 and determined that no impairment loss was incurred as a result of adopting the standard. The Company conducted its annual impairment testing during the fourth quarter of 2002 and determined that the fair values of its reporting units exceed the carrying values of those units.

#### ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk

The Company's operations are exposed to market risk from changes in foreign currency exchange rates, interest rates and natural gas prices that could impact its results of operations and financial condition. The Company manages its exposure to these market risks through its regular operations and financing activities and, when deemed appropriate, by using derivative financial instruments in accordance with established policies and procedures. The derivative financial instruments generally used include swaps, forward contracts and options. The derivative financial instruments utilized by the Company in its hedging activities are considered risk management tools and are not used for trading purposes. In addition, derivative financial instruments are entered into with a diversified group of major financial institutions in order to limit the exposure of nonperformance on such instruments.

International operations, including U.S. export sales, constitute a significant portion of the Company's revenues and identifiable assets. These operations result in a large volume of foreign currency commitment and transaction exposures and foreign currency net asset exposures. At December 31, 2002 and 2001, the Company's primary net foreign currency market exposures were dispersed through various countries and primarily included the euro and its legacy currencies, the British pound and the Japanese yen. Exposure to variability in currency exchange rates is mitigated, when possible, through the use of natural hedges, whereby purchases and sales in the same foreign currency and with similar maturity dates offset one another. The amount of hedging activity and management of commitment and transaction exposures is coordinated at the corporate level. Hedges are set to mature concurrently with the estimated timing of settlement of the underlying transactions.

Considering the Company's operating profile, at December 31, 2002, the result of a uniform 10% change in the value of the dollar relative to the currencies in which the Company's sales are denominated would result in a change in operating income of approximately \$4.5 million. A similar change in 2001 would have had approximately a \$1.7 million effect on operating income. This calculation assumes that each exchange rate would change in the same direction relative to the U.S. dollar, and does not factor in any potential changes in sales levels or local currency prices that may result from changes in exchange rates.

The Company uses commercial paper as a source of financing, which exposes the Company to changes in short–term interest rates. The Company manages its ratio of fixed to floating rate debt with the objective of achieving a mix that management believes is appropriate. To manage this mix in a cost effective manner, the Company, from time to time, enters into interest rate swap agreements in which it agrees to exchange various combinations of fixed and/or variable interest rates based on agreed–upon notional amounts that are supported by the Company's current debt position. In the first quarter of 2002, the Company entered into fixed–to–variable interest rate swaps to manage interest expense on \$75 million of fixed rate debt. No interest rate swaps were in place during 2001. Based

on the Company's debt position at December 31, 2002, a hypothetical change in interest rates of 1 percentage point for a one—year period would change income (loss) from continuing operations before income taxes by approximately \$1.0 million. This analysis does not consider any effect that a change in interest rates would have on overall economic activity or management actions to mitigate interest rate changes.

As of December 31, 2002, the Company had investments of \$154.8 million representing investment securities with maturities of three months or less. A hypothetical change in interest rates of 1 percentage point earned on these deposits for a one—year period would change income before income taxes by \$1.6 million.

Since the second quarter of 2001, as part of its risk management strategy, the Company has entered into fixed price swap and option contracts, including caps and floors, to manage its exposure to changes in natural gas prices. These natural gas contracts obligate the Company to make or receive a payment equal to the net change in the value of the contracts at their maturity. Such contracts are designated as hedges of the Company's forecasted purchases through 2003 and are effective in hedging the Company's exposure to changes in natural gas prices during this period.

The natural gas contracts that qualify as cash flow hedges under SFAS 133 are marked to market with unrealized gains and losses deferred through other comprehensive income (loss) and recognized in earnings when realized as an adjustment to cost of products sold. The fair value of these contracts at December 31, 2002 was immaterial to the Company's consolidated financial position.

Based on the Company's natural gas exposure at December 31, 2002, a hypothetical 10% change in natural gas prices for a one-year period would change income before income taxes by approximately \$1.0 million.

# ITEM 8. Financial Statements and Supplementary Data

# INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
Consolidated Statements of Operations for the years ended December 31, 2002, 2001 and 2000	31
Consolidated Balance Sheets at December 31, 2002 and 2001	32
Consolidated Statements of Cash Flows for the years ended December 31, 2002, 2001 and 2000	33
Consolidated Statements of Shareholders' Equity for the years ended December 31, 2002, 2001 and 2000	34
Notes to Consolidated Financial Statements	35
30	

# CONSOLIDATED STATEMENTS OF OPERATIONS

(millions, except per share data) Year Ended December 31		2002		2001		2000
Net Sales	\$	1,401.5	\$	1,352.8	\$	1,449.8
Operating Expenses						
Cost of products sold		1,070.2		1,121.1		1,033.2
Selling, general and administrative expenses		215.0		224.5		216.1
Special charges		5.1		148.6		54.3
		1,290.3		1,494.2		1,303.6
Operating Income (Loss)		111.2		(141.4)		146.2
Interest Income (Expense) – net		(27.6)		(32.8)		(31.6)
Other Income (Expense) – net		(14.9)		(46.8)		2.8
Income (Loss) from Continuing Operations before Income Taxes		68.7		(221.0)		117.4
Income Taxes (Credit)		21.3		(39.8)		36.6
Income (Loss) from Continuing Operations	\$	47.4	\$	(181.2)	\$	80.8
Discontinued Operations						
Income (Loss) from Discontinued Operations						
Before Minority Interest and Income Taxes	\$	121.6	\$	(131.4)	\$	49.8
Minority Interest		5.5		(4.5)		(2.3)
Income Taxes (Credit)		49.5		(27.6)		1.3
Income (Loss) from Discontinued Operations	\$	77.6	\$	(108.3)	\$	46.2
Net Income (Loss)	\$	125.0	\$	(289.5)	\$	127.0
					_	
Earnings (Loss) per Share:						
Basic and Diluted	*	0.61	Φ.	(0.50)	Φ.	
Continuing Operations	\$	0.94	\$	(3.60)	\$	1.54
Discontinued Operations		1.54		(2.16)		0.88
Net Income (Loss)	\$	2.48	\$	(5.76)	\$	2.42
Cash Dividends Declared per Share	\$	0.33	\$	0.32	\$	0.32

See Notes to Consolidated Financial Statements.

# CONSOLIDATED BALANCE SHEETS

2	2001
259.1	\$ 55.5
262.2	253.4
252.2	227.5
33.2	20.4
6.4	1.3
34.0	123.3
847.1	681.4
621.6	623.1
143.6	133.2
33.0 27.2	29.5 27.1
21.6	39.0
3.5	65.3
20.1	90.4
1,717.7	\$ 1,689.0
165.9	¢ 151.4
	\$ 151.4
117.0	131.4
108.3	88.7
4.5	4.0
8.0	10.9
14.5	43.7
418.2	430.1
432.6	500.8
103.1	67.9
12.1	34.6
6.0	5.3
_	36.8
73.0	73.0
133.7	133.3
1,682.7	1,574.2
(1,054.5)	(1,054.5)
(89.2)	(112.5)
745.7	613.5
	\$ 1,689.0
_	745.7

# CONSOLIDATED STATEMENTS OF CASH FLOWS

Year Ended December 31	2002	2001	2000
Operating Activities			
Income (loss) from continuing operations	\$ 47	.4 \$ (181.2	2) \$ 80.
Adjustments to reconcile income (loss) from continuing operations to net cash provided by			
operating activities – continuing operations:	7.0	7 70	21
Depreciation and depletion	76		
Amortization of intangible assets		.4 9.2	-
Provision for inventory write-downs		- 33.4 8)	
Deferred income taxes	`	.8) (96.7 .3 (0.7	,
Net (unremitted) earnings of affiliates			
Loss on disposition of assets		.5 10.2 .1 148.6	
Special charges Other	13		
	13	.4 0.4	9.
Changes in operating assets and liabilities, net of effects from business combinations:  Accounts receivable	0	.4 71.3	3 (43.
Inventories	(10		,
Other current assets	•		`
	,	,	,
Accounts payable and accrued expenses  Income taxes and other current liabilities	(12 11		,
	5		
Other noncurrent liabilities		.1 22.7	7 2.
Net Cash Provided by Operating Activities – Continuing Operations	152	.3 128.0	6 231.
Income (loss) from Discontinued Operations	77	.6 (108.3	3) 46.
Net operating activities – Discontinued Operations	(85	.1) 166.8	8 (71.
Net Cash (Used for) Provided by Operating Activities – Discontinued Operations Net Cash Provided by Operating Activities	(7 144	.5) 58.5 .8 187.	,
Investing Activities			
Dlant and aminorant additions	(64	0) (121.7	2) (122
Plant and equipment additions	(64	,	,
Business combinations, net of cash acquired	(11	.1) (30.4	4) (40.
Business combinations, net of cash acquired Proceeds from sale of assets	(11	.1) (30.4	4) (40. 5 (5.
Business combinations, net of cash acquired	(11	.1) (30.4	(40. 5 (5. (5. (40. (40. (40. (40. (40. (40. (40. (40
Business combinations, net of cash acquired Proceeds from sale of assets	(11	.1) (30.4 .4 1.4 .8) (1.5	(40. 55 (5. 55) (4.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations	(11 0 (1 (77 221	.1) (30.4 4 1.5 .8) (1.5 .3) (161.6	4)       (40.         5       (5.         (5)       (4.         6)       (183.         3)       76.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities	(11 0 (1 (77	.1) (30.4 4 1.5 .8) (1.5 .3) (161.6	4)       (40.         5       (5.         (5)       (4.         6)       (183.         3)       76.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities	(11 0 (1 (77 221 144	.1) (30.4 4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.9	(40. (40. (55. (5. (5. (4. (40. (40. (40. (40. (40. (40. (40.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short–term credit lines	(11 0 (1 (77 221 144	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.9	4) (40. 5 (5. 5) (4. 6) (183. 3) 76. 9) (107.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short–term credit lines Net repayments of commercial paper and other long–term obligations	(11 0 (1 (77 221 144	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.8	4)       (40.         5       (5.         (5)       (4.         (6)       (183.         3)       76.         (107.         2       3.         8)       (228.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short–term credit lines Net repayments of commercial paper and other long–term obligations Proceeds from stock options exercised	(11 0 (1 (77 221 144 (1 (80	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.8 - 0.2	4) (40. 5 (5. (5. (6) (183. 3) 76. (107. 2 3. 8) (228. 2 2.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short–term credit lines Net repayments of commercial paper and other long–term obligations Proceeds from stock options exercised Cash dividends paid	(11 0 (1 (77 221 144	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.5 .5) (15.5	4) (40. 5 (5. (5. (6) (183. 3) 76. (9) (107. 2 3. 8) (228. 2 2. 9) (16.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short–term credit lines Net repayments of commercial paper and other long–term obligations Proceeds from stock options exercised Cash dividends paid Repurchase of common stock	(11 0 (1 (77 221 144 (1 (80	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.5 .5) (15.5 .6) (2.5	4) (40. 5) (5. (5) (4. 6) (183. 3) 76. (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short–term credit lines Net repayments of commercial paper and other long–term obligations Proceeds from stock options exercised Cash dividends paid	(11 0 (1 (77 221 144 (1 (80	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.5 .5) (15.5	4) (40. 5) (5. (5) (4. 6) (183. 3) 76. (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short–term credit lines Net repayments of commercial paper and other long–term obligations Proceeds from stock options exercised Cash dividends paid Repurchase of common stock Other  Net Cash Used for Financing Activities – Continuing Operations	(11 0 (1 (77 221 144 (1 (80	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.8 .5) (15.5 .5) (15.5 .6.5 (15.5 .7) (2.2 .8) 1.9	4) (40. 5 (5. (5. (6) (183. 3) 76. (9) (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135. 9 (0.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short-term credit lines Net repayments of commercial paper and other long-term obligations Proceeds from stock options exercised Cash dividends paid Repurchase of common stock Other  Net Cash Used for Financing Activities – Continuing Operations Net Cash (Used for) Provided by Financing Activities – Discontinued Operations	(11 0 (1 (77 221 144 (1 (80 - (16 - (3 (101 (0)	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.6 .5) (15.9 .6.9) (167.6 .9) (167.6 .3) (4.6	4) (40. 5) (5. (5) (4. 6) (183. 3) 76. (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135. 9) (0. 6) (375. 0) 30.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short—term credit lines Net repayments of commercial paper and other long—term obligations Proceeds from stock options exercised Cash dividends paid Repurchase of common stock Other  Net Cash Used for Financing Activities – Continuing Operations Net Cash (Used for) Provided by Financing Activities – Discontinued Operations Net Cash Used for Financing Activities	(11 0 (1 (77 221 144 (1 (80 - (16 - (3 (101 (0) (102	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.6 .6.5) (15.9 .7 (2.2 .8) 1.9 .9) (167.6 .3) (4.6 .2) (171.6	4) (40. 4) (40. 5) (5. (5. (4. 6) (183. 3) 76. (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135. 9 (0. 6) (375. 0) 30. 6) (344.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short-term credit lines Net repayments of commercial paper and other long-term obligations Proceeds from stock options exercised Cash dividends paid Repurchase of common stock Other  Net Cash Used for Financing Activities – Continuing Operations Net Cash (Used for) Provided by Financing Activities – Discontinued Operations	(11 0 (1 (77 221 144 (1 (80 - (16 - (3 (101 (0) (102	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.6 .5) (15.9 .6.9) (167.6 .9) (167.6 .3) (4.6	4) (40. 4) (40. 5) (5. (5. (4. 6) (183. 3) 76. (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135. 9 (0. 6) (375. 0) 30. 6) (344.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short—term credit lines Net repayments of commercial paper and other long—term obligations Proceeds from stock options exercised Cash dividends paid Repurchase of common stock Other  Net Cash Used for Financing Activities – Continuing Operations Net Cash (Used for) Provided by Financing Activities – Discontinued Operations Net Cash Used for Financing Activities Effect of Exchange Rate Changes on Cash and Cash Equivalents	(11 (11 (77 221 144 (1 (80 	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.5 .5) (15.9 .6) (2.2 .8) 1.9 .9) (167.6 .3) (4.6 .2) (171.6 .7 7.5	4) (40. 4) (40. 5) (5. (5. (4. 6) (183. 3) 76. (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135. 9 (0. 6) (375. 0) 30. 6) (344. 3 (9.
Business combinations, net of cash acquired Proceeds from sale of assets Other  Net Cash Used for Investing Activities – Continuing Operations  Net Cash Provided by (Used for) Investing Activities – Discontinued Operations Net Cash Provided by (Used for) Investing Activities  Financing Activities  Net (repayments) borrowings under short—term credit lines Net repayments of commercial paper and other long—term obligations Proceeds from stock options exercised Cash dividends paid Repurchase of common stock Other  Net Cash Used for Financing Activities – Continuing Operations Net Cash (Used for) Provided by Financing Activities – Discontinued Operations Net Cash Used for Financing Activities	(11 0 (1 (77 221 144 (1 (80 - (16 - (3 (101 (0) (102 9	.1) (30.4 .4 1.5 .8) (1.5 .3) (161.6 .3 (12.5 .0 (173.5 .1) 5.2 .5) (156.6 .5) (15.5 .5) (15.5 .6.7 (2.5 .8) 1.5 .9) (167.6 .3) (4.6 .2) (171.6 .7 7.5	4) (40. 4) (40. 5) (5. (5. 5) (4. 6) (183. 3) 76. (107. 2 3. 8) (228. 2 2. 9) (16. 2) (135. 9 (0. 6) (375. 0) 30. 6) (344. 3 (9.

See Notes to Consolidated Financial Statements.

Cash and Cash Equivalents at End of Year

\$

259.1

\$

55.5

\$

218.6

# CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(millions)	Shares	2002 Amount	Shares	2001 Amount	Shares	2000 Amount
Common Stock						
Balance at January 1	73.0	\$ 73.0	73.0	\$ 73.0	72.9	\$ 72.9
Exercise of stock options net of shares exchanged		_			0.1	0.1
Balance at December 31	73.0	73.0	73.0	73.0	73.0	73.0
Additional Paid-In Capital						
Balance at January 1		133.3		132.5		132.0
Exercise of stock options net of shares exchanged		_		0.1		1.6
Tax benefits of early disposition of stock by optionees Restricted stock activity		— 0.9		0.7		0.2 1.0
Termination of shareholder's rights plan				0.7		1.0
Employee stock plan activity		(0.5)		_		(2.3)
Balance at December 31		133.7		133.3		132.5
Retained Earnings						
Balance at January 1		1,574.2		1,879.6		1,769.2
Net income		125.0		(289.5)		127.0
Dividends		(16.5)		(15.9)		(16.6)
Balance at December 31		1,682.7		1,574.2		1,879.6
Treasury Stock						
Balance at January 1	(22.8)	(1,054.5)	(22.7)	(1,052.3)	(18.4)	(923.5)
Shares repurchased	(22.0)	(1,03 1.3)	(0.1)	(2.2)	(4.5)	, ,
Employee stock plan activity		_		_	0.2	6.3
Balance at December 31	(22.8)	(1,054.5)	(22.8)	(1,054.5)	(22.7)	(1,052.3)
Accumulated Other Comprehensive Income (Loss)						
Cumulative Translation Adjustment						
Balance at January 1		(109.4)		(82.0)		(55.5)
Translation adjustment		54.1		(27.4)		(26.4)
Other						(0.1)
Balance at December 31		(55.3)		(109.4)		(82.0)
Minimum Pension Liability						
Balance at January 1		(1.8)		(1.1)		(1.0)
Minimum pension liability adjustment						
[net of taxes (credit) of \$(15.0), \$(0.4) and \$(0.1)]		(32.1)		(0.7)		(0.1)
Balance at December 31		(33.9)		(1.8)		(1.1)
Unrealized gain (loss) on derivative instruments						
Balance at January 1		(1.3)		_		_
Derivative activity [net of taxes (credit) of \$0.7 and \$(0.7)]		1.3		(1.3)		
Balance at December 31		_		(1.3)		
Total Balance at December 31		(89.2)		(112.5)		(83.1)
Total Stockholders' Equity	50.2	\$ 745.7	50.2	\$ 613.5	50.3	\$ 949.7
Comprehensive Income (Loss)						
Net income (loss)		\$ 125.0		\$ (289.5)		\$ 127.0
Translation adjustment		54.1		(27.4)		(26.4)
Minimum pension liability adjustment		(32.1)		(0.7)		(0.1)
Unrealized gain (loss) on derivative instruments		1.3		(1.3)		_
Total Comprehensive Income (Loss)		\$ 148.3		\$ (318.9)		\$ 100.5

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in millions, except as indicated)

## NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

## **Nature of Operations**

The Company is a diversified specialty chemical company. Primary manufacturing operations are located in the United States, Europe and Asia. The Company manages its business and reports segment information based on the nature of its products and services. The Company's segments include Polymer Additives, Performance Chemicals and Water Treatment. The Company's products are sold globally. The principal markets include: computer and business equipment, consumer electronics, data processing, construction materials, telecommunications, pharmaceuticals and pool and spa dealers and distributors.

In May 2002, the Company sold its remaining ownership in OSCA, Inc. (OSCA), formerly the Energy Services and Products business unit. The results of the Energy Services and Products business through May 2002 are reported as discontinued operations for all periods presented.

During the second quarter of 2002, the Company committed to a plan to divest the Fine Chemicals portion of the Performance Chemicals segment. As a result of these actions, the Company has reflected the Fine Chemicals business as discontinued operations for all periods presented.

Further information on the Company's segments is included in Note 15 to the Consolidated Financial Statements.

#### **Principles of Consolidation**

The consolidated financial statements include all significant majority-owned subsidiaries of the Company. All material intercompany accounts and transactions are eliminated in consolidation.

#### **Investments**

Investments in less than majority—owned entities (20% to 50% ownership) in which the Company does not have the ability to exercise significant influence over operating and financial policies of the investees are accounted for by the equity method, which is cost, plus equity in their undistributed earnings since acquisition. All other investments are carried at their fair values or at cost, as appropriate.

### **Use of Estimates**

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

### **Revenue Recognition**

Revenue from sales of products, including amounts billed to customers for shipping and handling costs, is recognized at the time (1) ownership and all risks of loss have been transferred to the buyer, which is generally upon shipment, (2) the price is fixed and determinable and (3) collectibility is reasonably assured. Provisions for discounts and rebates and returns and other adjustments are provided for in the period the related sales are recorded. Revenue from services is recognized when the services are rendered.

## **Shipping and Handling Costs**

Shipping and handling costs, including certain warehousing costs, are included in cost of products sold.

### **Cash Equivalents**

Investment securities with maturities of three months or less when purchased are considered to be cash equivalents.

#### Inventories

The Company values its inventories at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method.

### Plant and Equipment

Plant and equipment are stated at cost. Depreciation of buildings and equipment is provided over the estimated useful lives of the assets using the straight–line method. The estimated useful lives for purposes of computing depreciation are: buildings, 10–40 years; manufacturing equipment, 7–20 years; and office equipment, 3–5 years.

### Goodwill

Effective January 1, 2002, goodwill, the excess of investment over fair value of net assets acquired, is tested annually, or when events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying value. In prior years, goodwill was amortized over periods of 8 years to 40 years using the straight–line method. As of December 31, 2002 and 2001, accumulated goodwill amortization was \$28.5 million and \$26.7 million, respectively.

### Impairment of Long-Lived Assets and Intangible Assets

When events or circumstances indicate that the carrying amount of long—lived assets to be held and used or intangible assets might not be recoverable, the expected future undiscounted cash flows from the assets is estimated and compared with the carrying amount of the assets. Intangible assets are stated on the basis of cost and are being amortized by the straight—line method over the estimated future periods to be benefited. If the sum of the estimated undiscounted cash flows is less than the carrying amount of the assets, an impairment loss is recorded. The impairment loss is measured by comparing the fair value of the assets with their carrying amounts. Fair value is determined based on discounted cash flow or appraised values, as appropriate. Long—lived assets that are held for sale are reported at the lower of the assets' carrying amount or fair value less costs related to the assets' disposition.

### **Environmental Costs**

The Company participates in environmental assessments and remediation efforts at operating facilities, previously owned or operated facilities, or other waste sites. Costs related to these efforts are accrued when it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Liabilities for estimated remediation costs are recorded at undiscounted amounts, are based on experience and are regularly evaluated as efforts proceed.

### **Income Taxes**

Current income taxes are provided on income reported for financial statement purposes adjusted for transactions that do not enter into the computation of income taxes payable. Deferred income tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income taxes are provided on the portion of the income of foreign affiliates that is expected to be remitted to the parent company and be taxable. Unremitted earnings of foreign affiliates where income taxes have not been provided are immaterial.

### **Treasury Stock**

Shares of common stock repurchased under the Company's stock repurchase plans are recorded at cost as treasury stock. When the treasury shares are reissued, the Company uses a weighted–average method for determining cost. The difference between the cost of the shares and the reissuance price is included in additional paid–in capital.

## Stock-Based Compensation

Statement of Financial Accounting Standards (SFAS) 123, "Accounting for Stock-Based Compensation," as amended by SFAS 148, "Accounting for Stock-Based Compensation – Transition and Disclosure," established accounting and disclosure requirements using a fair value-based method of accounting for stock-based employee compensation plans. As provided for under SFAS 123, the Company accounts for stock-based compensation using the intrinsic value method prescribed in Accounting Principles Board Opinion 25, "Accounting for Stock Issued to Employees." Compensation cost for stock options, if any, is measured as the excess of the quoted market price of the Company's stock at the date of grant over the amount an employee must pay to acquire the stock. Compensation cost for restricted stock awards is recorded over the requisite vesting periods based on the market value on the date of grant. The compensation expense incurred in 2002, 2001 and 2000 related to restricted stock awards totaled \$0.9 million, \$0.7 million and \$1.0 million, respectively.

The following is a reconciliation of reported income (loss) from continuing operations and earnings per share to income (loss) from continuing operations and related earnings per share as if the Company used the fair value method of accounting for stock—based compensation.

	2002		2001		2000
				_	
Income (loss) – continuing operations	\$	47.4	\$	(181.2)	\$ 80.8
Stock-based employee compensation expense included in reported income, net of tax		0.6		0.5	0.1
Total stock-based employee compensation expense determined under fair value-based					
method, for all awards, net of tax		(4.6)		(3.4)	(3.9)
Pro forma income (loss) – continuing operations	\$	43.4	\$	(184.1)	\$ 77.0
Earnings per share – continuing operations					
As reported:					
Basic	\$	0.94	\$	(3.60)	\$ 1.54
Diluted	\$	0.94	\$	(3.60)	\$ 1.54
Pro forma:					
Basic	\$	0.86	\$	(3.66)	\$ 1.47
Diluted	\$	0.86	\$	(3.66)	\$ 1.47

## **Foreign Currency Translation**

Assets and liabilities of most foreign subsidiaries are translated at exchange rates in effect at the balance sheet date, and the statements of operations are translated at the average monthly exchange rates for the period. Translation gains and losses are recorded as a component of accumulated other comprehensive (loss) income in stockholders' equity until the foreign entity is sold or liquidated. Foreign currency transaction gains and losses are included in net income.

## **Derivative Financial Instruments**

The Company uses various derivative instruments including swaps, forward contracts and options to manage certain foreign currency, interest rate and natural gas price exposures. These instruments are entered into under the Company's corporate financial risk management policy to manage market

risk exposures and are not used for trading purposes. Management routinely reviews the effectiveness of the use of derivative instruments.

Derivatives used for hedging purposes must be designated as, and effective as, a hedge of the identified risk exposure at the designation of the contract. Accordingly, changes in the market value of the derivative contract must be highly correlated with changes in the market value of the underlying hedged item at inception of the hedge and over the life of the hedge contract. Any derivative instrument terminated, designated but no longer effective as a hedge or initially not effective as a hedge would be recorded at market value and the related gains and losses would be recognized in earnings. Derivatives not designated as hedges are adjusted to fair value through the consolidated statement of operations.

The Company recognizes all derivative instruments as either assets or liabilities in the consolidated balance sheets at fair value. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company designates the hedging instrument, based upon the exposure being hedged, as a fair value, cash flow or a hedge of a net investment in a foreign operation.

The Company classifies its derivative financial instruments as held or issued for purposes other than trading. Gains and losses on hedges of existing assets and liabilities are included in other income (expense) – net. Gains and losses from hedges of anticipated transactions are classified in the statement of operations consistent with the accounting treatment of the items being hedged.

### Reclassifications

Certain amounts in the prior year financial statements and related notes have been reclassified to conform to the current year presentation.

### **New Accounting Standards**

In December 2002, the Financial Accounting Standards Board (FASB) issued SFAS 148, "Accounting for Stock—Based Compensation – Transition and Disclosure." The statement amends SFAS 123, "Accounting for Stock—Based Compensation," to provide alternative methods of transition to SFAS 123's fair value method of accounting for stock—based employee compensation. In addition, SFAS 148 requires disclosure in the Summary of Significant Accounting Policies of the effects of the Company's accounting policy with respect to stock—based employee compensation on net income and earnings per share in annual and interim financial statements accounted for using the intrinsic value method prescribed by Accounting Principles Board Opinon (APB) 25, "Accounting for Stock Issued to Employees." The Company has adopted the disclosure provision of this statement as of December 31, 2002.

In June 2002, the FASB issued SFAS 146, "Accounting for Costs Associated with Exit or Disposal Activities." SFAS 146 requires that a liability for costs associated with exit or disposal activities be recognized when the liability is incurred rather than when an entity commits to an exit plan. SFAS 146 also provides that the liability be initially measured at fair value. The statement is effective for the Company beginning January 1, 2003. Management expects the new standard to have an impact on the timing of recognition of any future restructuring charges.

Effective January 1, 2002, the Company adopted SFAS 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," which addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes SFAS 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of," and the accounting and reporting provisions of APB Opinion No. 30, "Reporting the Results of Operations for a Disposal

of a Segment of a Business." OSCA and the Fine Chemicals portion of the Performance Chemicals business unit are reported as discontinued operations (see Note 3 to the Consolidated Financial Statements). As a result, the Company restated its consolidated financial position, results of operations and cash flows for all periods presented.

In June 2001, FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations," which will be effective for the Company January 1, 2003. The statement requires legal obligations associated with retirement of long—lived assets to be recognized at their fair value at the time that the obligations are incurred. Upon initial recognition of a liability, that cost should be capitalized as part of the related long—lived asset and allocated to expense over the useful life of the asset. The Company currently has legal obligations to plug bromine supply and disposal wells, as well as waste disposal wells, at the end of the assets useful lives. Upon adoption, the Company will record an increase in plant and equipment, net of \$0.6 million and recognize an asset retirement obligation of \$5.7 million, resulting in a cumulative effect from a change in accounting principle upon adoption that will reduce net income and stockholders' equity by \$3.5 million, net of income taxes.

In June 2001, the FASB issued SFAS 141, "Business Combinations," and SFAS 142, "Goodwill and Other Intangible Assets." The Company adopted these new standards January 1, 2002. Under the new rules, goodwill is no longer amortized but is subject to annual impairment tests in accordance with the statement. Other intangible assets continue to be amortized over their estimated useful lives.

With the adoption of SFAS 142, the Company ceased amortization of goodwill as of January 1, 2002. The following table provides a reconciliation of reported income (loss) from continuing operations, net of income taxes, and the associated earnings (loss) per share to amounts adjusted to reflect the exclusion of goodwill amortization, net of related income taxes.

	2002		2001			2000
Income (loss) – Continuing Operations:						
Reported income (loss) – continuing operations	\$	47.4	\$	(181.2)	\$	80.8
Add: Goodwill amortization, net of related income taxes		_		4.5		5.8
			_			
Adjusted income (loss) – continuing operations	\$	47.4	\$	(176.7)	\$	86.6
•					_	
Basic and Diluted Earnings per Share:						
Reported income (loss) per share – continuing operations	\$	0.94	\$	(3.60)	\$	1.54
Add: Goodwill amortization, net of related income taxes		_		0.09		0.11
Adjusted income (loss) per share – continuing operations	\$	0.94	\$	(3.51)	\$	1.65

The Company completed the transitional impairment tests required by SFAS 142 and determined that there was no impairment loss as a result of the adoption. The Company conducted its annual impairment testing during the fourth quarter of 2002 and has determined that the fair values of its reporting units exceed the carrying values of those units.

The following tables include information regarding the carrying values and related amortization expense of intangible assets as of and for the periods ended December 31, 2002 and 2001.

		_	2002 Gross Carrying Amount	2002 Accumulated Amortization	2001 Gross Carrying Amount	2001 Accumulated Amortization
$\mathbf{A}$	mortized Intangible Assets:					
	Non-compete agreements	\$	8.4	\$ (3.6)	\$ 5.5	\$ (2.5)
	Patents, trademarks and licenses		5.0	(3.6)	4.3	(3.2)
	Intellectual property		17.0	(2.6)	15.7	(1.7)
	Customer-related		11.4	(2.0)	8.6	(1.6)
	Other		6.4	(3.4)	7.4	(3.0)
	Total	\$	48.2	\$ (15.2)	\$ 41.5	\$ (12.0)

Amortization expense for the year ended December 31, 2002 was \$3.4 million. Future amortization expense for the next five years is estimated to be as follows: 2003 – \$3.5 million; 2004 – \$2.9 million; 2005 – \$2.2 million; 2006 – \$2.1 million; and 2007 – \$2.1 million.

On December 3, 2002, the Company acquired certain assets of Flexsys America's non-staining phenolic antioxidants business. Included in these assets were \$6 million of intangibles, which consisted of a \$2.7 million non-compete agreement, \$0.5 million of intellectual property and \$2.8 million of customer-related intangibles. These amounts have been included in the above table.

The changes in the carrying amount of goodwill for the years ended December 31, 2001 and 2002, are as follows:

	Polymer Additives		Water Treatment		Total
Goodwill:					
Balance as of January 1, 2001	\$ 109.0	\$	75.9	\$	184.9
Goodwill acquired	10.7		_		10.7
Goodwill impaired	(41.9)		_		(41.9)
Purchase accounting adjustments	(5.9)		(8.8)		(14.7)
Goodwill amortization expense	(3.3)		(3.2)		(6.5)
Effects of foreign currency	0.4		0.3		0.7
Balance as of December 31, 2001	\$ 69.0	\$	64.2	\$	133.2
Goodwill acquired	3.1		_		3.1
Effects of foreign currency	 5.3		2.0		7.3
Balance as of December 31, 2002	\$ 77.4	\$	66.2	\$	143.6
40				_	

## **NOTE 2: SPECIAL CHARGES**

### 2001 Repositioning Plan

On June 27, 2001, the Company's Board of Directors approved a detailed repositioning plan which provides for a series of cost reduction initiatives which were intended to further streamline operations, strengthen the Company's competitive position and continue to provide a strong platform for future growth. Additionally, on September 15, 2001 and December 6, 2001, the Company's Board of Directors approved an additional series of cost reduction initiatives developed to minimize the effects of the current economic conditions. The major components of these repositioning plans included the consolidation of certain Polymer Additives operations, resulting in two plant closures; elimination of approximately 485 manufacturing, research and development, sales and other management positions; and the impairment of certain underperforming and non–strategic long–lived assets, including goodwill.

The special charges related to this repositioning plan and included in continuing operations totaled \$153.6 million, \$118.9 million after income taxes, or \$2.36 per share, for the year ended December 31, 2001. The special charges consisted of \$106.1 million of asset impairments, including \$61.3 million for fixed asset impairments and \$44.8 million of impaired goodwill, \$25.6 million of severance costs, \$15.3 million for plant closure and environmental costs and \$6.6 million of other costs.

Net special charges for the year ended December 31, 2001 totaled \$148.6 million, \$115.2 million after income taxes or \$2.29 per share. This reflects the \$153.6 million of charges recorded in 2001 offset by a reversal of \$3.5 million related to changes in estimates in the 2001 special charges and certain reversals of the special charges taken in 2000 totaling \$1.5 million, as detailed below. The net effect of the special charge reversals after income taxes was \$3.7 million or \$0.07 per share. The net of the 2001 special charges and reversals are reflected in the 2001 consolidated statement of operations as a separate component of operating income.

A reconciliation of the reserve balance at December 31, 2002 and the activity (including the effects of foreign exchange) of the reserve in 2002 is as follows:

	Reserve	Adjustments		Reserve
	Balance at	to Original		Balance at
	December 31,	Reserve	2002	December 31,
Description	2001	Estimates	Activity	2002

Asset Impairment (non-cash):					
Polymer Additives	\$	— \$	6.0 \$	(6.0) \$	_
	-				
		_	6.0	(6.0)	_
Severance Costs:					
Polymer Additives		16.4	(1.6)	(10.5)	4.3
Performance Chemicals		0.2	_	(0.1)	0.1
Water Treatment		0.1	_	(0.1)	_
Corporate		1.7	_	(1.4)	0.3
		18.4	(1.6)	(12.1)	4.7
Plant Closure and Environmental:		15.4	1.0	(6.1)	10.3
Polymer Additives		13.4	1.0	(6.1)	10.3
Other (Corporate)		2.1	(0.3)	(1.1)	0.7
	\$	35.9 \$	5.1 \$	(25.3) \$	15.7
	Ψ	33.7 ¥	3.1 ψ	(23.3) ψ	13.7
		41			

As of December 31, 2002, \$15.7 million of the \$148.6 million charge remains to be spent. This remaining amount includes the effects of \$5.1 million of net special charges recorded in 2002 related to changes in estimates in the special charge reserves recorded in 2001. The major components of this remaining reserve relate to severance and plant closure costs yet to be spent for the two plant closures and the shutdown of two unprofitable product lines. The majority of the severance costs are expected to be paid out by the second quarter of 2003 and the plant closure and environmental costs by 2005.

Also, during 2001 the Company recorded lower of cost or market inventory write—downs totaling \$25.7 million. These write—downs were recorded as a component of cost of products sold and resulted primarily from significant declines in forecasted revenue for the Polymer Additives business unit. In addition, the Water Treatment business incurred some lower of cost or market valuation adjustments due to some unsuccessful promotional inventory buys.

Additionally, as part of these repositioning actions, the Company recorded a \$24.5 million liability for environmental remediation costs, \$7.4 million for plant shutdown operating inefficiencies, a \$1.5 million cumulative U.K. pension liability, \$0.9 million of accounts receivable write—offs and \$1.0 million of contract cancellation costs. These items amounted to \$35.3 million and were recorded in the 2001 consolidated statement of operations as follows: \$33.9 million to cost of products sold and \$1.4 million as a component of selling, general and administrative expenses.

Certain other charges were also recorded during 2001. These charges, which netted to \$33.8 million, included \$11.6 million related to the write—off of an uncollectible note receivable from the sale of a previously owned business, \$10.7 million for losses incurred on fixed asset replacement activities, primarily at one of the Company's U.S. plants, \$13.4 million of increases in litigation accruals resulting from estimated settlement amounts on outstanding litigation matters, a \$(3.2) million net foreign exchange gain arising from the repatriation of cash from a foreign subsidiary partially offset by a loss from a fair value adjustment on an intercompany loan of a foreign subsidiary and \$1.3 million of other costs. All of these charges are reflected in the 2001 consolidated statement of operations as a component of other income (expense) – net.

The following paragraphs provide detailed information relating to the special charges and inventory write—downs that were recorded in 2001. Litigation and environmental liability updates are contained in Note 18 – Commitments and Contingencies.

## SPECIAL CHARGES

## **Asset Impairments**

Asset impairment losses in Polymer Additives related to the closure of an underperforming operating site in the U.S. and one site in Europe. These charges included the impairment of fixed assets at each site and \$18.4 million of impaired goodwill attributable to the sites. In addition, these losses included the impairment of certain non–strategic bromine and flame retardant production assets at two U.S operating sites and the impairment of \$26.4 million of goodwill related to the 1997 acquisition of the antimony products business. The asset impairment charges for Performance Chemicals included the shut–down of two unprofitable product lines at a U.S. manufacturing site.

These impairment losses adjusted the carrying value of these assets to fair value. Fair value was determined using discounted cash flows for goodwill and for fixed assets either discounted cash flows or appraised values as appropriate. Any impaired fixed assets held for disposal were written down to fair value less costs of disposal. The adjusted carrying value of the assets, classified as held for use, are being depreciated or amortized over the estimated remaining lives of the assets.

### **Severance Costs**

Severance costs included the cost of separation payments to certain employees who were terminated. Determinations of the severance costs were negotiated individually with the employee, were based upon the provisions of statutory or contractual severance plans or, for the European locations, were negotiated with their unions and workers' councils. The severance charges included severance costs for the termination of approximately 485 positions. The severance plans include approximately 439 positions for Polymer Additives, four positions for Performance Chemicals and 42 positions for Water Treatment and Corporate.

### Plant Closure, Environmental and Other

The plant closure and environmental costs associated with the 2001 special charges related primarily to closure costs such as dismantling, decontamination and remediation that were or will be incurred in conjunction with the closure of the two operating sites discussed previously.

The other costs related primarily to legal and consulting costs associated with the special charge activities, the write—off of certain components of the Company's data processing software proprietary to one of the operating sites being closed, the write—off of certain spare parts inventories associated with the impaired fixed assets and costs resulting from the termination of an equipment lease.

### Inventory Write-Downs

The Company recorded a lower of cost or market inventory write—down totaling \$25.7 million during 2001. These inventory write—downs included \$13.0 million related to the Polymer Additives business unit, \$3.8 million to Performance Chemicals and \$8.9 million to Water Treatment. The Polymer Additives portion of the write—down reflected market adjustments resulting from declines in customer demand, and the Water Treatment portion provided for the revaluation of inventory resulting from some unsuccessful promotional inventory buys. These write—downs were calculated in accordance with the Company's inventory valuation accounting policies.

### 2000 Repositioning Plan

The major components of the 2000 repositioning plan included the consolidation of the Company's three antimony manufacturing operations, elimination of approximately 309 manufacturing and research and development positions, primarily in the Polymer Additives business unit, and impairment or disposal of certain underperforming and nonstrategic assets. The asset impairments related to four Polymer Additives manufacturing locations, including sites in Europe and the United States, and two Performance Chemicals locations, including sites in the United States and United Kingdom. The special charges related to this repositioning plan and included in continuing operations totaled \$56.4 million, \$38.9 million after income taxes or \$0.77 per share for 2000. The \$56.4 million special charge consisted of \$38.0 million for asset impairments, \$12.2 million for severance costs and \$6.2 million for plant closure and environmental costs.

Net special charges for the year ended December 31, 2000 totaled \$54.3 million. This reflected the \$56.4 million charge offset by reversals of \$2.1 million, which related to a change in estimate in the 2000 special charges and certain reversals of special charges taken in 1999 and 1998. The net effect of the special charge reversals after income taxes was \$1.5 million or \$0.03 per share. The net of the 2000 special charges and reversals are reflected in the 2000 consolidated statement of operations as a separate component of operating income.

A reconciliation of the reserve balance at December 31, 2002 and the 2002 activity in the reserve is as follows:

Description	Bala Dece	serve ance at nber 31,	-	2002 ctivity	B	Reserve alance at cember 31, 2002
Severance Costs:						
Polymer Additives	\$	0.2	\$	(0.1)	\$	0.1
Plant Closure and Environmental:						
Polymer Additives		4.5		(0.5)		4.0
	\$	4.7	\$	(0.6)	\$	4.1

The remaining 2000 reserves consist primarily of plant closure and environmental costs related to the closure of a brine pond in El Dorado, Arkansas.

#### NOTE 3: DISCONTINUED OPERATIONS

The sale of the Company's Energy Services and Products business unit, OSCA, to BJ Services Company was completed on May 31, 2002. Under the terms of the sale, BJ Services acquired all outstanding shares of OSCA, including the Company's 53.2% holding, for \$28.00 per share in cash or \$221 million, resulting in a gain of \$175.4 million. This transaction provided the Company with net proceeds of approximately \$200 million in cash, a part of which was used to reduce the Company's debt position. As a result of this transaction, the Company has reflected OSCA as discontinued operations for all periods presented.

During the second quarter of 2002, management, with the approval of the Board of Directors, committed to a plan to divest the Company's Fine Chemicals business, previously a part of the Performance Chemicals business unit. The Company is now engaged in efforts to sell the net assets of the Fine Chemicals business. As a result of these actions, the Company has reflected the Fine Chemicals business as discontinued operations for all periods presented.

The operating results from discontinued operations presented in the accompanying consolidated statements of operations are as follows:

Year Ended December 31		 2002	2001		2000
Net sales		 			
OSCA		\$ 58.1	\$ 175.9	\$	131.9
Fine Chemicals		55.2	66.0		88.7
Special charges – Fine Chemicals		26.7	118.5		9.1
Operating income (loss)					
OSCA		(16.3)	18.1		13.1
Fine Chemicals		(33.7)	(154.0)		(19.2)
Gain on sale of subsidiary stock – OSCA		175.4	9.4		60.4
Interest income (expense) – net		(0.4)	(1.3)		(1.0)
Other income (expense) – net		2.1	(8.1)		(5.8)
Income (loss) before income taxes		\$ 127.1	\$ (135.9)	\$	47.5
Income taxes (credit)		49.5	(27.6)		1.3
Income (loss) from discontinued operations		\$ 77.6	\$ (108.3)	\$	46.2
	44			_	

Included in special charges for the Fine Chemicals business in 2002 are \$22.9 million of fixed asset impairment charges and \$3.8 million of severance accruals. These charges were recorded in conjunction with the intended sale of the Fine Chemicals business. Fine Chemicals net special charges recorded in 2001 of \$118.5 million consisted of \$106.0 million of asset impairments, including \$22.0 million of fixed asset impairments and \$84.0 million of impaired goodwill, \$5.8 million of severance accruals, \$5.1 million of plant closure and environmental costs and \$1.4 million of other costs, as well as adjustments of \$0.2 million related to special charges taken in 2000. The 2001 charges were undertaken as a part of a detailed repositioning plan approved by the Company's Board of Directors in 2001. Included in 2000 operating income (loss) in 2000 are net special charges of \$9.1 million, which reflect \$10 million of charges recorded in 2000 offset by a reversal of \$0.8 million related to reversals of certain charges taken in 1999 and 1998. The 2000 charges of \$10 million included \$5.8 million of asset impairments and \$4.2 million of severance accruals.

Also included in 2002 operating income for Fine Chemicals are \$3.7 million of inventory write—downs. Fine Chemicals operating income in 2001 included \$18.9 million of inventory write—downs recorded as a part of the 2001 repositioning plan.

During 1997, the Board of Directors approved a plan to exit the furfural and derivatives business, Chemol and environmental services businesses. A portion of the Chemol business was sold during 1998, and essentially all remaining operations were concluded. The environmental services business was sold in January 1999, and the furfural and derivatives business was sold in June 1999. Remaining reserves for the 1997 discontinued operations amounted to \$1.7 million and \$3.4 million at December 31, 2002 and 2001, respectively. Net assets (liabilities) of the 1997 discontinued operations amounting to \$(0.3) million and \$(1.1) million have been included in other assets in the consolidated balance sheets at December 31, 2002 and 2001, respectively.

Included in the other income (expense) – net above in 2002 are charges of \$1.4 million related to the 1997 discontinued operations.

The assets and liabilities held for sale from discontinued operations related to OSCA and Fine Chemicals presented in the accompanying consolidated balance sheets are comprised of:

December	2	2002		2001
Current Assets:				
Cash and cash equivalents	\$	0.3	\$	16.2
Accounts receivable		14.0		57.1
Inventories		11.5		47.5
Prepaid expenses and other current assets		8.2		2.5
Total current assets	\$	34.0	\$	123.3
Non-Current Assets:				
Plant and equipment, net	\$	14.2	\$	88.5
Goodwill and other assets		5.9		1.9
Total non-current assets	\$	20.1	\$	90.4
Current Liabilities:				
Accounts payable and accrued expenses	\$	14.5	\$	43.5
Current portion, long-term debt		_		0.2
Total current liabilities		14.5		43.7
Non-Current Liabilities:				
Long-term debt, less current portion	\$	_	\$	27.0
Other non-current liabilities	•	12.1	_	7.6
Total non-current liabilities	\$	12.1	\$	34.6
Minority Interest – OSCA	\$	_	\$	36.8
-				

As of December 31, 2002, \$2.9 million of the \$26.7 million of special charges recorded in 2002 and \$7.9 million of the \$118.3 million of special charges recorded in 2001 remain to be spent. There are no amounts outstanding related to the charges taken in 2000. The major components of the remaining reserves are severance of \$1.5 million and plant closure and environmental costs of \$6.4 million. Plant closure and environmental costs have been allocated between accrued expenses and non–current liabilities based on the anticipated timing of these expenditures.

## NOTE 4: ACQUISITIONS AND SALE OF SUBSIDIARY STOCK

## Acquisitions

On December 3, 2002, the Company acquired certain assets of Flexsys America's non-staining phenolic antioxidants business for approximately \$11 million. Assets acquired included inventory, other intangibles and the process technology associated with Santonox® TBMC, Santovar® TAHQ and Santowhite® BBMC. Great Lakes will market these products under the Company's established line of Lowinox® non-staining antioxidants. Goodwill resulting from the acquisition amounted to approximately \$3 million.

On February 14, 2001, the Company acquired the Optical Monomers business from Akzo Nobel Polymer Chemicals LLC for approximately \$30 million in cash. The Optical Monomers business operates at a leased manufacturing site in Pasadena, Texas, and has sales and support networks throughout the United States and Europe. This acquisition was accounted for using the purchase method of accounting with its results of operations included since the date of acquisition. Goodwill resulting from the acquisition amounted to \$11.5 million.

On July 14, 2000, the Company acquired Aqua Clear for \$40.7 million. Aqua Clear, a manufacturer and distributor of specialty pool chemical products, operated a manufacturing site in Watervliet, New

York, which was closed in 2001. Aqua Clear continues to operate distribution sites in St. Louis, Missouri, and Waterford, New York, as well as sales and support networks throughout the United States and Canada. The acquisition of Aqua Clear was accounted for using the purchase method of accounting with its results of operations included since the date of acquisition. Goodwill resulting from the acquisition amounted to \$37.8 million.

These acquisitions were funded with available cash and borrowing capacity.

## Sale of Subsidiary Stock

On February 20, 2002, the Company announced that its Energy Services and Products business unit, OSCA, entered into a definitive merger agreement with BJ Services Company. The sale of OSCA was completed on May 31, 2002. Under the terms of the sale, BJ Services acquired all outstanding shares of OSCA, including the Company's 53.2% holding, for \$28.00 per share in cash, or \$221 million, resulting in a gain of \$175.4 million. This transaction provided the Company with net proceeds of approximately \$200 million in cash, a part of which was used to reduce the Company's debt position. As a result of this transaction, the Company has reflected OSCA as discontinued operations for all periods presented.

In addition, in each of the first and second quarters of 2001, the Company sold 250,000 shares of its OSCA Class B common stock pursuant to Rule 144 under the Securities Act of 1933 for a total of 500,000 shares being sold for the year ended December 31, 2001. The terms of these transactions provided that upon the sale of these Class B shares, the shares were automatically converted to OSCA Class A common stock. Net proceeds were \$5.4 million and \$6.3 million and the related taxable gains were \$4.2 million and \$5.2 million for the first and second quarters of 2001, respectively.

Effective June 15, 2000, the Company had sold 40% of its ownership in OSCA through an initial public offering. Net proceeds of approximately \$79 million from the initial sale were paid to the Company by OSCA to satisfy indebtedness. The initial sale resulted in a \$51.9 million gain to the Company, which was recognized in the second quarter of 2000. Subsequently, on July 13, 2000, the over–allotment option granted to the underwriters was exercised and resulted in an additional \$12 million of net proceeds. The over–allotment exercise resulted in an additional gain to the Company of \$8.5 million, which was recorded in the third quarter of 2000. The initial sale and the over–allotment option exercise resulted in the Company selling a total of 43.4% of its ownership interest in this subsidiary.

### NOTE 5: CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

December 31	2002	 2001
Cash	\$ 101.2	\$ 38.6
Cash equivalents	157.9	 16.9
	\$ 259.1	\$ 55.5

47

## NOTE 6: INVENTORIES

The major components of inventories are as follows:

December 31	2002	2001
Finished products Raw materials Supplies	\$ 186.4 33.5 32.3	\$ 155.6 41.6 30.3
	\$ 252.2	\$ 227.5

## NOTE 7: PLANT AND EQUIPMENT

Plant and equipment consist of the following:

December 31	2	0002	)2 20		
Land	\$	14.3	\$	14.6	
Buildings	Ψ	129.6	Ψ	117.3	
Equipment		1,150.0		1,129.1	
Construction in progress		31.9		52.4	
		1,325.8		1,313.4	
Less allowances for depreciation, depletion and amortization		(704.2)		(690.3)	
	\$	621.6	\$	623.1	

## **NOTE 8: DEBT**

Long-term debt is summarized as follows:

December 31 2002 2001

Notes payable	\$ 400.0	\$ 400.0
Commercial paper	_	72.4
Industrial development bonds	12.3	12.3
Other	28.3	27.0
	440.6	511.7
Less current portion	(8.0)	(10.9)
•		
	\$ 432.6	\$ 500.8

On July 15, 1999, the Company sold \$400 million of 7% notes due July 15, 2009. Proceeds from the sale of the notes were used to replace a portion of the commercial paper borrowings. The notes were sold under a shelf registration process. Under this process, the Company filed a Registration Statement on Form S–3 with the Securities and Exchange Commission and may sell various unsecured debt securities, common stock or rights or warrants to purchase common stock individually or in combination up to \$750 million. The amount of securities remaining to be sold on the registration statement is \$350 million.

On October 3, 2002, the Company renewed the 364–day portion of its unsecured revolving credit facility established on October 4, 2001. This 364–day credit facility was originally established along with a facility with a five–year term. Under these combined facilities, the Company may borrow up to \$462.5 million. These facilities are used to support the Company's commercial paper program and for general corporate purposes. The facility contains certain covenants that include, among others, requirements to limit the maximum ratio of Debt to EBITDA to 3.5 to 1, as defined in the agreement.

Debt to EBITDA, as defined in the agreement, was 1.3 as of December 31, 2002. Interest on borrowings outstanding under the agreement is based upon a variable rate tied to LIBOR. There were no outstanding borrowings on these facilities as of December 31, 2002 and 2001

The interest rate on industrial development bonds was 2.99% at December 31, 2002, and the bonds have maturities through 2025.

Commercial paper financing was classified as a component of long—term debt at December 31, 2001, since the Company had the ability and the intent to refinance these borrowings on a long—term basis either through continued commercial paper borrowings or utilization of available long—term credit facilities. There were no outstanding commercial paper borrowings as of December 31, 2002.

Long-term debt matures as follows: 2003, \$8.0 million; 2004, \$2.9 million; 2005, \$2.7 million; 2006, \$1.5 million; 2007, \$1.1 million; and thereafter, \$424.4 million.

During 2002, 2001 and 2000, interest costs were \$32.1 million, \$42.3 million and \$52.4 million, respectively, which included interest capitalized as additional costs of plant and equipment of \$0.6 million in 2002, \$1.0 million in 2001 and \$1.7 million in 2000. In these years, cash interest payments were \$33.9 million, \$42.5 million and \$52.8 million, respectively.

### NOTE 9: INCOME TAXES

The following is a summary of domestic and foreign income from Continuing Operations before income taxes, the components of the provisions for income taxes, a reconciliation of the United States federal income tax rate to the effective income tax rate and the components of deferred tax assets and liabilities.

### **Income Before Income Taxes:**

Year Ended December 31	2002		2002		2002		2002 2		2001		)1 2	
Domestic Foreign	\$	28.6 40.1	\$	(79.0) (142.0)	\$	59.7 57.7						
	\$	68.7	\$	(221.0)	\$	117.4						

### **Provisions for Income Taxes:**

Year Ended December 31	2002		2002 2001		2002 2001		2	2000
Current:								
Federal	S	\$ (53.5)	\$	45.8	\$	7.1		
State		(1.0)	)	(2.5)		5.0		
Foreign		19.1		6.4		7.5		
	•		_					
		(35.4)	)	49.7		19.6		
	•		_					
Deferred:								
Domestic		69.2		(93.9)		9.7		
Foreign		(12.5)	)	4.4		7.3		
	•		_					
		56.7		(89.5)		17.0		
	•							
		\$ 21.3	\$	(39.8)	\$	36.6		
49	•							

## **Effective Income Tax Rate Reconciliation:**

Year Ended December 31	2002	2001	2000
	25.00/	(25.0) 0/	25.00/
U.S. federal income tax rate Change resulting from:	35.0%	(35.0)%	35.0%
State income tax	(0.9)	(0.7)	2.7
Depletion	(3.0)	(0.8)	(1.6)
Export sales incentive	(2.1)	(0.4)	(2.1)
Tax-exempt interest	_	_	(0.7)
Dividends received deduction	_	_	(0.4)
Low income housing credit	(4.5)	(1.5)	(2.7)
International operations	1.6	2.4	(0.6)
Stock redemption –			
Huntsman	_	_	(0.6)
Nondeductible goodwill	_	3.8	0.3
Change in valuation allowance	6.0	14.9	1.5
Other	(1.1)	(0.7)	0.4

Effective income tax rate	31.0%	(18.0)%	31.2%
---------------------------	-------	---------	-------

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

## Components of Deferred Tax Assets and Liabilities:

ember 31		2002	2001		
Deferred tax assets					
Accrued expenses	\$	11.0	\$	21.6	
Special charges		3.9		1.2	
Tax credit carryforwards		36.9		29.1	
Net operating loss carryforwards		44.1		119.9	
Other		31.4		31.3	
Deferred tax assets		127.3		203.1	
Valuation allowance		(35.7)		(49.4)	
Deferred tax assets, net of valuation allowance	\$	91.6	\$	153.7	
Deferred tax liabilities					
Depreciation	\$	65.1	\$	54.1	
Other		16.6		33.0	
Deferred tax liabilities	\$	81.7	\$	87.1	
Net deferred tax assets	\$	9.9	\$	66.6	

As of December 31, 2002, the Company had tax credit carryforwards of \$36.9 million available. A valuation allowance of \$17.7 million has been recorded against the portion of these credit carryforwards for which utilization is uncertain. Of the amount of tax credit carryforwards for which no valuation allowance has been recorded, \$0.7 million expire in 2018; \$2.6 million expire in 2019; \$3.2 million expire in 2020; \$3.3 million expire in 2021; \$3.2 million expire in 2022; and the remaining \$6.2 million have no expiration dates. At December 31, 2002, the Company and certain of its foreign subsidiaries had net operating losses totaling \$119.0 million. These carryforwards will be available to offset \$44.1 million of future tax liabilities. A valuation allowance of \$18.0 million has

been recorded against the portion of these net operating loss carryforwards for which utilization is uncertain. Of the amount of net operating loss carryforwards for which no valuation allowance has been recorded, \$9.4 million expire in 2021 and the remaining \$16.7 million have no expiration dates.

Cash payments for income taxes were \$14.0 million, \$14.3 million and \$11.2 million in 2002, 2001 and 2000, respectively.

## NOTE 10: STOCKHOLDERS' EQUITY

The Board of Directors has authorized the Company to purchase shares of the Company's common stock in the open market or in privately negotiated transactions. No share repurchases were made in the current year. The Company purchased approximately 0.1 million shares during 2001 at an average price of \$22.19. A total of 2.8 million shares remain available under existing Board authorizations.

Under a Stockholders' Rights Plan adopted in 1999, for each outstanding share of common stock of the Company held by a stockholder, each stockholder had a right, which entitled the holder upon certain triggering events described in the Stockholders' Rights Plan, to acquire at the Right's then current exercise price, the number of shares of common stock of the Company (or, if applicable, an acquiring company) having a market value equal to twice the Right's exercise price.

On February 12, 2002, the Company's Board of Directors redeemed the outstanding Rights under the Stockholders' Rights Plan at a price of \$.01 per Right, paid to stockholders of record on April 1, 2002.

### NOTE 11: EARNINGS PER SHARE

Basic earnings per share is based on the weighted-average number of common shares outstanding during the period, while diluted earnings per share includes the effect of options and restricted stock that were dilutive and outstanding during the period. The computation of basic and diluted earnings per share is determined using net income or loss as reported as the numerator, and the number of shares included in the denominator is calculated as follows:

Year Ended December 31	2002	2001	2000
Denominator for basic earnings per share (weighted–average shares)  Effect of dilutive securities	50.2 0.1	50.3	52.4 0.1
Denominator for diluted earnings per share	50.3	50.3	52.5

Options to purchase shares of common stock of 3.0 million in 2002, 3.3 million in 2001 and 3.1 million in 2000 were outstanding, but were excluded from the computation of diluted earnings per share, because the exercise prices were greater than the average market price of the common shares during those years, and therefore the effect would have been antidilutive.

## NOTE 12: STOCK COMPENSATION PLANS

The Company has four plans that provide for the granting of stock awards to officers and key employees. The 2002, 1998 and 1993 Stock Compensation Plans have stock awards available for grant; the fourth plan, the 1984 Stock Compensation Plan, has no stock awards available for grant, but does have options exercisable as of December 31, 2002. The Company is authorized to grant options for up to 7.0 million shares under the 2002, 1998 and 1993 plans, of which 3.5 million have been granted. Options under the plans have been granted at the market value at the date of grant, become exercisable over periods of one to five years and expire 10 years from the date of grant.

In addition to the options awarded under the plans, the Company on April 6, 1998 granted the chief executive officer an option to acquire 0.7 million shares of the Company's stock. The options were granted at market value on the date of grant; 0.2 million of the shares became exercisable upon grant with the remaining shares exercisable ratably over four years. The options expire 10 years from the grant date.

The status of the Company's stock options is summarized below:

	Shares Under Option	Weighted– Average Exercise Price		
Outstanding at January 1, 2000	3.1	\$ 43.96		
Granted	0.8	30.15		
Exercised	(0.1)	23.10		
Terminated	(0.5)	40.67		
Outstanding at December 31, 2000	3.3	41.72		
Granted	0.8	32.78		
Exercised	0.0	30.10		
Terminated	(0.8)	41.69		
Outstanding at December 31, 2001	3.3	39.53		
Granted	0.9	22.12		
Exercised	0.0	23.44		
Terminated	(0.3)	47.24		
Outstanding at December 31, 2002	3.9	\$ 34.71		
Currently Exercisable	2.2	\$ 40.51		

During 2002, 2001 and 2000, the Company awarded restricted stock totaling approximately 20,000, 90,000 and 14,000 shares, respectively, to directors and other key employees. These awards become exercisable over a period of one to 10 years. The Company recognizes compensation expense consistent with the vesting of each award. The compensation expense incurred in 2002, 2001 and 2000 related to these awards totaled \$0.9 million, \$0.7 million and \$1.0 million, respectively.

The following table summarizes information concerning outstanding and exercisable options at December 31, 2002:

Range of Exercise Prices	4	\$22.00-\$35.99 \$36.00-\$50.99			\$51.00-\$68.99
Options outstanding:					
Weighted-average remaining contractual life		9.0 yrs		6.0 yrs	2.8 yrs
Weighted-average exercise price	\$	28.32	\$	41.90	\$ 61.99
Options outstanding (millions)		2.4		1.3	0.2
Options exercisable:					
Weighted-average exercise price	\$	32.56	\$	41.89	\$ 61.99
Options exercisable (millions)		0.9		1.1	0.2

The Company accounts for stock compensation costs in accordance with the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. Accordingly, no compensation cost has been recognized for its fixed stock option plans. The following table sets forth pro forma information as if compensation cost had been determined based on the fair value at the grant date for awards under the Company's stock plans consistent with the requirements of SFAS No. 123, "Accounting for Stock–Based Compensation." For

the purposes of the pro forma disclosure, the estimated compensation costs are amortized to expense over the options' vesting period, principally three years.

While no compensation expense has been recognized for the Company's stock option plans, outstanding options whose exercise prices were less than the average market price of common stock during the period are included in the determination of share dilution for the purposes of calculating diluted earnings per share.

December 31	2002		2002 2001		2001		2000
Weighted—average fair value per share of options granted during the year (1) Income (loss) from continuing operations:	\$	7.24	\$	10.81	\$ 11.67		
As reported		47.4		(181.2)	80.8		
Pro forma		43.4		(184.1)	77.0		
Diluted earnings per share:							
As reported		0.94		(3.60)	1.54		
Pro forma		0.86		(3.66)	1.47		
Assumptions:							
Expected volatility		28.9%		27.8%	28.3%		
Expected life in years		6.5		6.5	6.5		
Risk–free interest rate		4.7%		4.4%	6.7%		
Dividend yield		1.5%		1.1%	1.1%		

On date of grant using the Black-Scholes option pricing model, a pricing model acceptable under SFAS 123.

## **NOTE 13: RETIREMENT PLANS**

## **Defined Benefit Pension Plans**

(1)

The Company sponsors various noncontributory and contributory defined benefit retirement plans covering certain of its U.S. and non–U.S. employees. Retirement benefits are based upon years of service and the employee's compensation levels during this service period. The Company also has unfunded supplemental nonqualified defined benefit plans, which provide pension benefits for certain employees in excess of the tax–qualified plans' limits. The net periodic benefit cost is assessed in accordance with the advice of professionally qualified actuaries.

The Company's funding policy is to make contributions to the extent such contributions are tax deductible as actuarially determined and as permitted by regulatory authorities. The funded amounts reflect actuarial assumptions regarding compensation, interest and other projections. Plan assets are comprised primarily of equity securities, fixed—income securities and short—term investments.

The following table provides a progression of the plans' benefit obligations and fair value of plan assets for 2002 and 2001, and reconciles the funded status to the amounts recognized in the consolidated balance sheets for those years.

		U.S. Plans			Non-U.S. Plans			
		2002		2001		2002		2001
Changes in benefit obligation:								
Benefit obligation at beginning of year	\$	123.5	\$	116.2	\$	99.7	\$	80.6
Service cost		4.9		4.6		3.7		3.9
Interest cost		9.0		8.9		6.4		5.0
Plan participants' contributions		_		_		1.5		1.3
Net actuarial loss		7.7		2.4		24.6		13.7
Benefits paid		(4.5)		(8.6)		(3.6)		(3.1)
Foreign exchange loss (gain)		_		_		12.8		(1.7)
Benefit obligation at end of year	\$	140.6	\$	123.5	\$	145.1	\$	99.7
Changes in fair value of plan assets:								
Fair value of plan assets at beginning of year	\$	107.2	\$	128.6	\$	88.7	\$	108.5
Actual return on plan assets		(11.0)		(17.9)		(12.0)		(16.9)
Employer contributions		0.8		5.5		3.4		2.3
Benefits and expenses paid		(4.9)		(9.0)		(3.6)		(3.1)
Foreign exchange gain (loss)		`—		`—´		9.9		(2.1)
Fair value of plan assets at end of year	\$	92.1	\$	107.2	\$	86.4	\$	88.7
Funded status of plans:								
Funded status	\$	(48.5)	\$	(16.3)	\$	(58.7)	\$	(11.0)
Unrecognized prior service cost		0.4		0.3		_		_
Unrecognized transition obligation		0.2		0.3		_		_
Unrecognized net actuarial loss		39.8		11.6		69.3		19.2
Prepaid (accrued) benefit cost	\$	(8.1)	\$	(4.1)	\$	10.6	\$	8.2
Amounts recognized in the balance sheets consist of:								
Prepaid benefit costs	\$	_	\$	0.9	\$	10.6	\$	8.2
Accrued benefit liability		(8.4)		(5.7)		_		_
Additional minimum liability		(19.9)		(2.8)		(30.0)		_
Intangible asset		0.3		0.7		_		_
Accumulated other comprehensive loss		19.9		2.8		30.0		_
Prepaid (accrued) benefit cost	\$	(8.1)	\$	(4.1)	\$	10.6	\$	8.2
Weighted-average assumptions:								
Discount rates		7.0%		7.5%		5.5%		6.25%
Expected return on plan assets		9.0%		9.0%		7.0%		7.5%
Rate of compensation increases		4.0%		4.0%		3.75%		3.75%
	54							

The components of net periodic benefit costs are as follows:

	U.S. Plans				Non-U.S. Plans				
	2	2002	2001	2000	2002	2001	2000		
Service cost	\$	4.9 \$	4.8 \$	4.8 \$	3.7 \$	3.7 \$	3.4		
Interest cost		9.0	8.9	8.4	6.4	5.0	2.6		
Expected return on plan assets		(9.5)	(11.4)	(10.3)	(8.1)	(6.9)	(3.0)		
Amortization of prior service cost		0.1	0.2	0.1	`—				
Amortization of transition obligation		0.2	0.2	0.2	_	_	_		
Recognized net actuarial loss/(gain)		0.1	(0.9)	(0.4)	_	(0.3)	0.4		
Net periodic benefit cost	\$	4.8 \$	1.8 \$	2.8 \$	2.0 \$	1.5 \$	3.4		

The allocation of net periodic benefit cost is as follows:

	U.S. Plans				Non-U.S. Plans					
	200	02	200	)1	2000	2002		2001		2000
Continuing Operations Discontinued Operations	\$	4.8	\$	1.8	\$ 2.8	\$ 1.3 0.7	\$	1.0 0.5	\$	2.3 1.1
Net periodic benefit cost	\$	4.8	\$	1.8	\$ 2.8	\$ 2.0	\$	1.5	\$	3.4

Amounts applicable to the Company's U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets are summarized as follows as of the October 1 measurement date:

	2002	2001	
Projected benefit obligation	\$ 285.7	\$	223.2
Fair value of plan assets	178.5		195.9

Amounts applicable to the Company's U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets are summarized as follows as of the October 1 measurement date:

	 2002	2	2001	
Accumulated benefit obligation	\$ 226.3	\$	8.5	
Fair value of plan assets	178.5		_	

The Company provides no significant postretirement benefits other than pensions.

## **Defined Contribution Retirement Plans**

Certain Company employees participate in the Great Lakes Savings Plan, which is a defined contribution, 401(k) employee savings plan generally available to all U.S. full–time salaried, non–union hourly employees and certain union hourly employees. The plan is funded by contributions from participants and the Company. Contributions by the Company to the plan approximated \$2.7 million, \$2.9 million and \$3.4 million in 2002, 2001 and 2000, respectively.

The Company also maintains a supplemental savings plan, the Great Lakes Chemical Corporation Supplemental Savings Plan. The plan is nonqualified and restores the employer match that certain employees lose due to IRS limits on eligible compensation under the Great Lakes Savings Plan. Contributions to this plan by the Company approximated \$0.04 million, \$0.1 million and \$0.1 million in 2002, 2001 and 2000, respectively.

### NOTE 14: RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses were approximately \$26.0 million, \$28.1 million and \$25.6 million in 2002, 2001 and 2000, respectively.

## NOTE 15: SEGMENT INFORMATION

The Company is organized into three global segments: Polymer Additives, Performance Chemicals and Water Treatment. These segments are strategic business units that offer products and services that are intended to satisfy specific customer requirements. The units are organized and managed to deliver a distinct group of products, technology and services.

The Polymer Additives segment produces bromine–, phosphorus– and antimony–based flame retardants; antioxidants; UV absorbers; light stabilizers; optical monomers; and patented No Dust Blends (NDB<sup>TM</sup>). The segment serves suppliers in a wide variety of industries, including electrical and electronic, construction, automotive and furnishings.

The Performance Chemicals segment produces chemicals to exact specifications or to meet specific applications requirements. The product offering is characterized by technology—based product solutions that benefit specific customers. The businesses included in the segment are: agricultural products; brominated intermediates; fluorine chemicals for use in fire suppression systems, refrigerants and medical and pharmaceutical products; fine chemicals for pharmaceutical and life sciences companies; and toxicological testing services for pharmaceutical, chemicals and biotechnology customers. As a result of the Company's decision in 2002 to sell the Fine Chemicals portion of the Performance Chemicals business, the net assets of Fine Chemicals have been reclassified as assets held for sale and liabilities held for sale, with operating results reported in discontinued operations for all periods presented.

The Water Treatment segment is a producer of water treatment chemicals for the recreational and commercial swimming pool and spa water treatment industry. These products are sold to pool and spa dealers, distributors and mass market retailers. The Water Treatment segment also produces specialty biocides, antiscalants, corrosion inhibitors and other products for use in cooling tower water treatment; wastewater treatment; pulp and paper production; and desalination products.

The Company evaluates business unit performance and allocates resources based on the operating income, which represents net sales less cost of products sold and selling, general and administrative expenses and cash flows of each business unit. Each of the Company's segments uses bromine as a raw material in their production processes. Bromine is transferred at cost to all business segments. Their cost is based upon a bromine supply agreement. In addition, assets used in the production of bromine are allocated to each business unit based on the percentage of production consumed. The accounting policies of the reportable segments are the same as those described in the Summary of Significant Accounting Policies.

Corporate includes the corporate offices and any other activities not associated with a specific segment. Segment assets include primarily accounts receivable, inventory, net plant and equipment and other miscellaneous assets. Assets included in Corporate principally are cash and cash equivalents; deferred income taxes; certain investments and other assets; and certain unallocated plant and equipment, including the Company's ERP software systems. Geographic sales information is reported based on the location that invoices the external customer. Geographic long—lived assets

Year Ended December 31	d December 31 2002		2001		2000	
Net Sales by Segment to External Customers:	Φ	619.2	Φ.	501.7	Φ.	<b>COO</b> 1
Polymer Additives	\$	618.2	\$	581.7	\$	690.1
Performance Chemicals Water Treatment		232.7		250.2		280.5
water Treatment		543.0		507.0		474.5
Total sales of reportable segments		1,393.9		1,338.9		1,445.1
Corporate		7.6		13.9		4.7
	\$	1,401.5	\$	1,352.8	\$	1,449.8
Segment Profit (Loss):						
Polymer Additives	\$	16.4	\$	(70.8)	\$	52.4
Performance Chemicals		52.6		60.9		100.2
Water Treatment		83.1		54.1		85.0
Total profits of reportable segments		152.1		44.2		237.6
Corporate		(35.8)		(37.0)		(37.1)
Special charges		(5.1)		(148.6)		(54.3)
Operating income (loss)		111.2		(141.4)		146.2
Landin and Committee		(27.6)		(22.8)		(21.6)
Interest income (expense) – net Other income (expense) – net		(27.6) (14.9)		(32.8) (46.8)		(31.6)
Income (loss) before income taxes	\$	68.7	\$	(221.0)	\$	117.4
mediae (1088) before income taxes	<b>J</b>	08.7	Φ	(221.0)	Ψ	117.4
Depreciation Expense: Polymer Additives	\$	43.8	\$	39.4	\$	35.5
Performance Chemicals	Ψ	11.0	Ψ	7.9	φ	10.4
Water Treatment		14.6		14.1		13.3
Corporate		7.3		9.5		12.5
	\$	76.7	\$	70.9	\$	71.7
S	_					
Segment Assets: Polymer Additives	\$	792.6	\$	711.4	\$	813.3
Performance Chemicals	Ψ	173.5	Ψ	178.4	Ψ	118.3
Water Treatment		376.5		393.4		396.1
Corporate		321.3		193.2		362.6
Net assets of discontinued operations		(0.3)		(1.1)		1.1
	\$	1,663.6	\$	1,475.3	\$	1,691.4
	Ψ	1,505.0	Ψ	2,173.3	Ψ	1,071.7

57

Year Ended December 31	 2002		2001	2000
Investment in Equity	 			
Method Investees:				
Polymer Additives	\$ 13.6	\$	11.3	\$ 19.9
Expenditures for Long-lived Assets:				
Polymer Additives	\$ 33.4	\$	86.5	\$ 62.2
Performance Chemicals	8.2		20.0	23.
Water Treatment	21.3		18.5	17.
Corporate	1.9		6.2	29.:
	\$ 64.8	\$	131.2	\$ 132.9
Geographic Information				
Net Sales to External Customers:				
United States	\$ 894.5	\$	862.6	\$ 875.0
United Kingdom	126.0		148.8	204.3
Switzerland	158.3		121.7	129.

Other foreign		222.7		219.7	240.0
	\$	1,401.5	\$	1,352.8	\$ 1,449.8
Long-lived Assets:					
United States	\$	535.6	\$	575.3	\$ 615.9
United Kingdom		87.7		74.8	104.5
Other foreign		202.1		162.8	163.3
	_		_		
	\$	825.4	\$	812.9	\$ 883.7
	<u></u>				 

## NOTE 16: INVESTMENT IN AND ADVANCES TO UNCONSOLIDATED AFFILIATES

As of December 31, 2002, the Company's investment in unconsolidated affiliates consisted primarily of a 49% interest in Gulf Stabilizers Industries Limited, a Saudi Arabian manufacturer of antioxidants, and a 50% interest in Tetrabrom Technologies, Ltd., an Israeli manufacturer of tetrabromobisphenol—A. During 2000, the Company sold its remaining preferred stock in Huntsman Chemical Company (HCC). The Company had recognized pretax gains on sales of HCC preferred shares of \$3 million in 2000. Preferred stock dividends from HCC amounted to \$0.3 million in 2000. The Company is also a limited partner in certain low—income housing investments that generate benefits in the form of tax credits.

The Company's equity in earnings (loss) of unconsolidated affiliates was \$(2.1) million, \$0.7 million and \$5.7 million in 2002, 2001 and 2000, respectively.

## **NOTE 17: FINANCIAL INSTRUMENTS**

## Foreign Exchange Risk Management

In the normal course of business, operations of the Company are subject to risks associated with changing foreign exchange rates. These fluctuations can vary the costs of financing, investing and operating activities. Accordingly, the Company hedges certain portions of its exposure to foreign currency fluctuations through the use of options and forward exchange contracts to protect the value of its existing foreign currency asset and liability commitments and anticipated foreign currency revenues.

It is the Company's policy to enter into foreign currency hedging transactions only to the extent considered necessary to achieve the objectives stated above. The Company does not enter into foreign currency transactions for trading purposes. The Company enters into forward contracts to hedge portions of its foreign currency denominated, forecasted sales and subsequent cash flows.

The critical terms of the hedges are the same as the underlying forecasted transactions, and the hedges are considered perfectly effective to offset the changes in fair value of cash flows from the hedged transactions. Gains and losses on these instruments are generally recorded in other comprehensive income (loss) until the underlying transaction is recognized in net income.

The Company enters into currency option and forward contracts to hedge anticipated foreign currency transactions during the next 12 months. The principal currency hedged is the Japanese yen.

The Company uses currency swap contracts to hedge a long-term intercompany loan. These contracts hedge the euro against the British pound. The terms of the swap contracts match the loan principal repayment terms. Gains or losses on these contracts are reflected in earnings and are offset by losses or gains on the underlying intercompany loan.

In addition, the Company enters into certain foreign currency forward contracts that are not treated as hedges under SFAS 133 to hedge recognized foreign currency transactions. Gains and losses on these contracts are recorded in net earnings and are substantially offset by the earnings effect of the revaluation of the underlying foreign currency denominated transaction.

Gains and losses arising from the use of the above instruments are recorded in the statement of operations concurrently with gains and losses arising from the underlying hedged transactions. The impact on pretax income of the currency forwards and options used to mitigate gains and losses on foreign exchange was a net (loss) gain of approximately \$4.4 million, \$9.2 million and \$(1.6) million in 2002, 2001 and 2000, respectively.

The Company uses forward foreign exchange contracts to protect the value of its investments in its foreign subsidiaries in Europe. Realized and unrealized gains and losses from these hedges are not included in the income statement, but are shown in the cumulative translation adjustment account in other comprehensive income (loss), with the related amounts due to or from counterparties included in other liabilities or other assets.

During the year ended December 31, 2002, the Company recognized \$3.1 million of net losses, included in the cumulative translation adjustment, related to the forward foreign currency exchange contracts.

## **Interest Rate Risk Management**

The Company has employed certain hedging instruments to minimize its exposure to changes in interest rates, including an interest rate swap agreement. In 2000, the Company terminated a swap arrangement and as a result recognized a \$2.9 million gain, which is being amortized over the remaining term of the underlying 7% fixed rate notes that are due July 15, 2009. In 2002, the Company entered into a \$75 million interest rate swap accounted for as a fair value hedge to manage its exposure to interest rate changes.

Gains and losses arising from the use of such interest rate hedging instruments are recorded in the income statement concurrently with gains and losses arising from the underlying transactions. The impact on pretax income of interest rate risk management activities was a net gain of approximately \$2.1 million for 2002.

## Natural Gas Price Risk Management

The Company consumes natural gas during the normal course of production. The fluctuations of natural gas prices can vary the costs of production. During the second quarter of 2001, as part of its risk management strategy, the Company entered into fixed price swap and option contracts, including caps and floors, to manage its exposure to changes in natural gas prices. These natural gas contracts obligate the Company to make or receive a payment equal to the net change in the value

of the contracts at their maturity. Such contracts are designated as hedges of the Company's forecasted purchases up to November 2003 and are effective in hedging the Company's exposure to changes in natural gas prices during this period.

The natural gas contracts that qualify as cash flow hedges under SFAS 133 are marked to market with unrealized gains and losses deferred and recognized in earnings when realized as an adjustment to cost of products sold. Unrealized changes in fair value of contracts no longer effective as hedges are recognized in cost of products sold from the date that the contracts become ineffective until their expiration. The Company elected to terminate several contracts in 2002 with a supplier due to counterparty risk consideration. The amounts reclassified into earnings were immaterial. The impact on pretax income of natural gas risk management activities were a net (loss) of approximately \$(1.1) million in 2002 and approximately \$(1.8) million in 2001.

### Fair Value of Financial Instruments

For certain of the Company's financial instruments, including cash and cash equivalents; accounts and notes receivable; accounts payable; and accrued expenses, the stated values approximate fair value due to their short–term nature. Consequently, such financial instruments are not included in the following table that provides information about the notional amounts, carrying amounts and estimated fair values of other financial instruments, both on and off the balance sheets:

		2002				2001	
	Notional Amount	Carrying Amount	Fair Value		Notional Amount	Carrying Amount	Fair Value
Long-term debt including current portion	\$ _ \$	440.6	\$ 487.4	\$	_ \$	539.0	\$ 547.4
Interest rate swap agreements	75.0	9.3	9.3		_		_
Foreign currency options and forward contracts	140.6	(0.8)	(0.8)	)	102.5	3.4	3.4
Foreign currency swap contracts	36.2	3.3	3.3		22.9	5.2	5.2
Natural gas options and swap contracts	2.5	0.3	0.3		8.7	(2.6)	(2.6)

The estimated fair value of long-term debt is based primarily on quoted market prices for the same or similar issues. The fair values of option, forward exchange and swap contracts are based on quoted market prices of comparable instruments.

## Concentrations of Credit Risk

The Company sells a broad range of products to a diverse group of customers operating throughout the world. These industries generally are not significantly affected by changes in economic or other factors. Credit limits, ongoing credit evaluation and account—monitoring procedures are utilized to minimize the risk of loss. Collateral is generally not required. Counterparties to the currency swap agreements are major financial institutions. Credit losses from counterparty nonperformance are not anticipated.

### NOTE 18: COMMITMENTS AND CONTINGENCIES

The Company has various purchase commitments for raw materials, supplies and plant and equipment incident to the ordinary conduct of business. In the aggregate, such commitments are not at prices in excess of current market. At December 31, 2002, the Company had committed approximately \$18 million to complete capital projects.

At December 31, 2002, the Company had guaranteed \$22.2 million of debt of an unconsolidated affiliate. The unconsolidated affiliate was in violation of several covenants related to its debt that the Company guarantees. The affiliate is currently negotiating with the respective lenders to amend its

loan agreements. The banks have not called the loan, and the Company believes that a waiver or amendment will be received and has not recorded a liability as of December 31, 2002.

The Company has various operating leases primarily for the use of office space, computer equipment and services. Future minimum lease payments under these non-cancelable operating leases totaled \$48.9 million at December 31, 2002, due as follows: 2003 – \$10.7 million; 2004 – \$7.0 million; 2005 – \$7.0 million; 2006 – \$6.1 million; 2007 – \$5.3 million; 2008 and thereafter, \$12.8 million.

Rent expense for all operating leases amounted to \$14.8 million, \$19.2 million and \$15.8 million for 2001, 2000 and 1999, respectively.

The Company is subject to various lawsuits and claims with respect to matters such as governmental regulations, income taxes and other actions arising out of the normal course of business. The Company is also subject to contingencies pursuant to environmental laws and regulations that in the future may require the Company to take action to correct the effects on the environment of prior manufacturing and waste disposal practices.

The Company has been cooperating with the United States Department of Justice (DOJ) and the European Commission since the spring of 1998 in their respective investigations of the bromine and brominated products industry. Both investigations were initiated after the Company self–reported to those agencies certain business practices that raised questions under antitrust laws. As a result of the Company's cooperation, the Company and its current directors and employees were accepted into the DOJ's amnesty program. Concurrently, the Company sought favorable treatment under a program in the European Union that also rewards self–reporting and cooperation. To the Company's knowledge, no proceedings have ever been instituted in the European Union in connection with the investigation.

The Company believes it has fully complied with all applicable conditions to date and has continued to cooperate with the DOJ in connection with certain follow—up matters arising out of the investigation, all of which are covered by the Company's acceptance into the amnesty program. Although, to the Company's knowledge, there have been no additional matters that have arisen in connection with the investigations, the Company intends to continue to be in full compliance with the DOJ and European Union programs.

There were ten federal purported class action lawsuits and five California purported class actions naming the Company, each claiming treble damages arising out of an alleged conspiracy concerning the pricing of bromine and brominated products. The federal lawsuits were consolidated in the District Court for the Southern District of Indiana, which, over the Company's objections, certified a class of direct purchasers of certain brominated products.

On September 10, 2002, the Company agreed to settle all of the federal class actions. The settlement agreement affects direct purchasers from the Company of brominated diphenyl oxides (decabromodiphenyl oxide, octabromodiphenyl oxide and pentabromodiphenyl oxide) and their blends, tetrabromobisphenol—A and its derivatives and all methyl bromide products and their derivatives in the United States between January 1, 1995 and April 30, 1998. The Company agreed to a \$4.1 million cash payment and \$2.6 million in vouchers for the future purchase of decabromodiphenyl oxide and/or tetrabromobisphenol—A, to be distributed to class members. The settlement was reflected in the third quarter of 2002 as a reduction to litigation reserves previously recorded in prior periods.

Pursuant to the settlement agreement, the Company remitted the cash portion to an escrow account on November 8, 2002, subject to final approval of the settlement agreement by the federal court. After notice to class members, the federal court gave final approval to the settlement in

January 2003. The plaintiffs have submitted a plan of distribution for court approval. The plan included a form of voucher agreed to by the Company.

The California cases pending in the Superior Court for San Francisco County claim alleged violations of California competition laws and were stayed pending resolution of the federal cases. The cases are not impacted by the federal settlement. The Company has denied that the cases were legitimately filed as class actions, denies all liability and intends to defend the cases vigorously.

OSCA, the interest in which the Company divested to BJ Services Company as of May 31, 2002, is a party to certain pending litigation regarding a blowout of a well in the Gulf of Mexico operated by Newfield Exploration Company. In the lawsuit, the plaintiffs claimed that OSCA and the other defendants breached their contracts to perform work—over operations on the well and were negligent in performing those operations. On April 4, 2002, a jury reached a verdict on those claims, finding OSCA and the other defendants responsible for those claims and determining OSCA's share of the damages. In connection with the lawsuit, the Company asserted claims against its insurers and insurance brokers in support of insurance coverage for this incident. A related trial on these insurance coverage claims was conducted by the submission of legal briefs. Thereafter, the court issued its final judgments on the underlying liability claims and the insurance coverage claims, entering judgment against OSCA for a net amount of approximately \$13.3 million plus interest, and finding that such amount was only partially covered by insurance. Pursuant to an indemnification agreement between the Company and BJ Services entered into at the time of the sale of OSCA (see Note 4 to the Consolidated Financial Statements), Great Lakes has agreed to pay BJ Services a certain percentage of any uninsured cash damages in excess of an amount paid by OSCA upon settlement or final determination of this pending litigation. As of December 31, 2002, the Company recorded a \$9.0 million reserve in discontinued operations for this indemnification liability. Great Lakes and BJ expect to appeal some or all of the liability and insurance coverage decisions.

On May 28, 2002, Albemarle Corporation filed two complaints against the Company in the United States District Court for the Middle District of Louisiana, one alleging that the Company had infringed on three process patents held by Albemarle Corporation relating to bromine vacuum tower technology, and the other alleging that the Company had infringed or contributed or induced the infringement of a patent relating to the use of decabromodiphenyl ehtane as a flame retardant in thermoplastics. On a motion by the Company and over Albemarle's objection, the cases were consolidated. In addition, the Company has filed a counterclaim with the District Court in the flame retardant cases, alleging, among other things, that the Albemarle patent is invalid or was obtained as a result of inequitable conduct in the United States Patent and Trademark Office.

With respect to the Albemarle case, the Company believes that the allegations of the complaints are without basis factually or legally, and intends to defend the cases vigorously.

Litigation accruals of approximately \$16.8 million and \$13.2 million have been reflected in the Company's consolidated balance sheet as of December 31, 2002 and 2001, respectively.

The Company is subject to various U.S. and international federal, state and local environmental, health and safety laws and regulations. The Company is also subject to liabilities arising under the Comprehensive Environmental Response Compensation and Liability Act ("CERCLA"), the Resource Conservation and Recovery Act ("RCRA") and similar state and international laws that impose responsibility for remediation of hazardous substances and hazardous waste constituents released into the environment.

The Company provides reserves for environmental liabilities that management considers probable for which a reasonable estimate of the liability can be made. Accordingly, the Company's reserves for environmental liabilities, including reserves associated with restructuring charges, were approximately \$45.2 million and \$53.7 million at December 31, 2002 and 2001, respectively, with the current

portion of these liabilities included in accrued expenses and the long-term portion included in noncurrent liabilities. While it is difficult to predict or determine the outcome of actions brought against the Company or the ultimate cost of environmental matters, management believes that the ultimate cost, if any, in excess of the amounts already provided is not likely to have a material adverse effect on its consolidated financial position, consolidated results of operations or liquidity.

# NOTE 19: QUARTERLY FINANCIAL DATA (UNAUDITED)

A summary of the quarterly results of operations for the years ended December 31, 2002 and 2001 is as follows:

## QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)

2002 – Three Months Ended	Ma	rch 31(1)	June 30	September 30	December 31
Net sales	\$	305.0 \$	408.5	\$ 360.6	\$ 327.4
Operating expenses					
Cost of products sold		237.8	304.1	276.6	251.7
Selling, general and administrative expenses		50.4	58.6	54.3	51.7
Special charges		_	1.7	(0.4)	3.8
Operating income (loss) from Continuing Operations		16.8	44.1	30.1	20.2
Interest income (expense) – net		(8.5)	(7.1)	(6.2)	(5.8)
Other income (expense) – net		(0.6)	(5.0)	(4.3)	(5.0)
Income (loss) from Continuing Operations before income taxes		7.7	32.0	19.6	9.4
Income taxes (credit)		2.6	9.9	5.9	2.9
Income (loss) – Continuing Operations		5.1	22.1	13.7	6.5
Income (loss) – Discontinued Operations		(6.6)	83.8	(0.7)	1.1
Net income (loss)	\$	(1.5) \$	105.9	\$ 13.0 \$	\$ 7.6
Earnings (loss) per share: Basic					
Continuing Operations	\$	0.10 \$	0.44	\$ 0.27 \$	\$ 0.13(2
Discontinued Operations	\$	(0.13) \$	1.67	\$ (0.02) \$	\$ 0.02
Diluted					
Continuing Operations	\$	0.10 \$	0.44	\$ 0.27 \$	\$ 0.13(2
Discontinued Operations	\$	(0.13) \$	1.67	\$ (0.02) \$	\$ 0.02

2001 – Three Months Ended	ree Months Ended March 31(1) Ju		June 30	September 30	December 31	
Net sales	\$	342.1	\$ 406.3 \$	321.1 \$	283.3	
Operating expenses						
Cost of products sold		260.3	316.2	299.6	245.0	
Selling, general and administrative expenses		54.4	59.9	56.5	53.7	
Special charges		_	72.7	71.4	4.5	
Operating income (loss) from Continuing Operations		27.4	(42.5)	(106.4)	(19.9)	
Gain on sale of subsidiary stock			_	_	_	
Interest income (expense) – net		(8.7)	(8.7)	(7.5)	(7.9)	
Other income (expense) – net		(0.3)	(27.1)	(11.4)	(8.0)	
Income (loss) from Continuing Operations before income taxes	\ <u></u>	18.4	(78.3)	(125.3)	(35.8)	
Income taxes		6.8	(24.6)	(27.0)	5.0	
Income (loss) – Continuing Operations	\$	11.6	\$ (53.7) \$	(98.3) \$	(40.8)	
Income (loss) – Discontinued Operations	<b>*</b>	8.6	(100.0)	(8.3)	(8.6)	
Net income (loss)	\$	20.2	\$ (153.7) \$	(106.6) \$	(49.4)	
Earnings per share: Basic						
Continuing Operations	\$	0.23	\$ (1.07) \$	(1.95) \$	(0.81)	
Discontinued Operations Diluted	\$	0.17	(1.99) \$	(0.17) \$	(0.17)	
Continuing Operations	\$	0.23 \$	\$ (1.07) \$	(1.95) \$	(0.81)	
Discontinued Operations	\$	0.17	. , , ,	` '	` ,	

Amounts reported for the first quarter of 2002 and 2001 have been restated from the March 31, 2002 Form 10–Q as filed, due to the Fine Chemicals business being reported as discontinued operations in the second quarter of 2002.

Earnings per share from continuing operations for 2002 were reduced by \$0.01 per share, reflecting adjustments made subsequent to the Company's press release issued January 28, 2003.

64

## REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We have audited the accompanying consolidated balance sheets of Great Lakes Chemical Corporation as of December 31, 2002 and 2001, and the related consolidated statements of operations, cash flows and stockholders' equity for each of the three years in the period ended December 31, 2002. Our audits also included the financial statement schedule listed in the Index at Item 14(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Great Lakes Chemical Corporation at December 31, 2002 and 2001, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2002, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

As discussed in Note 1 to the Consolidated Financial Statements, the Company adopted Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets," in 2002.

Indianapolis, Indiana January 28, 2003

(1)

(2)

None.

### PART III

## Item 10. Directors and Executive Officers of the Registrant

Information regarding directors of the Company is contained under the headings "Proposal One: Election of Directors" in the Proxy Statement for the Company's Annual Meeting of Stockholders to be held on May 1, 2003, which is to be filed with the Securities and Exchange Commission pursuant to Regulation 14A of the Securities Exchange Act of 1934. This information is incorporated herein by reference. The executive officers of the Company are as follows:

### Mark P. Bulriss

Chairman, President and Chief Executive Officer

Officer since 1998

Mr. Bulriss, 51, was named president and chief executive officer of Great Lakes on April 1, 1998, and became chairman on May 4, 2000. Prior to joining Great Lakes, Mr. Bulriss served as president of AlliedSignal Polymers, a \$2.1 billion business unit of AlliedSignal (now Honeywell International) that manufactures polymers and markets nylon, technical fibers, plastics, film and chemical intermediates. Before being named president of its polymers unit, Mr. Bulriss served as president of AlliedSignal's electronic materials business. His extensive career in chemicals and plastics also includes 16 years with GE Plastics, a division of the General Electric Corporation. Mr. Bulriss previously served as a director and chairman of OSCA, Inc. and a director on the American Chemistry Council. Mr. Bulriss received a B.S. degree in Chemical Engineering from Clarkson University.

Larry J. Bloom
Executive Vice President
and President of Water Treatment

Officer since 2000

Mr. Bloom, 54, assumed the position of executive vice president of Great Lakes in 2000. He joined the Company in 1990 as a result of the acquisition by Great Lakes of Bio–Lab, Inc., where he has served as president since 1987. From 1970 to 1987, he held various sales, marketing and technical positions with Bio–Lab, Inc. Mr. Bloom is a graduate of Georgia Institute of Technology, receiving a B.S. degree in Chemical Engineering.

Angelo C. Brisimitzakis Executive Vice President, Flame Retardants and Brominated Performance Products Officer since 2000

Dr. Brisimitzakis, 44, joined Great Lakes in 1998 as vice president, global supply chain, following 14 years at General Electric Corporation, where he held leadership positions in sales, technology, business development, supply chain and business management functions. He was named an officer in 2000 and was named vice president for flame retardants in 2001. He assumed his current role in 2002. Dr. Brisimitzakis earned a Ph.D. in Chemistry from New York University and an M.B.A. in Marketing from New York University/Pace University

Richard T. Higgons Executive Vice President, Performance Chemicals and Business Development

Officer since 2001

Mr. Higgons, 60, joined Great Lakes in 2001. Prior to joining Great Lakes, Mr. Higgons was staff vice president for corporate development with Mallinckrodt, Inc., a position he held for five years. From 1991 to 1995, Mr. Higgons was vice president for business development for Mallinckrodt's chemical business. From 1988 to 1991, Mr. Higgons held several senior management positions in finance, business development and strategic planning for Imcera Group, Inc. Mr. Higgons received a B.S. degree in Accounting from Indiana Northern University.

## Henri Steinmetz Executive Vice President, Polymer Stabilizers

Officer since 2000

Mr. Steinmetz, 46, joined Great Lakes in October 1998. Prior to his current role, Mr. Steinmetz was vice president of commercial operations for polymer additives with responsibilities for the Americas, Europe, the Middle East and Africa. Prior to joining Great Lakes, Mr. Steinmetz was director of business development for MA Hanna Europe. He spent the majority of his career with General Electric Corporation in positions of increasing responsibility in the plastics, silicones and corporate divisions within the U.S. and Europe. Mr. Steinmetz holds a Masters degree in Metallurgy from the Technical University of Clausthal Zellerfeld (D) and an M.B.A. from Insead of Fontainebleau (F).

John B. Blatz Senior Vice President, Environmental, Health and Safety Officer since 2001

Mr. Blatz, 51, joined Great Lakes in 2001. Prior to joining Great Lakes, Mr. Blatz was with Dexter Corporation for 10 years, where his last position was vice president, environmental & process management. Previous positions included managing director and general counsel of Goldman Financial Group, Inc. for two years; positions with Emhart Corporation, now a part of Black & Decker, from 1980 to 1988; associate counsel with Scott Paper Company from 1978 to 1980, and private practice with the law firm O'Connor & Hannan. Mr. Blatz earned a J.D. from the University of Minnesota Law School in 1976 and a B.A. from Dartmouth College in 1973.

Bruce G. Davis Senior Vice President, Global Supply Chain Officer since 2001

Mr. Davis, 54, joined Great Lakes in April 2001 after serving as vice president, materials for IMC Global, Inc. His career includes service as the senior supply chain executive and a corporate officer of Witco Corporation from 1995 to 2000, and the Standard Products Company from 1993 to 1995. Mr. Davis spent 10 years in a series of leadership roles in materials, operations and supply chain with General Electric Corporation. A summa cum laude graduate of Old Dominion University, Mr. Davis holds a B.S. in Operations Research and Quantitative Methods.

## John J. Gallagher III Senior Vice President and Chief Financial Officer

Officer since 2001

Mr. Gallagher, 39, joined Great Lakes in May 2001. Prior to joining Great Lakes, Mr. Gallagher was vice president and chief financial officer at UOP LLC, a \$1.1 billion global joint venture of the Dow Chemical Company and Honeywell International, a position he held since 1999. Prior to UOP, Mr. Gallagher served in a number of positions of increasing responsibility at AlliedSignal (now Honeywell International) where he last held the position of vice president, finance and business development at Bendix Commercial Vehicle Systems. Prior to that, Mr. Gallagher had responsibilities for all of AlliedSignal as director, business analysis and planning, and previously director, finance and mergers and acquisitions. He also spent nine years at Price Waterhouse LLP as a management consultant on numerous M&A transactions, both in the U.S. and around the world. Mr. Gallagher is a CPA and graduated cum laude with a B.S. degree in Accounting from the University of Delaware.

Richard J. Kinsley Senior Vice President, **Human Resources & Communications** Officer since 1999

Mr. Kinsley, 45, joined Great Lakes in April 1999. Prior to joining Great Lakes, Mr. Kinsley served as vice president, human resources for the electronic materials division at AlliedSignal (now Honeywell International) for four years. Prior to AlliedSignal, he spent 10 years with The Pfaudler Companies, where he held senior management positions in sales and marketing, business development and human resources. Mr. Kinsley holds dual degrees in Economics and Business Administration from LeMoyne College and an M.B.A. from the University of Rochester.

Jeffrey M. Lipshaw Senior Vice President. **General Counsel and Secretary** 

Officer since 1999

Mr. Lipshaw, 48, joined Great Lakes in October 1999 after serving as of counsel with the Detroit-based law firm Dykema Gossett PLLC from February 1998. He was previously an associate and partner in the firm from 1979 until 1992. From 1993 through 1997, Mr. Lipshaw was vice president and general counsel of AlliedSignal Automotive in Southfield, Michigan. He holds an A.B. degree from the University of Michigan and a J.D. degree from Stanford University.

Zoe F. Schumaker Senior Vice President and Chief Information Officer Officer since 2001

Ms. Schumaker, 42, joined Great Lakes in 2001, after serving as vice president, information technology at Ingersoll-Rand Company's IR security and safety sector. From 1991 to 1999, Ms. Schumaker worked at Blount International, Inc., a diversified international manufacturer of outdoor products, industrial and power equipment, and sporting equipment, where she was vice president, information systems. From 1991 to 1997, Ms. Schumaker held several positions at Blount's outdoor products group, including director of information systems, manager of division information systems and manager of systems development. Prior to 1991, Ms. Schumaker held positions in consulting and systems development. She earned a B.A. degree in Psychology from the University of California at Berkeley and an M.B.A. from the University of Oregon in 1995.

## William L. Sherwood Vice President and Corporate Controller

Officer since 2002

Mr. Sherwood, 41, joined Great Lakes in 2000 as director, financial reporting. He was named as an officer and assumed his current position in 2002. Prior to joining Great Lakes, Mr. Sherwood was with Ernst & Young LLP in Indianapolis, Indiana, for 16 years, where he was an auditor and senior manager in the audit and assurance practice. Mr. Sherwood is a CPA and a CISA and holds a B.S. degree in Accounting from Butler University.

### Item 11. Executive Compensation

This information is set forth under the heading "Executive Compensation and Other Information" in the Company's 2003 Proxy Statement for the Company's Annual Meeting of Stockholders to be held on May 1, 2003 and is incorporated herein by reference.

## Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

This information is set forth under the heading "Security Ownership of Certain Beneficial Owners and Management" and "Equity Compensation Plan Information" in the Company's 2003 Proxy Statement for the Company's Annual Meeting of Stockholders to be held on May 1, 2003 and is incorporated herein by reference.

## Item 13. Certain Relationships and Related Transactions

None.

### Item 14. Controls and Procedures

Within the 90 days prior to the filing of this report, management, under the supervision of the Company's Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon this evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that these disclosure controls and procedures are effective, in all material respects, in ensuring that the information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported on a timely basis

There have been no significant changes in the Company's internal controls or in other factors subsequent to the date of the evaluation that could significantly affect these controls.

### **PART IV**

## Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K

## (a)(1) Financial Statements

The following consolidated financial statements of Great Lakes Chemical Corporation and related notes thereto, together with the report thereon of Ernst & Young LLP dated January 28, 2003, appearing on pages 23 through 49 are included herein:

Consolidated Statements of Operations – Years ended December 31, 2002, 2001 and 2000 Consolidated Balance Sheets – December 31, 2002 and 2001 Consolidated Statements of Cash Flows – Years ended December 31, 2002, 2001 and 2000 Consolidated Statements of Stockholders' Equity – Years ended December 31, 2002, 2001 and 2000 Notes to Consolidated Financial Statements – December 31, 2002.

## (a)(2) Financial Statement Schedule

The following Consolidated Financial Statement Schedule of Great Lakes Chemical Corporation is filed as part of Item 15(d) of this report and should be read in conjunction with the Consolidated Financial Statements.

Schedule II - Valuation and Qualifying Accounts

All other schedules for which provision is made in the applicable accounting regulation of the Securities and Exchange Commission are not required under the related instructions or are inapplicable, and therefore, have been omitted.

# (a)(3) Exhibits:

Exhibit No.	Description
(3)(i)	Restated Certificate of Incorporation (incorporated by reference to Exhibit (3)(i) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(3)(ii)	Amended and Restated By-Laws, as adopted by the Board of Directors on May 2, 2002.
(4)(i)	Indenture dated as of July 16, 1999, between the Company and The First National Bank of Chicago, as Trustee (incorporated by reference to the Company's Registration Statement on Form S–3 No. 333–78515)
(10)(i)	Supplemental Retirement Plan, as amended (incorporated by reference to Exhibit (10)(i) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(ii)(a)	Deferred Compensation Plan, as amended and restated effective January 1, 1997 (incorporated by reference to Exhibit (10)(ii) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(ii)(b)	Amendment to Deferred Compensation Plan, dated November 20, 1997 (incorporated by reference to the Company's Annual Report on Form 10–K for the year ended December 31, 1999)
(10)(iii)(a)	Supplemental Savings Plan effective January 1, 1995 as amended (incorporated by reference to Exhibit (10)(iii) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(iii)(b)	Amendment to Supplemental Savings Plan effective January 1, 2000, (incorporated by reference to Exhibit (10)(iii) to the Company's Annual Report on Form 10–K for the year ended December 31, 1999)
(10)(iv)	Standard Form of Severance Agreements (incorporated by reference to Exhibit (10)(iv) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(v)(a)	Non Employee Directors' Deferred and Long Term Compensation Plan (incorporated by reference to Exhibit (10)(vi) the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(v)(b)	Amendment No. 1 to Non Employee Directors' Deferred and Long Term Compensation Plan, effective May 6, 1998 (incorporated by reference to Exhibit (10)(v) to the Company's Annual Report on Form 10–K for the year ended December 31, 1999)
(10)(vi)	Split—Dollar Life Insurance (incorporated by reference to Exhibit (10)(vii) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(vii)	Standard Form of Change in Control Agreement (incorporated by reference to Exhibit (10)(viii) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(viii)	Directors Retirement Plan, effective January 1, 1993 (incorporated by reference to Exhibit (10)(ix) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)
(10)(ix)(a)	1998 Stock Compensation Plan (incorporated by reference to Exhibit 99.1 to the Company's Registration Statement on Form S–8 filed August 17, 1998)
(10)(ix)(b)	Amendment to 1998 Employee Stock Compensation Plan dated February 15, 1999 (incorporated by reference to Exhibit (10)(ix) to the Company's Annual Report on Form 10–K for the year ended December 31, 1999)

(10)(x) 1993 Employee Stock Compensation Plan as amended on November 21, 1997 (incorporated by reference to Exhibit (10)(x) to the Company's Annual Report on Form 10–K for the year ended December 31, 1997)

(10)(xi) 1984 Employee Stock Option Plan as amended February 10, 1997 (incorporated by reference to Exhibit (10)(xi) to the

Company's Annual Report on Form 10-K for the year ended December 31, 1997)

(10)(xii) Employment Agreement with Mark P. Bulriss effective April 1, 1998 (incorporated by reference to Exhibit (10)(b) to

the Company's Quarterly Report on Form 10-Q for the period ended March 31, 1998)

(10)(xiii) Stock Option and Restricted Stock Agreements with Mark P. Bulriss effective April 1, 1998 (incorporated by reference

to Exhibit (10)(a) to the Company's Quarterly Report on Form 10–Q for the period ended June 30, 1998)

Supplemental Executive Long Term Disability Benefit Plan effective January 1, 1995 (incorporated by reference to Exhibit (10)(xiv)(a) to the Company's Annual Report on Form 10–K for the year ended December 31, 2001)

Amendment to Supplemental Executive Long Term Disability Benefit Plan dated April 3, 1998 (incorporated by

reference to Exhibit (10)(xiv)(b) to the Company's Annual Report on Form 10-K for the year ended December 31,

2001)

(10)(xv) 2002 Stock Option and Incentive Plan

(21) Subsidiaries

(23) Consent of Independent Auditors (99)(i)(a) Statement of Chief Executive Officer (99)(i)(b) Statement of Chief Financial Officer

(b) Reports on Form 8–K

(10)(xiv)(a)

(10)(xiv)(b)

No Reports on Form 8-K were filed during the quarter ended December 31, 2002.

### GREAT LAKES CHEMICAL CORPORATION AND SUBSIDIARIES VALUATION AND QUALIFYING ACCOUNTS DECEMBER 31, 2002

### Additions

Description	Balance at Beginning of Period	Charges to Costs and Expenses	Charged to Other Accounts	Deductions	Balance at End of Period
2002:					
Reserve deducted from asset:					
Allowance for doubtful					
accounts receivable	\$ 5,845,000	\$ 1,809,000	\$ _	\$ 2,912,000 <sub>(A)</sub>	\$ 4,742,000
2001:					
Reserve deducted from asset:					
Allowance for doubtful accounts receivable	\$ 4,252,000	\$ 1,942,000	\$ _	\$ 349,000 <sub>(A)</sub>	\$ 5,845,000
2000:					
Reserve deducted from asset:					
Allowance for doubtful					
accounts receivable	\$ 3,986,000	\$ 226,000	\$ _	\$ $(40,000)^{(A)}$	\$ 4,252,000

(A)

Uncollectible accounts receivable written off, net of recoveries and foreign currency translation.

73

### **SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### GREAT LAKES CHEMICAL CORPORATION

(Registrant)

Date March 10, 2003 /s/ Mark P. Bulriss

> Mark P. Bulriss, Chairman, President and Chief Executive Officer (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Date	March 10, 2003	/s/ John J. Gallagher III
		John J. Gallagher III, Senior Vice President and Chief Financial Officer (Principal Financial Officer)
Date	March 10, 2003	/s/ William L. Sherwood
		William L. Sherwood, Vice President and Corporate Controller (Principal Accounting Officer)
Date	March 10, 2003	/s/ Nigel D. T. Andrews
		Nigel D. T. Andrews, Director
Date	March 10, 2003	/s/ James W. Crownover
		James W. Crownover, Director
Date	March 10, 2003	/s/ Thomas M. Fulton
		Thomas M. Fulton, Director
Date	March 10, 2003	/s/ Martin M. Hale

		Martin M. Hale, Director
Date	March 10, 2003	/s/ Louis E. Lataif
		Louis E. Lataif, Director
Date	March 10, 2003	/s/ John C. Lechleiter
		John C. Lechleiter, Director
Date	March 10, 2003	/s/ Mack G. Nichols
		Mack G. Nichols, Director
Date	March 10, 2003	/s/ Jay D. Proops
		Jay D. Proops, Director
		74

#### Certifications

### I, Mark P. Bulriss, certify that:

- I have reviewed this annual report on Form 10–K of Great Lakes Chemical Corporation;
- 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
- 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–14 and 15d–14) for the registrant and have:
  - designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
  - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the "Evaluation Date"); and
  - presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as
    of the Evaluation Date;
- 5.

  The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
  - all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
- 6. The registrant's other certifying officers and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: March 10, 2003 /s/ Mark P. Bulriss
Mark P. Bulriss, Chief Executive Officer

#### I, John J. Gallagher III, certify that:

- I have reviewed this annual report on Form 10–K of Great Lakes Chemical Corporation;
- 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
- 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–14 and 15d–14) for the registrant and have:
  - designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
  - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the "Evaluation Date"); and
  - presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as
    of the Evaluation Date;
- 5.

  The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
  - all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record,
    process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls;
    and
  - any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
- 6. The registrant's other certifying officers and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: March 10, 2003 /s/ John J. Gallagher III
John J. Gallagher III, Chief Financial Officer

<u>PART I</u>
ITEM 1. Business
ITEM 2. Properties
ITEM 3. Legal Proceedings
ITEM 4. Submission of Matters to a Vote of Security Holders
<u>PART II</u>
ITEM 5. Market for the Registrant's Common Equity and Related Stockholder Matters
ITEM 6. Selected Einancial Data

ITEM 6. Selected Financial Data

ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk

ITEM 8. Financial Statements and Supplementary Data

Item 9. Changes in and Disagreements with Accountants and Financial Disclosure PART III

Item 10. Directors and Executive Officers of the Registrant

Item 11. Executive Compensation

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 13. Certain Relationships and Related Transactions

Item 14. Controls and Procedures

PART IV

**QuickLinks** 

Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K

**SCHEDULE II** 

**SIGNATURES** 

Certifications

Exhibit (3)(ii)

# AMENDED AND RESTATED BY-LAWS OF GREAT LAKES CHEMICAL CORPORATION

### ARTICLE I Stockholders

Section 1. Annual Meeting. The annual meeting of the stockholders of the Corporation shall be held at the registered office of the Corporation in the State of Delaware or at such other place within or without the State of Delaware, as may be determined by the Board of Directors and as may be stated in the notice of the meeting. The annual meeting shall be held on such date and at such time as shall be designated from time to time by the Board of Directors. The business to be transacted at such meeting shall be the election of directors and such other business as shall properly be brought before the meeting.

No business may be transacted at an annual meeting of stockholders, other than business that is (a) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors (or any duly authorized committee thereof), (b) otherwise properly brought before the annual meeting by or at the direction of the Board of Directors (or any duly authorized committee thereof) or (c) otherwise properly brought before the annual meeting by any stockholder of the Corporation (i) who is a stockholder of record on the date of the giving of the notice provided for in this Section 1 and on the record date for the determination of stockholders entitled to vote at such annual meeting and (ii) who complies with the notice procedures set forth in this Section 1.

In addition to any other applicable requirements, for business to be properly brought before an annual meeting by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary of the Corporation.

To be timely, a stockholder's notice to the Secretary must be delivered to or mailed and received at the principal executive offices of the Corporation not less than one hundred twenty (120) days nor more than one hundred fifty (150) days prior to the anniversary date of the immediately preceding annual meeting of stockholders; *provided*, *however*, that in the event that the annual meeting called for a date that is not within thirty (30) days before or after such anniversary date, notice by the stockholder in order to be timely must be so received not later than the close of business on the tenth (10th) day following the day on which notice of the date of the annual meeting was mailed or public announcement of the date of the annual meeting was made, whichever first occurs. In no event shall the public announcement of an adjournment of an annual meeting commence a new time period for the giving of a stockholder's notice as described above.

To be in proper written form, a stockholder's notice to the Secretary must set forth as to each matter such stockholder proposes to bring before the annual meeting (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (ii) the name and record address of such stockholder, (iii) the class or series and number of shares of capital stock of the Corporation which are owned beneficially or of record by such stockholder, (iv) a description of all arrangements or understandings between such stockholder and any other person or persons (including their names) in connection with the proposal of such business by such stockholder and any material interest of such stockholder in such business and (v) a representation that such stockholder intends to appear in person or by proxy at the annual meeting to bring such business before the meeting.

No business shall be conducted at the annual meeting of stockholders except business brought before the annual meeting in accordance with the procedures set forth in this Section 1; provided,

however, that, once business has been properly brought before the annual meeting in accordance with such procedures, nothing in this Section 1 shall be deemed to preclude discussion by any stockholder of any such business. If the Chairman of an annual meeting determines that business was not properly brought before the annual meeting in accordance with the foregoing procedures, the Chairman shall declare to the meeting that the business was not properly brought before the meeting and such business shall not be transacted.

The term "public announcement" shall mean an announcement in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Section 2. Special Meetings. Special meetings of the stockholders may be called by the Board of Directors, by the Chairman, or by the President. At any time, upon the written request of any person or persons entitled to call a special meeting, it shall be the duty of the Secretary to send out notices of such meeting, to be held within or without the State of Delaware and at such time, but not less than fifteen days nor more than thirty days after receipt of the request, as may be fixed by the Board of Directors. If the Board of Directors shall fail to fix a time or place, the meeting shall be held at the registered office of the Corporation in the State of Delaware at such time as shall be fixed by the Secretary within the above limits.

### Section 3. Notice of Meetings and Adjourned Meetings.

- (a) A written or printed notice of each meeting of stockholders shall be given which shall state the place, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. The written or printed notice of any meeting shall be given not less than ten nor more than sixty days before the date of the meeting to each stockholder entitled to vote at such meetings. If mailed, notice shall be deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder at his address as it appears on the records of the Corporation. No publication of the notice of meetings shall be required. An affidavit of the Secretary or an Assistant Secretary or of the Transfer Agent of the Corporation that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. Any previously scheduled meeting of the stockholders may be postponed, and (unless the Certificate of Incorporation provides otherwise) any special meeting of the stockholders may be canceled, by resolution of the Board of Directors upon public notice given prior to the date previously scheduled for such meeting of stockholders.
- (b) Whether or not a quorum is present, any annual, regular or special meeting of the stockholders may be adjourned to another date by the Chairman of the meeting or by a majority vote by the shares represented at such meeting. When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty days, or if after the adjournment a new

record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

- (c) Whenever a notice of a meeting is required to be given to stockholders, a written waiver thereof, signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting, either in person or by proxy, shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of a meeting, to the transaction of any business because the meeting was not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice.
- Section 4. Quorum. Except as otherwise provided by law, a quorum at all meetings of stockholders shall consist of the holders of record of a majority of the shares entitled to vote thereat.
- Section 5. Conduct of Meeting. Meetings of the stockholders shall be presided over by the Chairman, or if he is not present, by the President, or if he is not present, by a Vice President or other person chosen at the meeting. The Secretary or an Assistant Secretary of the Corporation, or in his absence, a person chosen at the meeting, shall act as Secretary of the meeting.
- Section 6. Inspectors of Election. Whenever any stockholder present at a meeting of the stockholders shall request the appointment of inspectors, the Chairman of the meeting shall appoint inspectors who need not be stockholders. If the right of any person to vote at such meeting shall be challenged, the inspectors of election shall determine such right. The inspectors shall receive and count the votes either upon an election or for the decision of any question, and shall determine the result. Their certificate of any vote shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
- Section 7. Voting. All elections of directors shall be by written ballot. Only persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the Corporation, except as may be otherwise provided in the Restated Certificate of Incorporation of the Corporation. Nominations of persons for election to the Board of Directors may be made at any annual meeting of stockholders (a) by or at the direction of the Board of Directors (or any duly authorized committee thereof) or (b) by any stockholder of the Corporation (i) who is a stockholder of record on the date of the giving of the notice provided for in this Section 7 and on the record date for the determination of stockholders entitled to vote at such annual meeting and (ii) who complies with the notice procedures set forth in this Section 7.

In addition to any other applicable requirements, for a nomination to be made by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary of the Corporation.

To be timely, a stockholder's notice to the Secretary must be delivered to or mailed and received at the principal executive offices of the Corporation not less than one hundred and twenty (120) days nor more than one hundred fifty (150) days prior to the anniversary date of the immediately preceding annual meeting of stockholders; provided, however, that in the event that the annual meeting called for a date that is not within thirty (30) days before or after such anniversary date, notice by the stockholder in order to be timely must be so received not later than the close of business on the tenth (10th) day following the day on which notice of the date of the annual meeting was mailed or public announcement (as defined in Section 1) of the date of the annual meeting was made, whichever first occurs. In no event shall the public announcement of an adjournment of an annual meeting commence a new time period for the giving of a stockholder's notice as described above.

To be in proper written form, a stockholder's notice to the Secretary must set forth (a) as to each person whom the stockholder proposes to nominate for election as a director (i) the name, age, business address and residence address of the person, (ii) the principal occupation or employment of the person, (iii) the class or series and number of shares of capital stock of the Corporation which are owned beneficially or of record by the person and (iv) any other information relating to the person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act, and the rules and regulations promulgated thereunder; and (b) as to the stockholder giving the notice (i) the name and record address of such stockholder, (ii) the class or series and number of shares of capital stock of the Corporation which are owned beneficially or of record by such stockholder, (iii) a description of all arrangements or understandings between such stockholder and each proposed nominee and any other person or persons (including their names) pursuant to which the nomination(s) are to be made by such stockholder, (iv) a representation that such stockholder intends to appear in person or by proxy at the annual meeting to nominate the persons named in his notice and (v) any other information relating to such stockholder that would be required

to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder. Such notice must be accompanied by a written consent of each proposed nominee to be named as a nominee and to serve as a director if elected.

No person shall be eligible for election as a director of the Corporation unless nominated in accordance with the procedures set forth in this Section 7. If the Chairman of the annual meeting determines that a nomination was not made in accordance with the foregoing procedures, the Chairman shall declare to the meeting that the nomination was defective and such defective nomination shall be disregarded.

At every meeting of the stockholders, each stockholder entitled to vote at such meeting shall have, as to each matter submitted to a vote, one vote for each share of stock having voting rights registered in his name on the stock books of the Corporation.

At all meetings of stockholders, a stockholder may vote by proxy appointed by a written instrument signed by the stockholder or his duly authorized attorney in fact and delivered to the Secretary of the meeting, but no proxy shall be voted or acted upon after three years from its date, unless the proxy provided for a longer period.

A quorum being present, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote.

In all matters, other than the election of directors, the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter, a quorum being present, shall be the act of the stockholders.

Section 8. List of Stockholders. The Secretary or other officer of the Corporation having charge of the stock ledger shall prepare and make or cause to be prepared and made, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said election, arranged in alphabetical order, and showing the address of each such stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the

meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder or his proxy who may be present. Upon the willful neglect or refusal of the directors then in office to produce or cause to be produced such a list at any meeting for the election of directors, they shall be ineligible to any office at such meeting. The original or duplicate stock ledger shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list required by this section, or to vote in person or by proxy at such meeting.

#### Section 9. Fixing Date for Determination of Stockholders of Record.

- (a) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty nor less than ten days before the date of such meeting, nor more than sixty days prior to any other action.
  - (b) If no record date is fixed:
    - (i) The record date for determining stockholders entitled to notice of or to vote at a meeting of the stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.
    - (ii) The record date for determining stockholder for any other purpose shall be at the close of business on the date on which the Board of Directors adopts the resolution relating thereto.
- (c) A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

## ARTICLE II Directors

- Section 1. Number, Qualifications, Classes, Terms and Quorum. The business and affairs of the Corporation shall be managed under the direction of a Board of Directors which shall consist of nine members, none of whom need be a stockholder. The directors shall be classified with respect to the time for which they shall hold office by dividing them into three classes. The first class shall consist of three directors whose terms of office shall expire in 2000 and in every third year thereafter. The second class shall consist of three directors whose terms of office shall expire in 2001 and in every third year thereafter. The third class shall consist of three directors whose term of office shall expire in 2002 and in every third year thereafter. At each annual meeting of the stockholders of the Corporation, or any adjournment thereof, the successors to the directors whose terms shall expire in that year shall be elected to hold office for a term of three years. In any event, each director shall hold office until his successor is duly elected and qualified or until his earlier resignation or removal. Any director may resign at any time upon written notice to the Corporation. A majority of the total number of directors shall constitute a quorum for the transaction of business. The vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. The Board of Directors may elect a Chairman of the Board of Directors who shall preside at all meetings of the stockholders and of the Board of Directors. The Chairman of the Board of Directors who shall preside at all meetings of the stockholders and of Directors or as are incidental to his office.
- Section 2. Vacancies. Any vacancy and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director.
- Section 3. Meetings. The Board of Directors shall meet each year immediately after the annual meeting of the stockholders, at the place where the annual meeting of the stockholders is held, for the purpose of electing officers and for the conduct of any other business that may be brought before the meetings. Such meeting shall be held without notice. If such meeting is not held as herein provided, the election of officers may be had at any subsequent meeting of the Board of Directors. Regular meetings of the Board of Directors may be held at such time and place within or without the State of Delaware, as the Board of Directors may from time to time designate. Special meetings of the Board of Directors may be held upon the call of the Chairman of the Board, or two or more members of the Board of Directors, at any place, within or without the State of Delaware, upon not less than 48 hours notice, specifying the time, place and general purposes of the meeting, given to each director either personally, or by telephone, telegram, or by mail. At any meeting at which all of the directors are present, notice of the time, place and purposes thereof shall be deemed waived. Notice of any meeting may be waived in writing, either before, during, or after any meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the directors, or members of a committee of the directors, need be specified in any written waiver of notice. A majority of the directors present at any meeting, whether or not a quorum is present, may adjourn the meeting and no notice of such adjourned meeting need be given.
- Section 4. Committees. The Board of Directors may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of one or more directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members

thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.

Any such committee, to the extent provided in the resolution of the Board of Directors, shall have and may exercise the authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to amending the Certificate of Incorporation, adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange of all or substantially all of the Corporation's property and assets, recommending to the stockholders a dissolution of the Corporation or a revocation of a dissolution or amending the By–Laws of the Corporation; and, unless the resolution expressly so provides, no such committee shall have the power or authority to declare a dividend or authorize the issuance of stock.

Section 5. Action by Consent Without a Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.

Section 6. Meetings by Conference Telephone. Members of the Board of Directors or of any committee designated by the Board may participate in a meeting of such Board or committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this Section shall constitute presence in person at such meeting.

### ARTICLE III Officers

- Section 1. Officers. The officers shall consist of a Chief Executive Officer, a President, one or more Vice Presidents and/or Senior or Executive Vice Presidents, a Secretary, one or more Assistant Secretaries, a Treasurer, and one or more Assistant Treasurers. Such officers shall be elected by the Board of Directors and each officer shall hold office until his successor is elected and qualified or until his earlier resignation or removal. Any officer may resign at any time upon written notice to the Corporation. Any number of offices may be held by the same person, but no officer shall execute, act or verify any instrument in more than one capacity. The Corporation may have such other officers and agents as the Board of Directors may determine, who shall be elected or appointed by the Board of Directors and hold office for such terms as are prescribed by the Board of Directors. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise, shall be filled by the Board of Directors. The Board of Directors may remove any officer with or without cause.
- Section 2. Chief Executive Officer. Subject to the authority of the Board of Directors, the Chief Executive Officer shall administer the affairs of the Corporation and shall have such other powers and perform such other duties as are delegated to him by the Board of Directors, or by an authorized committee thereof, or are incidental to his office. During the time when the office of the Chairman of the Board is vacant, the Chief Executive Officer shall perform the duties of that office.
- Section 3. President. Subject to the authority of the Board of Directors, the President shall, during the absence or disability of the Chief Executive Officer, administer the affairs of the Corporation and shall have such other powers and perform such other duties as are incidental to his office or as are delegated to him by the Board of Directors, or an authorized committee thereof, or by the Chief Executive Officer.
- Section 4. Vice Presidents. Subject to the authority of the Board of Directors, the Vice Presidents, in the order designated by the Board of Directors, shall exercise the functions of the Chief Executive Officer and the President during the absence or disability of the Chief Executive

Officer and the President. Each Vice President shall have such other duties as are assigned to him from time to time by the Board of Directors or the Chief Executive Officer.

- Section 5. Other Officers. The Secretary and the Treasurer shall perform such duties as are incidental to their offices, or as are properly required of them by the Board of Directors or the Chief Executive Officer. The Assistant Secretaries shall, in the absence of the Secretary, perform the duties and exercise the powers of the Secretary, and shall perform such other duties as may be assigned by the Board of Directors or the Chief Executive Officer. Other subordinate officers elected or appointed by the Board of Directors shall exercise such powers and perform such duties as may be delegated to them.
- Section 6. Delegation of Authority. In the case of the absence or incapacity of any officer, or for any other reason that the Board of Directors may deem sufficient, the Board of Directors or, in the absence of any action by the Board of Directors, the Chief Executive Officer may delegate any or all of the duties or powers of such officer to any other officer or to any other director or to any other person.

# ARTICLE IV Certificates of Stock

- Section 1. Form. Every holder of stock in the Corporation shall be entitled to have a certificate signed by the Chairman of the Board of Directors, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary of the Corporation certifying the number of shares owned by him in such Corporation. If such certificate is countersigned (1) by a Transfer Agent other than the Corporation or its employee, or, (2) by a Registrar other than the Corporation or its employee, any other signature on the certificate may be a facsimile. In case any officer, Transfer Agent or Registrar who has signed or whose facsimile signature has been placed upon a certificate who has ceased to be such officer, Transfer Agent or Registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, Transfer Agent or Registrar at the date of issue.
- Section 2. Transfers. Transfers of shares of stock of the Corporation shall be made only on the books of the Corporation by the registered owner thereof, or his duly authorized attorney, with a Transfer Clerk or Transfer Agent appointed as specified in these By–Laws, and on surrender of the certificate or certificates for such shares of stock properly endorsed and with all taxes thereon paid. The person in whose name the shares of stock stand on the books of the Corporation shall be deemed by the Corporation to be the holder thereof for all purposes.
- Section 3. Transfer Agent and Registrar. The Board of Directors may appoint one or more Transfer Agents or Transfer Clerks and one or more Registrars, and may require all certificates for shares of stock to bear the signature or signatures of any of them.
- Section 4. Loss or Destruction. In case of loss or destruction of a certificate for shares, another certificate may be issued in lieu thereof in such manner and upon such terms as the Board of Directors shall authorize, either by general resolution or by special resolution in each particular case.

### ARTICLE V Fiscal Year

Section 1. Fiscal Year. The fiscal year of the Corporation shall begin on the first day of January of each year and shall end on the 31st day of December following.

### ARTICLE VI

Seal

Section 1. Corporation Seal. The Board of Directors shall provide a suitable corporate seal for use by the Corporation.

#### Indemnification

Section 1. Indemnification. Each person who was or is made a party or is threatened to be made a party to or is involved in or called as a witness in any action, suit or proceeding, whether civil, criminal, administrative or investigative, and any appeal therefrom (hereinafter, collectively a "Proceeding"), by reason of the fact that he or she, or a person of whom he or she is the legal representative, is, was or had agreed to become a director of the Corporation or is, was or had agreed to become an officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, shall be indemnified and held harmless by the Corporation to the fullest extent permitted under the General Corporation Law of the State of Delaware (the "DGCL"), as the same now exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than the DGCL permitted the Corporation to provide prior to such amendment), against all expenses, liabilities and losses (including attorneys' fees, judgments, fines, excise taxes or penalties pursuant to the Employee Retirement Income Security Act of 1974, as amended, and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith; provided, that except as explicitly provided herein, prior to a Change in Control of the Corporation, as defined herein, a person seeking indemnity in connection with a Proceeding (or part thereof) initiated by such person against the Corporation or any director, officer, employee or agent of the Corporation shall not be entitled thereto unless the Corporation has joined in or consented to such proceeding (or part thereof). For purposes of this Article, a "Change in Control of the Corporation" shall be deemed to have occurred if the conditions set forth in any one of the following clauses shall have been satisfied: (a) any "person" (as such term is used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934 (as in effect as of December 7, 1995 (the "Exchange Act")) other than (i) the Corporation, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Corporation, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the stockholders of the Corporation in substantially the same proportions as their ownership of shares of the Corporation (any such person is hereinafter referred to as a "Person"), is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Corporation representing more than 50% of the combined voting power of the Corporation's then outstanding securities (not including in the securities beneficially owned by such Person any securities acquired directly from the Corporation); (b) there is consummated a merger or consolidation of the Corporation with or into any other corporation, other than a merger or consolidation which would result in the holders of the voting securities of the Corporation outstanding immediately prior thereto holding securities which represent, in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Corporation, immediately after such merger or consolidation, more than 70% of the combined voting power of the voting securities of either the Corporation or the other entity which survives such merger or consolidation or the parent of the entity which survives such merger or consolidation; (c) the stockholders of the Corporation approve any plan or proposal for the liquidation or dissolution of the Corporation or an agreement for the sale or disposition by the Corporation of all or substantially all the Corporation's assets; or (d) during any period of two consecutive years (not including any period prior to December 7, 1995), individuals who at the beginning of such period constitute the Board of Directors and any new director (other than a director designated by a Person who has entered into an agreement with the Corporation to effect a

transaction described in clause (a), (b) or (c) of this paragraph) whose election by the Board or nomination for election by the Corporation's stockholders was approved by a vote of at least two–thirds  $(^2/^3)$  of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof. For purposes of this Article VII, where a Change in Control of the Corporation results from a series of related transactions, the Change in Control of the Corporation shall be deemed to have occurred on the date of the consummation of the first such transaction. For purposes of clause (a) of this paragraph, the stockholders of another corporation (other than the Corporation or a corporation described in clause (iv)), in the aggregate, shall be deemed to constitute a Person.

Prior to a Change in Control of the Corporation, any indemnification under Section 1 (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the DGCL. Such determination shall be made (1) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to such action, suit or proceeding, or (2) if such quorum is not obtainable, or, even if obtainable a quorum of disinterested directors so directs, by independent legal counsel (who may be the regular counsel of the Corporation) in a written opinion or (3) by the stockholders.

Following a Change in Control of the Corporation, any indemnification under this Section 1 (unless ordered by a court) shall be paid by the Corporation unless within 60 days of such request for indemnification a determination is made, in a written opinion, by special independent counsel selected by the person requesting indemnification and approved by the Corporation (which approval shall not be unreasonably withheld), which counsel has not otherwise performed services (other than in connection with similar matters) within the five years preceding its engagement to render such opinion for such person or for the Corporation or any affiliates (as such term is defined in Rule 405 under the Securities Act of 1933, as amended) of the Corporation (whether or not they were affiliates when services were so performed) ("Independent Counsel"), that indemnification of such person is not proper under the circumstances because such person has not met the necessary standard of conduct under the DGCL. Unless such person has theretofore selected Independent Counsel pursuant to this Section 1 and such Independent Counsel has been approved by the Corporation, legal counsel approved by a resolution or resolutions of the Board of Directors prior to a Change in Control of the Corporation shall be deemed to have been approved by the Corporation as required. Such Independent Counsel shall determine as promptly as practicable whether and to what extent such person would be permitted to be indemnified under applicable law and shall render its written opinion to the Corporation and such person to such effect. The Corporation agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such Independent Counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Article or its engagement pursuant hereto. In making a determination under this Section 1, the Independent Counsel referred to above shall determine that indemnification is permissible unless cle

Section 2. Payment of Expenses in Advance. Expenses, including attorneys' fees, incurred by a person referred to in Section 1 of this Article in defending a proceeding shall be paid by the Corporation in advance of the final disposition of such proceeding, including any appeal therefrom, upon receipt of an undertaking (the "Undertaking") by or on behalf of such person to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Corporation.

Section 3. Right of Claimant to Bring Suit. If a claim under Section 1 hereof is not paid in full by the Corporation within 60 days after a written claim has been received by the Corporation or if expenses pursuant to Section 2 hereof have not been advanced within 10 days after a written request for such advancement, accompanied by the Undertaking, has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the

unpaid amount of the claim or the advancement of expenses. (If the claimant is successful, in whole or in part, in such suit or any other suit to enforce a right for expenses or indemnification against the Corporation or any other party under any other agreement, such claimant shall also be entitled to be paid the reasonable expense of prosecuting such claim.) It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required Undertaking has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the DGCL for the Corporation to indemnify the claimant for the amount claimed. After a Change in

Control of the Corporation, the burden of proving such defense shall be on the Corporation, and any determination by the Corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant had not met the applicable standard of conduct required under the DGCL shall not be a defense to the action nor create a presumption that claimant had not met such applicable standard of conduct.

- Section 4. Indemnity Not Exclusive. The indemnification and advancement of expenses provided by, or granted pursuant to, the other sections of this Article VII shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any statute, by—law, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office. The Board of Directors shall have the authority, by resolution, to provide for such other indemnification of directors, officers, employees or agents as it shall deem appropriate.
- Section 5. Insurance Indemnification. The Corporation shall have power to purchase and maintain insurance to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise, against any expenses, liabilities or losses, whether or not the Corporation would have the power to indemnify such person against such expenses, liabilities or losses under the provisions of this Article VII or the DGCL.
- Section 6. Continuation of Indemnification; Enforceability. The provisions of this Article shall be applicable to all proceedings commenced after its adoption, whether such arise out of events, acts, omissions or circumstances which occurred or existed prior or subsequent to such adoption, and shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such person. This Article shall be deemed to grant each person who, at any time that this Article is in effect, serves or agrees to serve in any capacity which entitles him to indemnification hereunder rights against the Corporation to enforce the provisions of this Article, and any repeal or other modification of this Article or any repeal or modification of the DGCL or any other applicable law shall not limit any rights of indemnification then existing or arising out of events, acts, omissions or circumstances occurring or existing prior to such repeal or modification, including, without limitation, the right to indemnification for proceedings commenced after such repeal or modification to enforce this Article with regard to acts, omissions, events or circumstances occurring or existing prior to such repeal or modification.
- Section 7. Severability. If this Article or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each director and officer of the Corporation as to costs, charges and expenses (including attorneys' fees), judgments, fines and amounts paid in settlement with respect to any proceeding, whether civil, criminal, administrative or investigative, including an action by or in the right of the Corporation, to the full extent permitted by any applicable portion of this Article that shall not have been invalidated and to the full extent permitted by applicable law.

### ARTICLE VIII Amendments

Section 1. Amendments. The Board of Directors shall have the power to make, alter or repeal the By-Laws of the Corporation at the annual or any regular meeting of the Board of Directors or by unanimous written consent without a meeting, or at any special meeting called for such purposes.

AMENDED AND RESTATED BY-LAWS ADOPTED BY THE BOARD OF DIRECTORS ON MAY 2, 2002.

/s/ Karen Witte Duros
Karen Witte Duros, Assistant Secretary

QuickLinks

Exhibit (3)(ii)

Exhibit (10)(xv)

### GREAT LAKES CHEMICAL CORPORATION 2002 STOCK OPTION AND INCENTIVE PLAN

1. Plan Purpose. The purpose of the Plan is to promote the long—term interests of the Company and its shareholders by providing a means for attracting and retaining officers, directors and key employees of the Company and its Affiliates.

### 2. Definitions. The following definitions are applicable to the Plan:

"Affiliate" means any "parent corporation" or "subsidiary corporation" of the Company as such terms are defined in Code sections 424(e) and (f), respectively.

"Affiliated SAR" means a SAR that is granted in connection with a related Option, and which automatically will be deemed to be exercised at the same time that the related Option is exercised. The deemed exercise of an Affiliated SAR will not necessitate a reduction in the number of Shares subject to the related Option.

"Award" means the grant by the Committee of Incentive Stock Options, Non-Qualified Stock Options, SARs, Restricted Shares, Restricted Share Units, Performance Shares or any combination thereof, as provided in the Plan.

"Award Agreement" means the written agreement setting forth the terms and provisions applicable to each Award granted under the Plan.

"Base Price" means the amount over which the appreciation in value of a Share will be measured upon exercise of a SAR.

"Board" means the Board of Directors of the Company.

"Cause" means (a) a Participant's dishonesty, fraud or misconduct with respect to the business or affairs of the Company or any Affiliate which materially and adversely affects the operations or reputation of the Company or any Affiliate (monetarily or otherwise); (b) a Participant's conviction of a felony crime or a crime involving moral turpitude or entry of a plea of nolo contendre thereof; (c) a Participant's violation of the Company's Code of Conduct; or (d) a Participant's violation of the Company's or an Affiliate's drug and/or alcohol policy.

"Change in Control" means each of the events set forth in any one of the following paragraphs:

- any "person" (as such term is used in Section 13(d) and 14(d) of the Exchange Act (as in effect as of the date of this Plan) other than (i) the Company, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of shares of the Company (any such person is hereinafter referred to as a "Person"), is or becomes the "beneficial owner" (as defined in Rule 13d–3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 20% of the combined voting power of the Company's then outstanding securities (not including in the securities beneficially owned by such Person any securities acquired directly from the Company);
- there is consummated a merger or consolidation of the Company with or into any other corporation, other than a merger or consolidation which would result in the holders of the voting securities of the Company outstanding immediately prior thereto holding securities which represent, in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company, immediately after such merger or consolidation, more than 70% of the combined voting power of the voting securities of

either the Company or the other entity which survives such merger or consolidation or the parent of the entity which survives such merger or consolidation;

- (c)
  the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company's assets to any Person; or
- during any period of two consecutive years (not including any period prior to the date of this Agreement), individuals who at the beginning of such period constitute the Board of Directors and any new director (other than a director designated by a Person who has entered into an agreement with the Company to effect a transaction described in (a), (b), or (c) above) whose election by the Board or nomination for election by the Company's stockholders was approved by a vote of at least two–thirds (<sup>2</sup>/<sub>3</sub>) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof.

For purposes of this Plan, where a change in control of the Company results from a series of related transactions, the change in control of the Company shall be deemed to have occurred on the date of the consummation of the first such transaction. For purposes of paragraph (a) above, the stockholders of another corporation (other than the Company or a corporation described in clause (iv) of paragraph (a)) shall be deemed to constitute a Person. Further, it is understood by the parties that the sale, transfer, or other disposition of a subsidiary of the Company shall not constitute a change in control of the Company giving rise to payments or benefits under this Plan.

"Code" means the Internal Revenue Code of 1986, as amended, and its interpretive regulations.

"Company" means Great Lakes Chemical Corporation, a Delaware corporation.

"Continuous Service" means, in the case of an Employee, the absence of any interruption or termination of service as an Employee of the Company or an Affiliate; and in the case of an individual who is not an Employee, the absence of any interruption or termination of the service relationship between the individual and the Company or an Affiliate. Service will not be considered interrupted in the case of sick leave, military leave or any other leave of absence approved by the Company or in the case of a Participant's transfer between the Company and an Affiliate or any successor to the Company.

"Director" means any individual who is a member of the Board.

"Disability" means total and permanent disability as determined by the Committee pursuant to Code section 22(e)(3).

"EBITDA" means earnings before interest, taxes, depreciation and amortization.

"Employee" means any person, including an officer or Director, who is employed by the Company or any Affiliate.

"Exchange Act" means the Securities Exchange Act of 1934, as amended.

"Exercise Price" means the price per Share at which the Shares subject to an Option may be purchased upon exercise of the Option.

"Freestanding SAR" means a SAR that is granted independently of any Option.

"Incentive Stock Option" means an option to purchase Shares granted by the Committee pursuant to the terms of the Plan that is intended to qualify under Code section 422.

"Market Value" means the last reported sale price on the last trading date preceding the date in question (or, if there is no reported sale on such date, on the last preceding date on which any

reported sale occurred) of one Share on the New York Stock Exchange, or, if the Shares are not listed on the New York Stock Exchange, on the principal exchange on which the Shares are listed for trading, or, if the Shares are not listed for trading on any exchange, the average trading price of one Share on the date in question as reported on the Nasdaq National Market or any similar system then in use, or, if the Shares are not listed on the Nasdaq National Market, the mean between the closing high bid and low asked quotations of one Share on the date in question as reported by Nasdaq or any similar system then in use, or, if no such quotations are available, the fair market value on such date of one Share as the Committee shall determine.

"Non-Qualified Stock Option" means an option to purchase Shares granted by the Committee pursuant to the terms of the Plan, which option is not intended to qualify under Code section 422.

"Option" means an Incentive Stock Option or a Non-Qualified Stock Option.

"Participant" means any individual selected by the Committee to receive an Award.

"Performance Cycle" means the period of time, designated by the Committee, over which Performance Shares may be earned.

"Performance Shares" means Shares awarded pursuant to Section 14 of the Plan.

"Plan" means the Great Lakes Chemical Corporation 2002 Stock Option and Incentive Plan.

"Reorganization" means the liquidation or dissolution of the Company, or any merger, consolidation or combination of the Company (other than a merger, consolidation or combination in which the Company is the continuing entity and which does not result in the outstanding Shares being converted into or exchanged for different securities, cash or other property or any combination thereof).

"Restricted Period" means the period of time selected by the Committee for the purpose of determining when restrictions are in effect under Section 11 or 12 of the Plan with respect to Restricted Shares or Restricted Share Units.

"Restricted Shares" means Shares that have been contingently awarded to a Participant by the Committee subject to the restrictions referred to in Section 11 of the Plan, so long as such restrictions are in effect.

"Restricted Share Units" means an Award of units pursuant to Section 12 of the Plan. Each Restricted Share Unit shall, at all times, be equal in value to the Market Value of one Share of the Company.

"Retirement" means, in the case of an Employee, a termination of Continuous Service by reason of the Employee's retirement under the Company's Retirement Plan for Certain Employees, or, any other defined benefit retirement plan sponsored by the Company or an Affiliate, that the Employee is eligible to retire under, or any successor plan.

"Stock Appreciation Right" or "SAR" means an Award, granted alone or in connection with a related Option, pursuant to Section 13 of the Plan.

"Securities Act" means the Securities Act of 1933, as amended.

"Shares" means the shares of common stock, \$1.00 par value, of the Company.

"Tandem SAR" means a SAR that is granted in connection with a related Option, the exercise of which requires forfeiture of the right to purchase an equal number of Shares under the related Option (and when a Share is purchased under the Option, the SAR is canceled to the same extent).

3. Administration. The Plan will be administered by the Committee, which will consist of two or more members of the Board, each of whom will be a "non-employee director" as provided under Rule 16b-3 of the Exchange Act, and an "outside director" as provided under Code section 162(m). The members of

(a) select Participants and grant Awards; (b) determine the number of Shares to be subject to types of Awards generally, as well as to individual Awards granted under the Plan; (c) determine the terms and conditions upon which Awards will be granted under the Plan; (d) prescribe the form and terms of Award Agreements; (e) establish procedures and regulations for the administration of the Plan; (f) interpret the Plan; and (g) make all determinations deemed necessary or advisable for the administration of the Plan.

A majority of the Committee will constitute a quorum, and the acts of a majority of the members present at any meeting at which a quorum is present, or acts approved in writing by all members of the Committee without a meeting, will be acts of the Committee. All determinations and decisions made by the Committee pursuant to the provisions of the Plan will be final, conclusive, and binding on all persons, and will be given the maximum deference permitted by law.

- 4. Participants. The Committee may select from time to time Participants in the Plan from those officers, Directors and key Employees of the Company or its Affiliates who, in the opinion of the Committee, have the capacity for contributing in a substantial measure to the successful performance of the Company or its Affiliates.
  - 5. Shares Subject to Plan, Limitations on Grants and Exercise Price. Subject to adjustment by the operation of Section 15 hereof:
    - (a)

      The maximum number of Shares that may be issued with respect to Awards made under the Plan is 2,500,000 Shares. The number of Shares that may be granted under the Plan to any Participant during the term of the Plan under all forms of Awards will not exceed 150,000 Shares per calendar year.
    - The Shares with respect to which Awards may be made under the Plan may either be authorized and unissued shares or issued shares heretofore or hereafter reacquired and held as treasury shares. Any Award that expires, terminates or is surrendered for cancellation, or with respect to Restricted Shares, which is forfeited (so long as any cash dividends paid on such Shares are also forfeited), may be subject to new Awards under the Plan with respect to the number of Shares as to which a termination or forfeiture has occurred.
    - (c)

      The Exercise Price for any Award made under the Plan may not be less than the Market Value of the Shares as of the date of the award.
- 6. General Terms and Conditions of Options. The Committee will have full and complete authority and discretion, except as expressly limited by the Plan, to grant Options and to prescribe the terms and conditions (which need not be identical among Participants) of the Options. Each Option will be evidenced by an Award Agreement that will specify: (a) the Exercise Price, (b) the number of Shares subject to the Option, (c) the expiration date of the Option, (d) the manner, time and rate (cumulative or otherwise) of exercise of the Option, (e) the restrictions, if any, to be placed upon the Option or upon Shares that may be issued upon exercise of the Option, (f) the conditions, if any, under which a Participant may transfer or assign Options, and (g) any other terms and conditions as the Committee, in its sole discretion, may determine. The Committee may, as a condition of granting any Option, require that a Participant agree to surrender for cancellation one or more Options previously granted to such Participant.

#### 7. Exercise of Options.

- (a)

  Except as provided in Section 18, an Option granted under the Plan will be exercisable during the lifetime of the Participant to whom such Option was granted only by the Participant, and except as provided in Section 8 of the Plan, no Option may be exercised unless at the time the Participant exercises the Option, the Participant has maintained Continuous Service since the date of the grant of the Option.
- (b)

  To exercise an Option under the Plan, the Participant must give written notice to the Company specifying the number of Shares with respect to which the Participant elects to

exercise the Option together with full payment of the Exercise Price. The date of exercise will be the date on which the notice is received by the Company. Payment may be made either (i) in cash (including check, bank draft or money order), (ii) by tendering Shares already owned by the Participant for at least six (6) months or such longer period required for financial reporting purposes to avoid a charge to earnings prior to the date of exercise and having a Market Value on the date of exercise equal to the Exercise Price, (iii) through the delivery of a notice that the Participant has placed a market sell order with a broker with respect to Shares issuable upon exercise of the Option and the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company to cover the Exercise Price, or (iv) by any other means determined by the Committee in its sole discretion and, with respect to Incentive Stock Options, reflected in the Award Agreement as of the date of grant.

- 8. Termination of Options. Unless otherwise specifically provided by the Committee in the Award Agreement or any amendment thereto, Options will terminate as provided in this Section.
  - (a)
    Unless sooner terminated under the provisions of this Section, Options will expire on the earlier of the date specified in the Award Agreement or the expiration of ten (10) years from the date of grant.
  - (b)

    If the Continuous Service of a Participant is terminated for reason of Retirement, all outstanding options will become fully vested and the Participant may exercise all outstanding Options in full within the period of two (2) years immediately succeeding the Participant's Retirement.
  - (c)

    If the Continuous Service of a Participant is terminated for Cause, all rights under any Options granted to the Participant will terminate immediately upon the Participant's cessation of Continuous Service, and the Participant will (unless the Committee, in its sole discretion,

waives this requirement) repay to the Company within ten (10) days the amount of any gain realized by the Participant upon any exercise of an Option, awarded under this Plan, within the 90-day period prior to the cessation of Continuous Service.

- (d)

  If the Continuous Service of a Participant is terminated voluntarily by the Participant for any reason other than death, Disability, or Retirement, the Participant may exercise outstanding Options to the extent that the Participant was entitled to exercise the Options at the date of cessation of Continuous Service, but only within the period of three (3) months immediately succeeding the Participant's cessation of Continuous Service, and in no event after the applicable expiration dates of the Options.
- (e)

  If the Continuous Service of a Participant is terminated by the Company without Cause, the Participant may exercise outstanding Options to the extent that the Participant was entitled to exercise the Options at the date of cessation of Continuous Service, but only within the period of two (2) years immediately succeeding the Participant's cessation of Continuous Service, and in no event after the applicable expiration dates of the Options.
- In the event of the Participant's death or Disability, the Participant or the Participant's beneficiary, as the case may be, may exercise outstanding Options to the extent that the Participant was entitled to exercise the Options at the date of cessation of Continuous Service, but only within the period of two (2) years immediately succeeding the Participant's cessation of Continuous Service by reason of death or Disability, and in no event after the applicable expiration date of the Options.
- Notwithstanding the provisions of the foregoing paragraphs of this Section 8, the Committee may, in its sole discretion, establish different terms and conditions pertaining to the effect of the cessation of Continuous Service, to the extent permitted by applicable federal and state law.
- 9. Restrictive Covenants. In its discretion, the Committee may condition the grant of any Award under the Plan upon the Participant agreeing to covenants in favor of the Company and/or any Affiliate (including, without limitation, covenants not to compete, not to solicit employees and customers, and not to disclose confidential information) that may have effect following the termination of employment with the Company or any Affiliate, and after the Award has been exercised, including, without limitation, the requirement to disgorge any profit, gain or other benefit received upon exercise of the Award prior to any breach of any covenant.

#### 10. Incentive Stock Options

- (a) Incentive Stock Options may be granted only to Participants who are Employees. Any provisions of the Plan to the contrary notwithstanding, (a) no Incentive Stock Option will be granted more than ten (10) years from the earlier of the date the Plan is adopted by the Board of Directors of the Company or approved by the Company's Shareholders, (b) no Incentive Stock Option will be exercisable more than ten (10) years from the date the Incentive Stock Option is granted, (c) the Exercise Price of any Incentive Stock Option will not be less than the Market Value per Share on the date such Incentive Stock Option is granted, (d) any Incentive Stock Option will not be transferable by the Participant to whom such Incentive Stock Option is granted other than by will or the laws of descent and distribution and will be exercisable during the Participant's lifetime only by such Participant, (e) no Incentive Stock Option will be granted that would permit a Participant to acquire, through the exercise of Incentive Stock Options in any calendar year, under all plans of the Company and its Affiliates, Shares having an aggregate Market Value (determined as of the time any Incentive Stock Option is granted) in excess of \$100,000 (determined by assuming that the Participant will exercise each Incentive Stock Option on the date that such Option first becomes exercisable), and (f) no Incentive Stock Option may be exercised more than three (3) months after the Participant's cessation of Continuous Service for reasons other than Disability or death of the Participant, or more than one (1) year after the Participant's cessation of Continuous Service due to the Disability or the death of the Participant, Notwithstanding the foregoing, in the case of any Participant who, at the date of grant, owns shares possessing more than 10% of the total combined voting power of all classes of capital stock of the Company or any Affiliate, the Exercise Price of any Incentive Stock Option will not be less than 110% of the Market Value per Share on the date such Incentive Stock Option is granted and such Incentive Stock Option will not be exercisable more than five (5) years from the date such Incentive Stock Option is granted.
- Notwithstanding any other provisions of the Plan, if for any reason an Option granted under the Plan that is intended to be an Incentive Stock Option fails to qualify as an Incentive Stock Option, such Option will be deemed to be a Non–Qualified Stock Option, and such Option will be deemed to be fully authorized and validly issued under the Plan.
- 11. Terms and Conditions of Restricted Shares. The Committee will have full and complete authority, subject to the limitations of the Plan, to grant Awards of Restricted Shares and to prescribe the terms and conditions (which need not be identical among Participants) in respect of the Awards. Unless the Committee otherwise specifically provides in the Award Agreement, an Award of Restricted Shares will be subject to the following provisions:
  - At the time of an Award of Restricted Shares, the Committee will establish for each Participant a Restricted Period during which, or at the expiration of which, the Restricted Shares will vest. Subject to paragraph (e) of this Section, the Participant will have all the rights of a shareholder with respect to the Restricted Shares, including, but not limited to, the right to receive all dividends paid on the Restricted Shares and the right to vote the Restricted Shares. The Committee will have the authority, in its discretion, to accelerate the time at which any or all of the restrictions will lapse with respect to any Restricted Shares prior to the expiration of the Restricted Period, or to remove any or all restrictions, whenever it may determine that such action is appropriate by reason of changes in applicable tax or

other laws or other changes in circumstances occurring after the commencement of the Restricted Period.

(b)
Subject to Section 17, if a Participant ceases Continuous Service for any reason, including death, before the Restricted Shares have vested, a Participant's rights with respect to the unvested portion of the Restricted Shares will terminate and be returned to the Company.

Each certificate issued in respect to Restricted Shares will be registered in the name of the Participant and deposited by the Participant, together with a stock power endorsed in blank, with the Company and will bear the following (or a similar) legend:

"The transferability of this certificate and the shares represented hereby are subject to the terms and conditions (including forfeiture) contained in the Great Lakes Chemical Corporation 2002 Stock Option and Incentive Plan and an Award Agreement entered into between the registered owner and Great Lakes Chemical Corporation. Copies of the Plan and Award Agreement are on file in the office of the Secretary of Great Lakes Chemical Corporation."

- (d)
  At the time of an Award of Restricted Shares, the Participant will enter into an Award Agreement with the Company in a form specified by the Committee agreeing to the terms and conditions of the Award.
- At the time of an Award of Restricted Shares, the Committee may, in its discretion, determine that the payment to the Participant of dividends declared or paid on the Restricted Shares by the Company, or a specified portion thereof, will be deferred until the earlier to occur of (i) the lapsing of the restrictions imposed with respect to the Restricted Shares, or (ii) the forfeiture of such Restricted Shares under paragraph (b) of this Section, and will be held by the Company for the account of the Participant until such time. In the event of deferral, there will be credited at the end of each year (or portion thereof) interest on the amount of the account at the beginning of the year at a rate per annum as the Committee, in its discretion, may determine. Payment of deferred dividends, together with accrued interest, will be made upon the earlier to occur of the events specified in (i) and (ii) of this paragraph.
- (f)

  At the expiration of the restrictions imposed by this Section, the Company will redeliver to the Participant the certificate(s) and stock powers, deposited with the Company pursuant to paragraph (c) of this Section and the Shares represented by the certificate(s) will be free of all restrictions.
- (g) No Award of Restricted Shares maybe assigned, transferred or encumbered.
- 12. Award of Restricted Share Units. The Committee will have full and complete authority, subject to the limitations of the Plan, to grant Awards of Restricted Share Units and to prescribe the terms and conditions (which need not be identical among Participants) in respect of the Awards. Unless the Committee otherwise specifically provides in the Award Agreement, an Award of Restricted Share Units will be subject to the following provisions:
  - At the time of an Award of Restricted Share Units, the Committee will establish for each Participant a Restricted Period during which, or at the expiration of which, the Restricted Share Units will vest. The Committee will have the authority, in its discretion, to accelerate the time at which any and all of the restrictions will lapse with respect to any Restricted Share Units prior to the expiration of the Restricted Period, or to remove any or all restrictions, whenever it may determine that such action is appropriate by reason of changes in applicable tax or other laws or other changes in circumstances occurring after the commencement of the Restricted Period.
  - (b)
    Subject to Section 17, if a Participant ceases Continuous Service for any reason, including death, before the Restricted Share Units have vested, a Participant's rights with respect to

the unvested portion of the Restricted Share Units will terminate and be returned to the Company.

- (c)
  As soon as practicable following vesting, the Company shall deliver to the Participant the number of Shares equal to the number of Restricted Share Units that have vested, minus the number of Shares necessary to cover applicable withholding taxes.
- 13. Grant of SARs. Subject to the terms and conditions of the Plan, an Award of SARs may be made to Participants at any time and from time to time as determined by the Committee, in its sole discretion. The Committee may grant Affiliated SARs, Freestanding SARs, Tandem SARs, or any combination thereof as follows:
  - (a)

    The Committee, subject to the limitations of the Plan, will have complete discretion to determine the terms and conditions (which need not be identical among all Participants) of SARs granted under the Plan. Each SAR Award will be evidenced by an Award Agreement specifying the terms and conditions of the Award, including its term, the Base Price and the conditions of exercise.
  - (b)

    The Base Price of Shares with respect to a Tandem or Affiliated SAR Award will equal the Exercise Price of the Shares under the related Option.
  - Tandem SARs may be exercised for all or part of the Shares subject to the related Option upon the surrender of the right to exercise the equivalent portion of the related Option. A Tandem SAR may be exercised only with respect to the Shares for which its related Option is then exercisable. With respect to a Tandem SAR granted in connection with an Incentive Stock Option: (i) the Tandem SAR will expire no later than the expiration of the underlying Incentive Stock Option; (ii) the value of the payout with respect to the Tandem SAR will be for no more than one hundred percent (100%) of the difference between the Exercise Price of the underlying Incentive Stock Option and the Market Value of the Shares subject to the underlying Incentive Stock Option at the time the Tandem SAR is exercised; and (iii) the Tandem SAR will be exercisable only when the Market Value of the Shares subject to the Incentive Stock Option exceeds the Exercise Price of the Incentive Stock Option.
  - d)
    Upon exercise of a SAR, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying:
    - (i)

      The difference between the Market Value of a Share on the date of exercise over the Base Price; times

(ii)

The number of Shares with respect to which the SAR Award is exercised.

At the discretion of the Committee, payment for a SAR may be in cash, Shares or a combination thereof.

14. Performance Shares. The Committee, in its sole discretion, may from time to time authorize the grant of Performance Shares upon the achievement of performance goals (which may be cumulative and/or alternative) as may be established, in writing, by the Committee based on any one or any combination of the following business criteria: (a) earnings per Share; (b) return on equity; (c) return on assets; (d) operating income; (e) market value per Share; (f) EBITDA; (g) cash flow; (h) net income (before or after taxes); (i) working capital or components thereof, (j) EVA®; (k) margin percentage or (l) the Company's stock price. As determined in the discretion of the Committee, performance goals may differ among Participants and/or relate to performance on a Company—wide or divisional basis. At the time as it is certified, in writing, by the Committee that the performance goals established by the Committee have been attained or otherwise satisfied within the Performance Cycle, the Committee will authorize the payment of cash in lieu of Performance Shares or the issuance of Performance Shares registered in the name of the Participant, or a combination of cash and Shares. The grant of an Award of Performance Shares will be evidenced by an Award Agreement containing the terms and conditions of the Award as determined by the Committee. To the extent required under Code section 162(m), the business criteria under which performance goals

are determined by the Committee will be resubmitted to shareholders for reapproval no later than the first shareholder meeting that occurs in the fifth year following the year in which shareholders previously approved the Plan.

Subject to Section 17, if the Participant ceases Continuous Service before the end of a Performance Cycle for any reason other than Retirement, Disability, or death, the Participant will forfeit all rights with respect to any Performance Shares that were being earned during the Performance Cycle. The Committee, in its sole discretion, may establish guidelines providing that if a Participant ceases Continuous Service before the end of a Performance Cycle by reason of Retirement, Disability, or death, the Participant will be entitled to a prorated payment with respect to any Performance Shares that were being earned during the Performance Cycle.

- 15. Adjustments Upon Changes in Capitalization. In the event of any change in the outstanding Shares subsequent to the effective date of the Plan by reason of any reorganization, recapitalization, stock split, stock dividend, combination or exchange of shares, merger, consolidation or any change in the corporate structure or Shares of the Company, the maximum aggregate number and class of Shares as to which Awards may be granted under the Plan and the number and class of Shares, the Exercise Price of any outstanding Options and the Base Price of any outstanding SAR Awards with respect to which Awards theretofore have been granted under the Plan will be appropriately adjusted by the Committee to prevent the dilution or diminution of Awards. The Committee's determination with respect to any adjustments will be conclusive. Any Shares or other securities received, as a result of any of the foregoing, by a Participant with respect to Restricted Shares will be subject to the same restrictions and the certificate(s) or other instruments representing or evidencing the Shares or other securities will be legended and deposited with the Company in the manner provided in Section 11 of this Agreement.
- 16. Effect of Reorganization. Unless otherwise provided by the Committee in the Award Agreement, Awards will be affected by a Reorganization as follows:
  - (a)

    If the Reorganization is a dissolution or liquidation of the Company then (i) the restrictions on Restricted Shares and Restricted Share Units will lapse and (ii) each outstanding Option or SAR Award will terminate, but each Participant to whom the Option or SAR was granted will have the right, immediately prior to the dissolution or liquidation, to exercise the Option or SAR in full, notwithstanding the provisions of Section 10, and the Company will notify each Participant of such right within a reasonable period of time prior to any dissolution or liquidation.
  - If the Reorganization is a merger or consolidation, upon the effective date of the Reorganization (i) each Participant will be entitled, upon exercise of an Option in accordance with all of the terms and conditions of the Plan, to receive in lieu of Shares, shares or other securities or consideration as the holders of Shares are entitled to receive pursuant to the terms of the Reorganization; and (ii) each holder of Restricted Shares or Restricted Share Units will be entitled to receive shares or other securities as the holders of Shares received which will be subject to the restrictions set forth in Sections 11 and 12 unless the Committee accelerates the lapse of such restrictions and the certificate(s) or other instruments representing or evidencing the shares or other securities is legended and deposited with the Company in the manner provided in Section 11 of this Plan.

The adjustments contained in this Section and the manner of application of such provisions will be determined solely by the Committee.

17. Effect of Change in Control. If the Continuous Service of any Participant of the Company or any Affiliate is involuntarily terminated, for whatever reason, at any time within twelve (12) months after a Change in Control, unless the Committee has otherwise provided in the Award Agreement, (a) any Restricted Period with respect to an Award of Restricted Shares and Restricted Share Units will lapse upon the Participant's termination of Continuous Service and all Restricted Shares and Restricted Share Units will become fully vested in the Participant to whom the Award

was made; and (b) with respect to Performance Shares, the Participant will be entitled to receive a prorata payment of Shares to the same extent as if the Participant ceases Continuous Service by reason of Retirement under Section 14 of the Plan. If a tender offer or exchange offer for Shares (other than such an offer by the Company) is commenced, or if an event specified in paragraphs (c) or (d) of the definition of a Change in Control contained in Section 2 occurs, unless the Committee has otherwise provided in the Award Agreement, all Option and SAR Awards theretofore granted and not fully exercisable will become exercisable in full upon the happening of such event and will remain exercisable in accordance with their terms; provided, however, that no Option or SAR which has previously been exercised or otherwise terminated will become exercisable.

- 18. Assignments and Transfers. Except as otherwise expressly authorized by the Committee in the Award Agreement or any amendment thereto during the lifetime of a Participant, no Award nor any right or interest of a Participant in any Award under the Plan may be assigned, encumbered or transferred otherwise than by will or the laws of descent and distribution.
- 19. Employee Rights Under the Plan. No officer, Employee or other person will have a right to be selected as a Participant nor, having been so selected, to be selected again as a Participant, and no officer, Employee or other person will have any claim or right to be granted an Award under the Plan or under any other incentive or similar plan of the Company or any Affiliate. Neither the Plan nor any action taken under the Plan will be construed as giving any Employee any right to be retained in the employ of the Company or any Affiliate.

- 20. Delivery and Registration of Shares. The Company's obligation to deliver Shares with respect to an Award will, if the Committee requests, be conditioned upon the receipt of a representation as to the investment intention of the Participant to whom such Shares are to be delivered, in such form as the Committee will determine to be necessary or advisable to comply with the provisions of the Securities Act or any other applicable federal or state securities laws. It may be provided that any representation requirement will become inoperative upon a registration of the Shares or other action eliminating the necessity of the representation under the Securities Act or other state securities laws. The Company will not be required to deliver any Shares under the Plan prior to (a) the admission of such Shares to listing on any stock exchange or system on which Shares may then be listed, and (b) the completion of any registration or other qualification of the Shares under any state or federal law, rule or regulation, as the Company determines to be necessary or advisable.
- 21. Withholding Tax. Prior to the delivery of any Shares or cash pursuant to an Award, the Company has the right and power to deduct or withhold, or require the Participant to remit to the Company, an amount sufficient to satisfy all applicable tax withholding requirements. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit or require a Participant to satisfy all or part of the tax withholding obligations in connection with an Award by (a) having the Company withhold otherwise deliverable Shares, or (b) delivering to the Company Shares already owned for a period of at least six months and having a value equal to the amount required to be withheld. The amount of the withholding requirement will be deemed to include any amount that the Committee determines, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date that the amount of tax to be withheld is to be determined for these purposes. For these purposes, the value of the Shares to be withheld or delivered will be equal to the Market Value as of the date that the taxes are required to be withheld.
- 22. Termination, Amendment and Modification of Plan. The Board may at any time terminate, and may at any time and from time to time and in any respect amend or modify the Plan; provided, however, that to the extent necessary and desirable to comply with Rule 16b–3 under the Exchange Act or Code section 422 (or any other applicable law or regulation, including requirements of any stock exchange or quotation system on which the Company's common stock is listed or quoted), shareholder approval of any Plan amendment will be obtained in the manner and to the degree as is required by the applicable law or regulation; and provided further, that no termination,

amendment or modification of the Plan will in any manner affect any Award theretofore granted pursuant to the Plan without the consent of the Participant to whom the Award was granted or the transferee of the Award.

- 23. Repricing. Notwithstanding any provision in the Plan to the contrary and except for adjustments made pursuant to Section 15 of the Plan (relating to the adjustment of Shares and related Awards upon certain changes in capitalization), the Exercise Price of any outstanding Option granted under the Plan and the Base Price of any outstanding SAR Award granted under the Plan may not be decreased after the date of grant nor may any outstanding Option or SAR Award granted under the Plan be surrendered to the Company as consideration for the grant of a new Option or SAR Award with a lower Exercise Price or Base Price, as applicable.
- 24. Effective Date and Term of Plan. The Plan will become effective upon its adoption by the Board of Directors and shareholders of the Company. Unless sooner terminated pursuant to Section 22, no further Awards may be made under the Plan after ten (10) years from the effective date of the Plan.
  - 25. Governing Law. The Plan and Award Agreements will be construed in accordance with and governed by the internal laws of the State of Delaware.

Adopted by the Board of Directors of Great Lakes Chemical Corporation as of

February 12, 2002

Adopted by the Shareholders of Great Lakes Chemical Corporation as of

May 2, 2002

/s/ RICHARD J. KINSLEY

Richard J. Kinsley, Senior Vice President Human Resources and Communications

**OuickLinks** 

Exhibit (10)(xv)

### SUBSIDIARIES

Antimony Products (Proprietary) Ltd.  Aqua Clear Industries, L.L.C.  ASCK, Inc.  Delaware U.S.  ASCENSIS, Inc.  Canada  ASEPSIS, Inc.  Canada  ASEPSIS, Inc.  BAYROL Derica S.A.  France  BAYROL Derica S.A.  France  BAYROL Derica S.A.  Spain  Bior-Lab Canada, Inc.  Bior-Lab, Inc.  Bior-Lab (Landa, Inc.)  Bior-Lab (Landa,	Name of Corporation	Jurisdiction
Aqua Clear Industries, L.IC. ASCK, Inc. Delaware U.S. ASCENIS, Inc. Canada ASEPSIS, Inc. Canada ASEPSIS, Inc. Georgia U.S. ASIA Sabilizers Co., Ltd. Korea BAYROI, Deutschland GmbH Germany Bayroi, Lab Canada, Inc. Canada Bio-Lab Canada, Inc. Canada Ca	1167201 Ontario Limited	Canada
ASCK, Inc.  ASEPSIS, Inc.  Canada  ASEPSIS, Inc.  Carada  BAYROL Deurschland GmbH  Germany  BAYROL Deurschland GmbH  Bio-Lab Canada, Inc.  Canada  Bio-Lab Canada, Inc.  Canada  Bio-Lab Canada, Inc.  Canada  Bio-Lab Canada, Inc.  Delaware U.S.  BioLab (Gulf) GmbH  Switzerland  BioLab Ansiralia Pty, Ltd.  BioLab Ansiralia Pty, Ltd.  BioLab Ansiralia Pty, Ltd.  BioLab Textile Additives, LLC  Delaware U.S.  BioLab Textile Additives, LLC  BioLab Textile Additives, LLC  BioLab Textile Additives, LLC  BioLab Textile Additives, LLC  Carada  BioLab Textile Additives, LLC  BioLab Textile Addit	Antimony Products (Proprietary) Ltd.	South Africa
ASEPSIS, Inc.  ASEPSIS, Inc.  Georgia/U.S.  ASIA Stabilizers Co., Ltd.  BAYROL Deutschland GmbH  Germany  BAYROL Deutschland GmbH  Germany  BAYROL Deutschland GmbH  Germany  BAYROL Berica S.A.  France  BAYROL Berica S.A.  Spain  Bio Lab Canada, Inc.  Canada  Bio-Lab Inc.  Delaware/U.S.  Biol ab (dult) GmbH  Switzerland  BioLab (dult) GmbH  Switzerland  BioLab Australia Pty. Ltd.  Biolab Services, Inc.  Delaware/U.S.  BioLab Textile Additives, LLC  Delaware/U.S.  BioLab Textile Additives, LLC  Delaware/U.S.  BioLab Textile Additives, LLC  Delaware/U.S.  Chemol France S.A.  France  Chemol France S.A.  France  Chemol France S.A.  France  Chemol France S.A.  Chemol Resevenyuarsasg International  Gi. Development, Ltd.  Gi C. Holdings (Netherlands) B.V.  The Netherlands  Gi. Holdings (Netherlands) B.V.  The Netherlands  Great Lakes (UK) Limited  Duited Kingdom  Barbados  Great Lakes Chemical (Burpe) GmbH  Great Lakes Chemical (Gurp GmbH  Switzerland  Great Lakes Chemical (Gurp GmbH  Great Lakes Chemical (Gurp GmbH  Switzerland  Great Lakes Chemical (Sp Pe Ltd.  Singapore	Aqua Clear Industries, L.L.C.	New York/U.S.
ASPENIS, Inc.  Georgia/U.S.  ASIA Stabilizers Co., Ltd.  BAYROL Deutschland GmbH  Germany  BAYROL Berica S.A.  France  BAYROL Berica S.A.  France  BO-Lab, Inc.  Canada  Bio-Lab Canada, Inc.  Delaware/U.S.  BioLab (Gitt) GmbH  Switzerdand  BioLab Arabia Limited  Saudi Arabia  BioLab Arabia Limited  Saudi Arabia  BioLab Arabia Limited  Saudi Arabia  BioLab Arabia Limited  Solub Services, Inc.  Delaware/U.S.  BioLab Textile Additives, Lt.C  Delaware/U.S.  BioLab Textile Additives, Lt.C  Delaware/U.S.  BioLab Textile Additives, Lt.C  Delaware/U.S.  Chemol France S.A.  France  Chemol France S.A.  France  Chemol France S.A.  France  Chemol France S.A.  France  Chemol Reservenytarsasia International  Git, Development, Ltd.  Git, Development, Ltd.  GLC Holdings (Netherlands) B.V.  The Netherlands  GLK Holdings (Netherlands) B.V.  Git Services, Inc.  Delaware/U.S.  Great Lakes Chemical (Burbados) Limited  Great Lakes Chemical (Burbados) Limited  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Cutope) GmbH  Great Lakes Chemical (Gulf) GmbH  Great	ASCK, Inc.	Delaware/U.S.
ASIA Stabilizers Co., Ltd. BAYROL Deutschland GmbH Germany BAYROL Deutschland GmbH BAYROL Deutschland GmbH BAYROL Deutschland GmbH BAYROL Deutschland S.A. BAYROL Iberica S.A. BAYROL Iberica S.A. Spain Bio-Lab Canada Bio-Lab Canada, Inc. Canada Bio-Lab Canada, Inc. Delaware U.S. BioLab, Inc. Delaware U.S. BioLab (Gulf) GmbH Switzerland BioLab Australia Ply, Ltd. BioLab Australia Ply, Ltd. BioLab Australia Ply, Ltd. BioLab Australia Ply, Ltd. BioLab Textile Additives, LLC Delaware U.S. BioLab U.K. Limited United Kingdom BLSA Industries (Pty) Ltd South Africa Blue Systemes S.A.S. France Chemol France S.A. France Chemol France S.A. France Chemol Rexevenytarsasag International Hungary Gl. Development, Ltd. Gl. Choldings GmbH Switzerland GLK Holdings (Metherlands) B.V. Great Lakes (UK) Limited United Kingdom Great Lakes Chemical (Barbados) Limited Great Lakes Chemical (Gurpo) GmbH Switzerland Great Lakes Chemical (Sp Pe Ltd. Singapore Great Lakes Chemical (Sc Pe Ltd. Singapore	ASEPSIS, Inc.	Canada
BAYROL Deutschland GmbHI BAYROL Berica S.A. BAYROL Berica S.A. Bio-Lab Canada Bio-Lab, Inc. Canada Bio-Lab, Inc. Delaware/U.S. BioLab (Gulf) GmbH Switzerland BioLab Arabia Limited Saudi Arabia Limited Saudi Arabia Limited BioLab Astralia Pty, Ltd. Australia BioLab Services, Inc. Delaware/U.S. BioLab Pettile Additives, LLC Delaware/U.S. BioLab Vertile Additives, LLC Delaware/U.S. BioLab U.K. Limited United Kingdom BLSA Industries (Pty) Ltd South Africa Blue Systemes S.A.S. France Chemol France S.A. Chemol France S.A. Chemol France S.A. Chemol Reszvenytarsasag International GL Poldings GmbH Switzerland GLC Holdings GmbH Switzerland GLK Holdings (Netherlands) B.V. Gl K Services, Inc. Great Lakes (UK) Limited United Kingdom Great Lakes (UK) Limited Hong Kong Great Lakes (UK) Limited Hong Kong Great Lakes Chemical (Barbados) Limited Hong Kong Great Lakes Chemical (Garl) GmbH Switzerland Great Lakes Chemical (Golf) GmbH Switzerland Great Lakes Chemical (Netherlands) B.V. The Netherlands Great Lakes Chemical (Golf) GmbH Switzerland Great Lakes Chemical (Netherlands) B.V. The Netherlands Great Lakes Chemical (Netherlands) B.V.	ASEPSIS, Inc.	Georgia/U.S.
BAYROL FRANCE S.A.  BAYROL Iberica S.A.  Spain  Bio Lab Canada, Inc.  Canada  Bio Lab, Inc.  Delaware/U.S.  BioLab (Gulf) GmbH  Switzerland  BioLab Arabia Limited  Saudi Arabia  BioLab Astralia Pty, Ltd.  Australia  BioLab Services, Inc.  Delaware/U.S.  BioLab Textile Additives, LLC  Delaware/U.S.  Grean Ceccomple France  Chemol France  Chemol France S.A.  France  Chemol Reszvenytarsassa International  Hungary  GL Development, Ltd.  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Holdings (Netherlands) B.V.  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Netherlands) B.V.  The Netherlands	ASIA Stabilizers Co., Ltd.	Korea
BAYROL Iberica S.A.  Bio-Lab Canada  Bio-Lab Canada, Inc.  Canada  Bio-Lab, Inc.  Delaware/U.S.  BioLab (Gulf) GmbH  Switzerland  BioLab Arabia Limited  Saudi Arabia  BioLab Astralia Pty, Ltd.  Australia  BioLab Astralia Pty, Ltd.  Australia  BioLab Astralia Pty, Ltd.  Delaware/U.S.  BioLab Textile Additives, LLC  Delaware/U.S.  BioLab U.K. Limited  United Kingdom  BLSA Industries (Pty) Ltd  South Africa  Blue Systemes S.A.S.  France  Chemol France S.A.  Chemol France S.A.  Chemol Rezvenyturasasg International  Hungary  GL Development, Ltd.  British West Indies  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Burpop) GmbH  Great Lakes Chemical (Gurpop) GmbH  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Netherlands) B.V.  The Netherlands	BAYROL Deutschland GmbH	Germany
Bio-Lab Canada, Inc.  Delaware/U.S.  BioLab (Gulf) GmbH  Switzerland  BioLab Arabia Limited  Saudi Arabia  BioLab Astralia Pty, Ltd.  Australia  BioLab Astralia Pty, Ltd.  Australia  BioLab Services, Inc.  Delaware/U.S.  BioLab Textile Additives, LLC  Delaware/U.S.  BioLab U.K. Limited  United Kingdom  BLSA Industries (Pty) Ltd  South Africa  Blue Systemes S.A.S.  France  Chemol France S.A.  France  Chemol France S.A.  France  Chemol Reszvenytarsasag International  Hungary  GL Development, Ltd.  British West Indies  GLC Holdings GmbH  Switzerland  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Special Corporation de Mexico, S.A. de C.V.  Mexico  Mexico  Mexico  Mexico	BAYROL FRANCE S.A.	France
Bio-Lab, Inc. Delaware/U.S. BioLab (Gulf) GmbH Switzerland BioLab Arabia Limited Saudi Arabia BioLab Arabia Limited Adustralia Pty. Ltd. Australia BioLab Australia Pty. Ltd. Australia BioLab Delaware/U.S. BioLab Textile Additives, LLC Delaware/U.S. BioLab U.K. Limited United Kingdom BI.S.A Industries (Pty) Ltd South Africa Blue Systemes S.A.S. France Chemol Reszvenytarsasag International Hungary GL Development, Ltd. British West Indies GLC Holdings (Netherlands) B.V. The Netherlands GLK Holdings (Netherlands) B.V. The Netherlands GLK Services, Inc. Delaware/U.S. Great Lakes (UK) Limited United Kingdom Great Lakes (Hungary Great Lakes Chemical (Gurpop) GmbH Great Lakes Chemical (Gurpop) GmbH Switzerland Great Lakes Chemical (Gulf) GmbH Switzerland Great Lakes Chemical (Gulf) GmbH Switzerland Great Lakes Chemical (Netherlands) B.V. The Netherlands	BAYROL Iberica S.A.	Spain
BioLab (Gulf) GmbH  BioLab Arabia Limited  Saudi Arabia  BioLab Arabia Limited  Saudi Arabia  BioLab Australia Pty, Ltd.  Australia  Biolab Services, Inc.  Delaware/U.S.  BioLab Textile Additives, LLC  BioLab Textile Additives, LLC  BioLab U.K. Limited  United Kingdom  BLSA Industries (Pty) Ltd  South Africa  Blue Systemes S.A.S.  Chemol France  Chemol France S.A.  Chemol France S.A.  Chemol Rezvenytarsasag International  Hungary  GL Development, Ltd.  British West Indies  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Europe) GmbH  Switzerland  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Wetherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (S) Ptc Ltd.  Great Lakes Chemical (S) Ptc Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.	Bio-Lab Canada, Inc.	Canada
BioLab Arabia Limited BioLab Australia Ply. Ltd. BioLab Australia Ply. Ltd. BioLab Services, Inc. BioLab Textile Additives, LLC BioLab UK. Limited United Kingdom BLSA Industries (Pty) Ltd South Africa Blue Systemes S.A.S. France Chemol France S.A. Chemol France S.A. Chemol Reszvenytarsasag International Hungary GL Development, Ltd. British West Indies GLC Holdings GmbH Switzerland GLK Holdings (Netherlands) B.V. The Netherlands GREAL Lakes (Chemical (Barbados) Limited Great Lakes Chemical (Europe) GmbH Great Lakes Chemical (Gulf) GmbH Great Lakes Chemical (Netherlands) B.V. The Netherlands Great Lakes Chemical (Netherlands) B.V. The Netherlands Great Lakes Chemical (Netherlands) B.V. The Netherlands Great Lakes Chemical (Buff) GmbH Great Lakes Chemical (Netherlands) B.V. The Netherlands Great Lakes Chemical (S) Pte Ltd. Singapore Great Lakes Chemical (Corporation de Mexico, S.A. de C.V. Mexico	Bio-Lab, Inc.	Delaware/U.S.
BioLab Australia Pty. Ltd. Biolab Services, Inc. Delaware/U.S. BioLab Textile Additives, LLC Delaware/U.S. BioLab U.K. Limited United Kingdom BLSA Industries (Pty) Ltd South Africa Blue Systemes S.A.S. France Chemol France S.A. Chemol France S.A. Chemol Reszvenytarsasag International Hungary GL Development, Ltd. British West Indies GLC Holdings GmbH Switzerland GLK Holdings (Netherlands) B.V. The Netherlands GLK Services, Inc. Delaware/U.S. Great Lakes (UK) Limited United Kingdom Great Lakes Chemical (Burope) GmbH Switzerland Great Lakes Chemical (Burope) GmbH Switzerland Great Lakes Chemical (Burope) GmbH Switzerland Great Lakes Chemical (Rufope) Ft.Ld. Singapore Great Lakes Chemical (Copporation de Mexico, S.A. de C.V.	BioLab (Gulf) GmbH	Switzerland
Biolab Services, Inc.  Delaware/U.S.  BioLab Textile Additives, LLC  BioLab U.K. Limited  United Kingdom  BLSA Industries (Pty) Ltd  South Africa  Blue Systemes S.A.S.  France  Chemol France S.A.  Chemol France S.A.  France  Chemol Reszvenytarsasag International  Hungary  GL Development, Ltd.  British West Indies  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Gurpop) GmbH  Switzerland  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Overlands) B.V.  The Netherlands  Great Lakes Chemical (Overlands) B.V.  The Netherlands  Great Lakes Chemical (Overlands) B.V.  Mexico  Mexico	BioLab Arabia Limited	Saudi Arabia
BioLab Textile Additives, LLC  BioLab U.K. Limited  United Kingdom  BLSA Industries (Pty) Ltd  South Africa  Blue Systemes S.A.S.  France  Chemol France S.A.  France  Chemol Reszvenytarsasag International  Hungary  GL Development, Ltd.  British West Indies  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Europe) GmbH  Switzerland  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Spreados) Limited  Great Lakes Chemical (Spreados) Limited  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Spreados) Limited  Great Lakes Che	BioLab Australia Pty. Ltd.	Australia
BioLab U.K. Limited  BLSA Industries (Pty) Ltd  South Africa  Blue Systemes S.A.S.  France  Chemol France S.A.  France  Chemol Reszvenytarsasag International  Hungary  GL Development, Ltd.  British West Indies  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes (Limited Barbados) Limited  Barbados  Great Lakes Chemical (Barbados) Limited  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Sp Pte Ltd.  Great Lakes Chemical (Netherlands) B.V.  Mexico  Mexico	Biolab Services, Inc.	Delaware/U.S.
BLSA Industries (Pty) Ltd  Blue Systemes S.A.S.  France  Chemol France S.A.  Chemol Reszvenytarsasag International  GL Development, Ltd.  GLC Holdings GmbH  GLK Holdings (Netherlands) B.V.  GLK Services, Inc.  GLA Services, Inc.  Great Lakes (UK) Limited  Great Lakes Chemical (Burope) GmbH  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  Great Lakes Chemical (Special Services) Great Lakes Chemical (Special Services) Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Special Services) Great Lakes Chemical (Corporation de Mexico, S.A. de C.V.  Mexico	BioLab Textile Additives, LLC	Delaware/U.S.
Blue Systemes S.A.S.  Chemol France S.A.  Chemol Reszvenytarsasag International  Hungary  GL Development, Ltd.  British West Indies  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (S) Pte Ltd.  Singapore  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.	BioLab U.K. Limited	United Kingdom
Chemol Reszvenytarsasag International Hungary  GL Development, Ltd. British West Indies  GLC Holdings GmbH Switzerland  GLK Holdings (Netherlands) B.V. The Netherlands  GLK Services, Inc. Delaware/U.S.  Great Lakes (UK) Limited United Kingdom  Great Lakes Chemical (Barbados) Limited Barbados  Great Lakes Chemical (Europe) GmbH Switzerland  Great Lakes Chemical (Far East) Limited Hong Kong  Great Lakes Chemical (Gulf) GmbH Switzerland  Great Lakes Chemical (Netherlands) B.V. The Netherlands  Great Lakes Chemical (Oulf) GmbH Switzerland  Great Lakes Chemical (Netherlands) B.V. The Netherlands  Great Lakes Chemical (Netherlands) B.V. The Netherlands  Great Lakes Chemical (S) Pte Ltd. Singapore  Great Lakes Chemical Corporation de Mexico, S.A. de C.V. Mexico	BLSA Industries (Pty) Ltd	South Africa
Chemol Reszvenytarsasag International Hungary  GL Development, Ltd. British West Indies  GLC Holdings GmbH Switzerland  GLK Holdings (Netherlands) B.V. The Netherlands  GLK Services, Inc. Delaware/U.S.  Great Lakes (UK) Limited United Kingdom  Great Lakes Chemical (Barbados) Limited Barbados  Great Lakes Chemical (Europe) GmbH Switzerland  Great Lakes Chemical (Far East) Limited Hong Kong  Great Lakes Chemical (Gulf) GmbH Switzerland  Great Lakes Chemical (Netherlands) B.V. The Netherlands  Great Lakes Chemical (Netherlands) B.V. The Netherlands  Great Lakes Chemical (S) Pte Ltd. Singapore  Great Lakes Chemical Corporation de Mexico, S.A. de C.V. Mexico	Blue Systemes S.A.S.	France
GL Development, Ltd.  GLC Holdings GmbH  Switzerland  GLK Holdings (Netherlands) B.V.  The Netherlands  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Europe) GmbH  Switzerland  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (S) Pte Ltd.  Singapore  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Chemol France S.A.	France
GLC Holdings (Netherlands) B.V.  GLK Holdings (Netherlands) B.V.  GLK Services, Inc.  GLK Services, Inc.  Great Lakes (UK) Limited  Great Lakes Chemical (Barbados) Limited  Great Lakes Chemical (Burope) GmbH  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  Great Lakes Chemical (Netherlands) B.V.  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Chemol Reszvenytarsasag International	Hungary
GLK Holdings (Netherlands) B.V.  GLK Services, Inc.  Delaware/U.S.  Great Lakes (UK) Limited  United Kingdom  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Europe) GmbH  Switzerland  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (Netherlands) B.V.  Great Lakes Chemical (S) Pte Ltd.  Singapore  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	GL Development, Ltd.	British West Indies
GLK Services, Inc.  Great Lakes (UK) Limited  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Europe) GmbH  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Gulf) GmbH  Switzerland  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	GLC Holdings GmbH	Switzerland
Great Lakes (UK) Limited  Great Lakes Chemical (Barbados) Limited  Barbados  Great Lakes Chemical (Europe) GmbH  Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	GLK Holdings (Netherlands) B.V.	The Netherlands
Great Lakes Chemical (Barbados) Limited  Great Lakes Chemical (Europe) GmbH  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	GLK Services, Inc.	Delaware/U.S.
Great Lakes Chemical (Europe) GmbH  Great Lakes Chemical (Far East) Limited  Hong Kong  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  The Netherlands  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Great Lakes (UK) Limited	United Kingdom
Great Lakes Chemical (Far East) Limited  Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Great Lakes Chemical (Barbados) Limited	Barbados
Great Lakes Chemical (Gulf) GmbH  Great Lakes Chemical (Netherlands) B.V.  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Great Lakes Chemical (Europe) GmbH	Switzerland
Great Lakes Chemical (Netherlands) B.V.  Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Great Lakes Chemical (Far East) Limited	Hong Kong
Great Lakes Chemical (S) Pte Ltd.  Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Great Lakes Chemical (Gulf) GmbH	Switzerland
Great Lakes Chemical Corporation de Mexico, S.A. de C.V.  Mexico	Great Lakes Chemical (Netherlands) B.V.	The Netherlands
	Great Lakes Chemical (S) Pte Ltd.	Singapore
Great Lakes Chemical France SAS France	Great Lakes Chemical Corporation de Mexico, S.A. de C.V.	Mexico
	Great Lakes Chemical France SAS	France

Great Lakes Chemical Global, Inc.	Delaware/U.S.
Great Lakes Chemical Japan Limited	Japan
Great Lakes Chemical Konstanz GmbH	Germany
Great Lakes Europe Unlimited	United Kingdom
Great Lakes Holding (Europe) AG	Switzerland
Great Lakes Holding Deutschland GmbH	Germany
Great Lakes Holding SAS	France
Great Lakes Manufacturing (Germany) GmbH	Germany
Great Lakes Manufacturing (UK) Limited	United Kingdom
Great Lakes Manufacturing Italy S.r.l.	Italy
Great Lakes Sales (Europe) GmbH	Switzerland
Great Lakes Sales (Germany) GmbH	Germany
Great Lakes Sales (UK) Limited	United Kingdom
Great Lakes Sales France SAS	France
Great Lakes Sales Italy S.r.l.	Italy
Great Lakes SAS	France
Great Lakes Technology (Belgium) N.V.	Belgium
Great Lakes Technology Italy Srl	Italy
Great Lakes Trading Company, Inc.	Delaware/U.S.
Gulf Stabilizers Industries Sales FZCO	Dubai
Gulf Stabilizers Industries, Ltd.	Saudi Arabia
Hydrotech Chemical Corporation	Canada
Hydrotech Chemical Corporation Pty. Ltd	Australia
INTERBAYROL, A.G.	Switzerland
ISCI, Inc.	Indiana/U.S.
MPC S.A.S.	France
Niagara Insurance Company, Ltd	Bermuda
PABU Services, Inc.	Delaware/U.S.
PCBU Services, Inc.	Delaware/U.S.
Poolbrite (SA) (PTY) Ltd	South Africa
POOLTIME GmbH	Germany
QO Chemicals GmbH	Germany
QO Chemicals Inc.	Delaware/U.S.
Recreational Water Products, Inc.	Delaware/U.S.
Recreational Water Products Pty. Ltd.	Australia
Recreational Water Products Inc.	Canada
WIL Research Laboratories, Inc.	Indiana/U.S.

Exhibit 23

### CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation by reference in Post–Effective Amendment Number 1 to the Registration Statement Number 33–02074 on Form S–8, dated February 3, 1995, in Registration Statement Number 33–02075 on Form S–8, dated December 11, 1985, in Registration Statement Number 33–42477 on Form S–3, dated August 28, 1991, in Registration Statement Number 33–57589 on Form S–8, dated February 3, 1995, in Registration Statement Number 33–00543 on Form S–8, dated January 30, 1996, in Registration Statement Number 333–49127 on Form S–8 dated April 1, 1998, in Registration Statement Number 333–61609 on Form S–8, dated August 17, 1998, in Registration Statement Number 333–78515 on Form S–3, dated May 14, 1999, in Registration Statement Number 333–100787 on Form S–8, dated October 28, 2002, and in Registration Statement Number 333–101719 on Form S–8 dated December 6, 2002, of our report dated January 28, 2003, with respect to the consolidated financial statements and schedule of Great Lakes Chemical Corporation included in the Annual Report on Form 10–K for the year ended December 31, 2002.

/s/ ERNST & YOUNG LLP

Indianapolis, Indiana March 10, 2003

QuickLinks

Exhibit 23

**Exhibit** (99)(i)(a)

### STATEMENT OF CHIEF EXECUTIVE OFFICER

The undersigned chief executive officer of Great Lakes Chemical Corporation hereby certifies that this Annual Report on Form 10–K for the year ended December 31, 2002 ("Periodic Report") fully complies with the requirements of section 13(a) of the Securities and Exchange Act of 1934 (15 U.S.C. 78m) and that information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Great Lakes Chemical Corporation.

/s/ Mark P. Bulriss Mark P. Bulriss, Chief Executive Officer

Dated: March 10, 2003

QuickLinks

Exhibit (99)(i)(a)

**Exhibit** (99)(i)(b)

### STATEMENT OF CHIEF FINANCIAL OFFICER

The undersigned chief financial officer of Great Lakes Chemical Corporation hereby certifies that this Annual Report on Form 10–K for the year ended December 31, 2002 ("Periodic Report") fully complies with the requirements of section 13(a) of the Securities and Exchange Act of 1934 (15 U.S.C. 78m) and that information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Great Lakes Chemical Corporation.

/s/ John J. Gallagher III John J. Gallagher III, Chief Financial Officer Dated: March 10, 2003

QuickLinks

Exhibit (99)(i)(b)

Created by 10KWizard Technology www.10KWizard.com